Development of Mycobacterium tuberculosis DNA gyrase as a target for antibacterial chemotherapy by Karkare, Shantanu
1 
 
 
 
 
 
 © This copy of the thesis has been supplied on condition that anyone who 
consults it is understood to recognise that its copyright rests with the author and 
that no quotation from the thesis, nor any information derived therefrom, may 
be published without the authors prior, written consent. 
 
 
      
 
Shantanu Karkare 
 
Development of Mycobacterium 
tuberculosis DNA gyrase  
as a target for antibacterial 
chemotherapy 
September 2010 
This thesis is submitted in partial fulfilment of the requirements of the 
degree of Doctor of Philosophy at the University of East Anglia. 
John Innes Centre 
 
2 
 
 
 
ABSTRACT 
 
Bacterial DNA gyrase is one of the proven targets for antibacterial 
chemotherapy.  It is a type II DNA topoisomerase found in all bacteria. Most of 
our current information is related to the enzyme from Escherichia coli (E. coli), 
a Gram-negative bacterium, with limited information about the gyrase from 
Mycobacterium tuberculosis (M. tuberculosis), a Gram-positive bacterium. The 
emergence of multidrug-resistant tuberculosis (MDR-TB) and extremely drug-
resistant tuberculosis (XDR-TB) with no new classes of drugs has posed a great 
challenge for the effective and short-term treatment of tuberculosis. Thus, it has 
become important to understand and investigate established drug targets, such 
as DNA gyrase, in M. tuberculosis. Although there are similarities between the 
gyrases from these two bacteria, there are key differences, which can be 
potentially exploited for identifying new drugs for tuberculosis. This work 
describes the identification of a putative Ca2+-binding site in M. tuberculosis 
GyrA and discovery of naphthoquinones as novel inhibitors of DNA gyrase.  
In the absence of a complete crystal structure for M. tuberculosis GyrA, a 
homology model was constructed for biochemical and site-directed mutagenesis 
experiments involving the putative Ca2+-binding site. These experiments 
indicate that Ca2+ has a potential regulatory role in M. tuberculosis. Virtual 
screening was performed to identify novel inhibitors targeting the Ca2+-binding 
site. 
Diospyrin, a naphthoquinone was identified as a potent inhibitor of DNA 
gyrase. This work has demonstrated that diospyrin inhibits DNA gyrase with a 
novel mechanism and that the GyrB N-terminal domain is the potential target 
site. Docking studies were performed to predict the diospyrin-binding site in 
GyrB.
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Chapter 1: General Introduction 
 
1.1 Tuberculosis  
Tuberculosis (TB) is an infectious disease caused by the Gram-positive 
actinobacteria Mycobacterium tuberculosis (M. tuberculosis). It is an intracellular 
pathogen with high lipid content in the cell wall. It is also a slow-growing obligate 
aerobe. The Zein-Neelsen acid-fast staining procedure is used for microscopic 
examination of the bacteria because of its lipid-rich cell wall (Figure 1.1). TB 
infection first affects the lungs (pulmonary TB) and then spreads to lymph nodes 
affecting bones, kidneys and causing meningitis. It is a droplet infection that spreads 
by breathing droplets in the air containing the TB bacteria. 
 
 
Figure 1.1: M. tuberculosis stained with Zein-Neelsen stain (Young et al., 2008). 
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TB is a serious public health problem worldwide due to the AIDS epidemics, 
the advent of multidrug-resistant tuberculosis (MDR-TB) and extremely-drug 
resistant tuberculosis (XDR-TB) strains and the lack of new drugs in the market. 
Every year there are approximately 400,000 cases of MDR-TB, which is a specific 
form of drug-resistant TB. It occurs when the TB bacteria are resistant to at least 
isoniazid and rifampicin, the two most powerful anti-TB drugs. XDR-TB is a form of 
MDR-TB resistant to any fluoroquinolone, and at least one of the three second-line 
drugs (capreomycin, kanamycin, and amikacin). 
 WHO launched the DOTS programme (directly observed therapy, short 
courses) as a TB control strategy in 1994 (Young et al., 2008). DOTS has relied on 
passive detection of microscopy smear-positive samples from patients. Although 
DOTS has been very successful at standardizing care practices and increasing cure 
rates, case-detection targets have been more difficult to achieve (Young et al., 2008). 
According to the latest WHO report published in 2009, 9.27 million new 
cases of TB occurred in 2007, 2 billion people are infected with TB, 12 million are 
co-infected with TB/HIV and two million people die every year. Asia (the south-east 
and western pacific regions) and Africa accounts for 55% and 31% respectively for 
all the cases worldwide. North & South America, eastern and Mediterranean regions 
also contribute to the global cases (Figure 1.2) (Bauquerez et al., 2009). Though 
most cases of TB occur in Africa and Asia, in the UK about 8,000 cases of TB are 
reported each year and this number is rising slowly.   
TB can be prevented by BCG (Bacillus Calmette-Guérin) vaccination, but it 
only protects between 70-80% of people who receive it. At present, the treatment 
time for TB is six to nine months with doses of multi-drug combinations. It has been 
nearly 35 years since the introduction of a new class of compounds for the TB 
treatment and until now, no significant advancements have been made in this area.  
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Based on the mechanism of action (Figure 1.3), the present antituberculosis 
drugs can be classified into following  categories (Janin, 2007): 
1. Inhibitors of DNA-based processes: Fluoroquinolones and 
Rifampicin. 
2. Inhibitors of protein synthesis: Streptomycin, Linezolid and 
Capreomycin. 
3. Peptidoglycan and arabinogalactam biosynthesis inhibitors: 
Ethambutol and Amoxicillin. 
4. Fatty acid biosynthesis inhibitors: Isoniazid, Pyrazinamide and PA-
824. 
Drugs such as fluoroquinolone target DNA gyrase which is the focus of my research. 
 
 
 
Figure 1.2: A global map showing the estimated TB incidence rates by country 
in 2007 (Bauquerez et al., 2009). 
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Figure 1.3 : Mechanism of action of different TB drugs. 
(http://www.nlm.nih.gov/medlineplus/tuberculosis.html). 
 
Despite the availability TB therapy, the emergence of MDR and XDR-TB has 
created demands for new effective drugs. Pharmaceutical companies have on-going 
programs in TB therapeutics, but it is not their primary focus. Active not-for-profit 
partnerships are playing important roles in accelerating the discovery and 
development of new TB drugs. For example, the TB Alliance and Bayer have signed 
an historic agreement to conduct a global clinical development program, seeking to 
register moxifloxacin for TB eradication. Moxifloxacin is a fluoroquinolone and an 
inhibitor of DNA gyrase. 
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1.2 DNA topology 
 DNA is the carrier of genetic information and it takes part in important cellular 
processes such as DNA replication and transcription. Several enzymes such as 
polymerases are involved in these processes and are sensitive to DNA topology for 
their activity. DNA topoisomerases have the ability to maintain DNA topology and 
solve topological problems that arise from processes such as transcription and DNA 
replication. 
The determination of the structure of double-stranded DNA (Watson & Crick, 
1953) in 1953 started the era of modern molecular biology. DNA is a right-handed 2 
nm wide double-helical structure consisting of two strands of polynucleotide chain in 
opposite directions. The individual chains are joined together in pairs by double or 
triple hydrogen bonds between the purine and pyrimidine bases in each chain 
perpendicular to the helix axis (A = T; G ≡ C). According to the Watson and Crick 
model, there are ~10 base pairs (bp) for every turn of helix and a repeat distance of 3.4 
nm for each successive turn. This form of the DNA double helix is known as the B-
form. It is likely that the B-form represents the predominant conformation of DNA in 
cells; A- and Z-forms of DNA also exist. The existence of Z-form of DNA in vivo is 
debatable but the presence of A-DNA has been proposed at specific sites such as 
promoter regions (Shakked et al., 1981) and transcription factor binding sites (Fairall 
et al., 1989). Cruciforms, DNA triplexes and DNA quadruplexes are some other 
alternative DNA structures. 
Bacterial plasmids, exists in a closed-circular form in which both the strands of 
the double-helical DNA are closed to form circles. This closed-circular DNA can be 
deformed under torsional stress to form supercoiled DNA (Sc). Supercoiling can be 
manifested as a change in twist (Tw) and / or a change in writhe (Wr). While twist is 
the number of double-helical turns in a given length of DNA, writhe quantifies the 
coiling of the path of a DNA helix in space. Each closed-circular DNA molecule has a 
linking number and it is called a topoisomer. Linking number (Lk) is the number of 
times the two strands of closed-circular DNA are linked.  
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Lk = Tw + Wr 
The Lk of closed circular DNA is changed through the breakage and the 
religation of one or both DNA strands.  Positively supercoiled closed-circular DNA 
has a positive average linking difference (∆LK), while negatively supercoiled closed-
circular DNA has a negative average linking difference. The linking difference is the 
difference between the linking number of a particular topoisomer of closed-circular 
DNA (Lk) and the average linking number of relaxed DNA under given conditions  
(Lk° = No. bp/ helical repeat). Lk° for the classical pBR322 plasmid is 415.3, if h = 
10.5 bp/turn under standard conditions (0.2 M NaCl, pH 7, 37°C). 
∆Lk = Lk- Lkº 
Closed-circular DNA without any constraint of DNA helix and with average 
linking difference of zero is the relaxed DNA. Specific linking difference (σ) compares 
the topological properties of DNA molecules of varying length. It is represented by the 
following equation. 
σ = ∆Lk / Lk° 
Double-stranded DNA can also form knots and catenanes. Knots were first 
observed in single- and double-stranded DNA (Liu et al., 1976, Liu et al., 1981). 
Catenanes were first observed in 1967 in the mitochondria of human cells (Clayton & 
Vinograd, 1967, Hudson & Vinograd, 1967). All these topological isomers 
(supercoiled DNA, relaxed DNA, knots and catenanes) of DNA can be studied by 
agarose gel electrophoresis. A closed-circular DNA molecule becomes more compact 
with increased writhe. As a result, compact DNA molecules migrate faster through the 
gels than topologically relaxed DNA molecules. DNA topoisomerases can interconvert 
between these different topological forms. 
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1.3 Biological significance of DNA topology 
DNA topology is important for biological processes such as genome 
compaction, recombination, DNA replication, transcription, gene expression and 
chromosomal segregation.  Genome compaction requires appropriate DNA topology, 
given the size of cells in which they are packaged.  For example, the length of E. coli 
genome is ~1600 µM enclosed in a rod-shaped cell that is ~1 µM in diameter and 
 ~3-5 µM in length (Zimmerman, 2006). The DNA is negatively supercoiled and 
compacted into nucleoids in order to fit the E. coli chromosome within the cell. The 
nucleoids occupy less than 25% of the intracellular volume (Worcel & Burgi, 1972, 
Woldringh & Nanninga, 1985). 
In case of eukaryotes the DNA forms nucleosomes consisting of 146 bp of 
DNA wrapped around the histone complex H2A/H2B/H3/H4 (Bates & Maxwell, 
2005). This results in positive supercoils in the DNA which are then removed by 
topoisomerases to give negatively supercoiled DNA constrained within the 
nucleosomes (Bates & Maxwell, 2005). In prokaryotes, DNA gyrase introduces 
negative supercoils into DNA, which are then constrained by DNA-binding proteins. 
In eukaryotes, histones constrain the negative supercoiling of chromosomal DNA. 
Initiation of DNA replication requires unwinding of the DNA region forming the 
origin of replication. Negative supercoiling favours DNA unwinding and hence it is 
likely to favour the initiation of replication (Bates and Maxell, 2005). During the 
replication process, positive supercoils are formed ahead of the replication fork. 
These positive supercoils are likely to be removed by DNA gyrase and topo IV 
(Bates & Maxwell, 2005). Catenation may also result when two replication forks 
converge at the end of replication. Catenated DNA can be resolved by type II DNA 
topoisomerases. Both DNA gyrase and topo IV can decatenate DNA in E. coli (Steck 
& Drlica, 1984, Adams et al., 1992). In case of M. tuberculosis, DNA gyrase 
performs efficient DNA decatenation in the absence of topo IV. 
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Similarly during transcription, movement of RNA polymerase results in 
positive and negative supercoiling ahead and behind the transcription bubble. This is 
called the ‘twin domain model for transcription’ (Liu & Wang, 1987). These positive 
and negative supercoils are removed by DNA gyrase and topo I respectively (Figure 
1.4). 
1.4 DNA topoisomerases 
1.4.1 Introduction 
DNA topoisomerases are a broad class of enzymes responsible for 
maintaining and manipulating the topological state of DNA (Corbett & Berger, 
2003). These enzymes are required for vital processes in a cell such as DNA 
replication, transcription, recombination and chromatin remodeling; therefore they 
are found in all organisms including eukaryotes (yeast, plants, and animals), 
prokaryotes, viruses and archea. Due to the important role played by topoisomerases 
in maintaining the cell viability, they are attractive clinical targets for antibiotics and 
chemotherapeutics (Maxwell, 2003). The first topoisomerase, E. coli topo I (E. coli 
ω protein) was discovered in 1971 (Wang, 1971) followed by a second 
topoisomerase (eukaryotic type I) in 1972 (Champoux & Dulbecco, 1972). 
    Based on the mechanism of action, topoisomerases can be classified into two 
broad families, type I and type II. Type I topoisomerases cleave one strand, while type 
II cleave both strands, while manipulating the topological state of DNA. Both type I 
and type II topoisomerase can relax supercoiled DNA. This is important during 
transcription and DNA replication, which is when positive supercoils are generated 
ahead of RNA polymerase or DNA polymerase and negative supercoils are generated 
behind them (Liu & Wang, 1987, Cortes et al., 2003) as shown in the Figure 1.4B. 
Type I and type II can also decatenate interlinked chromosomes formed during 
replication. Except prokaryotic type I topoisomerase and reverse gyrase, most DNA 
topoisomerases relax both negatively and positively supercoiled DNA. DNA gyrase 
and reverse gyrase are the only DNA topoisomerase that are able to introduce 
supercoils into DNA at the cost of ATP hydrolysis. While DNA gyrase introduces 
negative supercoils into DNA, reverse gyrase introduces positive supercoils.  
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Decatenation and unkotting are other topological simplification reactions that are 
catalysed by DNA topoisomerases. Decatenation involves unlinking two unlinked 
DNA plasmids and unknotting removes knots from circular plasmids. 
 
 
Figure 1.4: Significance of DNA topoisomerase. (A) Summary of different 
reactions catalysed by DNA topoisomerase. (B) DNA topoisomerase are required to 
resolve the changes in DNA topology during replication and transcription 
(Schoeffler & Berger, 2008). 
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As shown in Figure 1.5 type I  topoisomerases can be further subdivided into 
type IA and type IB, and type II into type IIA and type IIB based on structure and 
mechanism. The different types of topoisomerase can be found from single cell E. coli 
to higher eukaryotes. Within the bacterial world, topoisomerases are widely 
distributed. In  E. coli four topoisomerases are found: DNA topoisomerase I, III (type 
IA), DNA gyrase and DNA topoisomerase IV (type IIA) (Wang, 2002, Wang, 1985). 
In some mesophilic bacteria topo III is absent. Other mesophiles have only two 
topoisomerases, one homologous to E. coli DNA gyrase and the second homologous to 
E. coli topo I. Reverse gyrase and topoisomerase V (type IB) are found in 
Hyperthermophiles. In Archaea, a reverse gyrase, a type IA topo, and topo VI are 
found. Saccharomyces cerevisiae and Schizosaccharomyces pombe have topo I (type 
IB), topo II (type IIA) and topo III (type IA). All higher eukaryotes have topo I and 
most have two type IIA isoforms (topo IIα, topo II β). They also contain two isoforms 
of topo III (topo IIIα, topo III β). The distribution of DNA topoisomerase is 
summarised in Table 1.1.  
 
Figure 1.5: Classification of Topoisomerase based on structure and mechanism. 
  
Chapter 1 
 
28 
 
Organism Type Topoisomerase 
Archaea  IA, IIB Reverse gyrase, type IA topo and topo VI 
E. coli IA, IIA Topo I, III, DNA gyrase and DNA 
topoisomerase IV 
M. tuberculosis IA, IIA DNA gyrase, Topo I  
Hyperthermophiles IA, IB Reverse gyrase, topoisomerase V 
Schizosaccharomyce. 
pombe and S. cerevisiae  
IA, IIA, IB Topo I, topo II and topo III  
Higher eukaryotes IA, IIA, IB, 
IIB 
Topo I, type IIA isoforms (topo IIα, topo 
II β),  topo III (topo IIIα, topo III β), topo 
VI 
Table 1.1:  Diversity of topoisomerase in the cellular world. 
 
1.4.2 Type IA topoisomerases 
 Type IA topoisomerases form transient 5′-phospho-tyrosine covalent 
intermediates, releasing a free 3′-OH strand and allowing passage of the intact strand 
through the broken strand. The sub-type includes eubacterial DNA topoisomerase I, 
eubacterial DNA topoisomerase III, mammalian DNA topoisomerase III (α/β), 
eubacterial reverse gyrase and archaeal reverse gyrase. Type IA are able to relax 
negative supercoiling in the presence of Mg2+,   knot / unknot and catenate both single-
stranded circles and double-stranded plasmids having nicks or gaps (Champoux, 
2001).  
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All the members of this family share the following properties: 
1. They are all monomers with the exception of the Methanopyrus kandleri topoV 
(Krah et al., 1996) reverse gyrase. 
2. DNA strand cleavage is accompanied by covalent attachment of one of the 
DNA ends to the enzyme through a 5´ phosphodiester bond to the active site 
tyrosine.  
3. Relaxation of negatively supercoiled DNA only in the presence of Mg2+. 
4.  Relaxation of negative supercoils does not go to completion and the change in 
the linking number is in the steps of one. 
5. In addition to the ability to relax negative supercoils, these enzymes can 
catalyse the knotting, unkotting and interlinking of single-stranded circles as 
well as the knotting, unkotting, catenation and decatenation of gapped or 
nicked duplex DNA circles. 
     Besides the similarities, there are certain function and structural 
differences among the members of the family.  For example E. coli topoisomerase 
III is much more effective at decatenation than topoisomerase I, and carries out this 
role in precatenane unlinking during DNA replication (DiGate & Marians, 1988, 
Hiasa et al., 1994). In contrast to topoisomerase I, both yeast and E. coli 
topoisomerases III lack a Zn2+- binding domain altogether. Surprisingly human 
topoisomerase III has a Zn2+- binding domain with significant homology to that 
found in E. coli (Hanai et al., 1996). 
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1.4.3 Structure of type IA topoisomerase 
 
Figure 1.6: Domain alignment of type IA topoisomerase showing the structural 
diversity (Bates & Maxwell, 2005). 
 Within the same type IA subfamily there is diversity in the structure of the 
enzymes, as shown in the Figure 1.6. Type IA enzymes, like type IIA and IIB 
topoisomerases (Figure 1.7), have 5Y-CAP domains and Toprim domains (Corbett & 
Berger, 2004). Both these domains are important for DNA binding and cleavage. 5Y-
CAP is a ‘winged-helix fold’ that bears the catalytic tyrosine residue that covalently 
attaches to the 5´ end of DNA (Corbett & Berger, 2004).  The‘ Toprim’ domain is 
required for cleavage and has a cluster of acidic residues that are thought to form a 
binding site for Mg2+ ions (Corbett & Berger, 2004). These acidic residues are also 
brought close to the catalytic residues of the 5Y-CAP domains (Corbett & Berger, 
2004). In addition to these domains, a CAP-like domain is present which is similar to 
the 5Y-CAP domain but it lacks the active-site tyrosine. This CAP-like domain, along 
with the 5Y-CAP domain, forms a hole in the centre of the protein having a diameter 
of ~ 25 Ǻ (Corbett & Berger, 2004).  
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Figure 1.7: Structure of  E. coli topo III and Archaeoglobus fulgidus reverse 
gyrase (Corbett & Berger, 2004).  
There are some structural differences between the different members of type 
IA family.  For example the E. coli topo I possess a 30-Da C-terminal region that bears 
five tandem Zn2+-binding site, and the enzyme has been shown to bind up to two Mg 2+ 
ions not observed in E. coli topo III. In the same way reverse gyrase, contains a 
distinctive helicase-like domain and a type IA topoisomerase domain in the same 
polypeptide. This distinct structure of reverse gyrase provides it the distinctive ability 
for ATP-dependent positive supercoiling of DNA. 
Topo I from M. tuberculosis (Yang et al., 1996, Annamalai et al., 2009) and M. 
smegmatis (Bhaduri et al., 1998) have also been purified and characterised. The gene 
encoding topo I in M. tuberculosis is 2700 nucleotide long encoding a 900 amino acid 
polypeptide with a molecular mass of 99,353 Da. The amino acid sequence identity in 
comparison to E. coli and Synechococcus topo I is 22 and 30% respectively.  
M. tuberculosis topo I like other topo Is relaxes negatively supercoiled DNA in a Mg2+ 
-dependent, ATP–independent reaction. However, there are differences between M. 
tuberculosis and E. coli at the structural and functional level. Unlike E. coli topo I it 
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does not contain a Zn2+-finger DNA binding motif in the C-terminal domain (Yang et 
al., 1996) and is less efficient in removing  negative supercoils from partially relaxed 
DNA. Interestingly like E. coli,  M. tuberculosis topo I ’s  preferred site for cleavage 
has a C nucleotide in the -4 position, with reference to its clevage site (Annamalai et 
al., 2009). 
M. smegmatis topo I is the largest enzyme subunit (110-kDa) of the type IA 
family. It has all the typical properties of type I topoisomerases. However, like M. 
tuberculosis topo I it is different from the prototype E. coli topo I.  It does not contain 
any bound Zn2+ indicating the absence of the Zn2+-binding motif in DNA binding. 
Unlike M. tuberculosis DNA gyrase it is not inhibited by spermidine and is relatively 
stable at high temperatures. The enzyme activity is stimulated by single-strand DNA-
binding protein (Sikder et al., 2001, Bhaduri et al., 1998). M. smegmatis topo I also 
has a specific cleavage site, which is a pentanucleotide motif (CG/TCT¦T; ¦ represents 
the cleavage site) (Sikder & Nagaraja, 2000). It has also been shown that the enzyme 
induced localized structural distortion upstream to the strong topoisomerase site 
(Bhaduri et al., 2000) (Sikder & Nagaraja, 2001). 
Topo I is a potential drug target. At present a lot of efforts are being directed to 
identify effective mycobacterial topo I inhibitors (Leelaram et al., 2010). In the past 
diospyrin, a naphthoquinone (described in chapter 4) has been shown to inhibit 
eukaryotic topo I (Tazi et al., 2005). At present topo I is one of the pipeline targets for 
the discovery of effective antibacterial at TB Alliance. 
1.4.4 Mechanism of action of type IA topoisomerase 
The mechanism of action of type I A topoisomerase will be discussed by taking 
the example of E. coli topo I (Figure 1.8). A single strand of the DNA duplex  
(Li et al., 2001) is cleaved followed by covalent bond formation between the active 
site tyrosine (Y319 in E. coli topo I) and the 5' phosphate of one of the free ends of the 
cleaved strand (Tse & Wang, 1980).  In order to facilitate the intact strand passage, the 
protein domain, which possesses the active site tyrosine bound to the 5' end of the 
broken strand, moves to create a gap. Once the intact strand has been transported 
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through the gap, the broken strand is religated and the DNA is released. The linking 
number of the DNA changes by one with every round of strand passage. This 
mechanism has also been refereed to as 'the enzyme-bridging model' (Champoux, 
2001). 
 
 
Figure 1.8: General mechanism of action of type I topoisomerase demonstrating 
the single-stranded cleavage facilitating the strand passage for topological 
simplification (Champoux, 2001). 
1.4.5 Type IB topoisomerases 
Type IB forms a 3′-phosphotyrosine covalent intermediate, releases the 5′-OH  
strand and leaves the broken strand free to rotate around the intact strand. This sub-
type includes eukaryotic DNA topoisomerase I, poxvirus DNA topoisomerase and 
eubacterial topoisomerase V (from Methanopyrus). Type IB can relax both negative 
and positive supercoils in a metal-independent process, unlike type IA topoisomerases. 
There are structural differences between the vacinina topo I (v-topoI) and human topo I 
  
Chapter 1 
 
34 
 
(h-topoI). Human topo I is larger (Figure 1.10) and has several extra domains (765 
amino acids) in comparison to vacinina topo I (314 amino acids). Human topo I has a 
highly charged and unstructured 24-kDa domain at its N-terminus (Stewart et al., 
1996). Although the function of this domain is not clear, it has shown to bind DNA 
downstream of the cleavage site to control DNA rotation (Lisby et al., 2001). 
There are three major sub domains (I, II, III) that wrap around the DNA 
duplex. Major portions of these domains comprise most of the IB/Int catalytic domain. 
The catalytic tyrosine of h-topoI (human) is present on a small 6-kDa domain at its C-
terminus connected to the central body of the enzyme by a 7-kDa coiled linker 
elements.  The linker region together with positively charged helices in sub domains I 
and II of the core region are thought to regulate the DNA rotation during the 
topoisomerase reaction (Lue et al., 1995, Redinbo et al., 2000, Stewart et al., 1998). 
This arrangement of the catalytic residues is not found in v-topoI (virus) and it lacks 
the linker region. 
Another type IB topoisomerase from the archeon M. Kandleri (110- kDa) is 
unique in structure and activity (Slesarev et al., 1993). The 44-kDa  N-terminal domain 
is similar to the IB/Int catalytic domain and the remaining 66-kDa has twelve 50 amino 
acid sequence repeats, each having helix-hairpin-helix DNA binding motifs (Belova et 
al., 2001). Topo V activity is similar to the other type IB topoisomerase but topo V 
also aids enzyme processivity and possess apurinic site (AP) lyase activity (Belova et 
al., 2001). A recently solved  crystal structure of the N-terminal fragment of 
topoisomerase V shows no structural similarity with other type IB members, so it is not 
clear whether it should be classified as a member of typeIB or  as a separate family of 
type IC (Taneja et al., 2006). 
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1.4.6 Mechanism of action of type IB topoisomerases 
The crystal structures of several forms of the human enzyme with non-
covalently and covalently bound DNA have been determined (Redinbo et al., 1998, 
Redinbo et al., 2000, Stewart et al., 1998). These structures have provided clues to 
elucidate the enzyme mechanism. The energy for the relaxation mechanism is obtained 
from that stored in the supercoiled DNA. The unique structure of type IB allows it 
clamp DNA between sub domain I/II and sub domain III/C-terminal domain (Figure 
1.9 a,b). DNA clamping is followed by single-strand cleavage and formation of a 
phosphotyrosine bond between the protein and the 3´ end of the cleaved strand (Cheng 
et al., 1998) (Figure 1.9 c,d). After the formation of DNA-topo, complex, controlled 
rotation of the helix duplex downstream of the cleavage site occurs and the enzyme 
opens up to allow this (Figure 1.9 e). This rotation of the helix duplex is important to 
relieve any torsional stress within the DNA substrate (Stewart et al., 1998). Finally the 
5´ end of the cleaved DNA is relegated to the 3´ end and the DNA is released (Cheng 
et al., 1998).  
 
Figure 1.9:  Detailed mechanism of human topoisomerase I. (Champoux, 2001). 
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Figure 1.10:  Structure of human topo I. (A) Human topo I bound with DNA (PDB 
code : 1A36) viewed down the DNA axis. (B) A cartoon of the Human topo I showing 
the features of different domains (Champoux, 2001). 
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1.4.7 Type II DNA topoisomerases 
    The enzymes in this category introduce double-strand breaks in a DNA 
duplex and allow the passage of another duplex through the break. Like type IA 
topoisomerases a covalent bond is formed between the tyrosine in the enzyme and the 
5´ phosphate of the DNA strands (Roca & Wang, 1992, Roca, 1995). The segment of 
DNA with the double-stranded breaks is called the G or ‘gate’ segment, and the DNA 
duplex transported through the gap in the G segment is called T or ‘transported’ 
segment. The broken ends of the G segment are religated after the passage of the T 
segment. All type II enzymes are ATP-dependent multimeric enzymes. The different 
topological reactions catalysed by type II topoisomerases are shown in the Figure 
1.11. 
 
Figure 1.11: Reactions catalysed by type-II topoisomerases (Bates & Maxwell, 
2005). 
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 Type II topoisomerases are again divided into two families:  
1. Type IIA includes bacterial DNA gyrase (E. coli and M. tuberculosis), 
topoisomerase IV (E. coli and M. smegmatis), and eukaryotic topoisomerase II.  
2. Type IIB only includes topoisomerase VI. In the presence of ATP/Mg2+ 
topoisomerase VI is able to relax both positively and negatively supercoiled DNA 
and decatenate DNA (Bergerat et al., 1994, Buhler et al., 2001). 
Type II topoisomerase catalyse all the topological reactions such as supercoiling/ 
relaxation, catenation / decatenation, knotting/ unknotting as shown in Figure 1.11. 
Depending on the location of G and T segments, different topological changes take 
place. When the G and T segments are located on the same DNA molecule then 
relaxation, knotting / unknotting of the DNA take place (Roca, 1995). However, if the 
G and T segments are located on different DNA molecules then catenation / 
decatenation take place. 
1.4.8 Structure of Type IIA topoisomerases 
  Type IIA topoisomerases are a diverse group of enzymes, which vary in 
subunit composition. For example, eukaryotic type II topoisomerases are homodimers 
and bacterial type II topoisomerases (topo IV and DNA gyrase) are heterotetramers. 
However, there are structural and sequence homologies between them (Figure 1.12). 
The B- and A- subunits of the bacterial type II topos are homologues to the N- and C-
terminal halves of eukaryotic type II topos (Lynn et al., 1986). This sequence and 
structural homology demonstrate evolutionary relationship between the prokaryotic 
and eukaryotic type II topos (Corbett & Berger, 2004, Champoux, 2001). Similarly the 
active-site tyrosine is present in a single polypeptide in the case of eukaryotic type II 
topos in a region which is equivalent to the GyrA/ ParC subunits in the case of 
bacterial type II topos (Champoux, 2001). Although the DNA gyrase core structure is 
similar to other type II topos, its C-terminus is different and has a DNA-binding 
domain with a β-propeller fold (Corbett et al., 2004, Ruthenburg et al., 2005). This 
domain is essential for the supercoiling activity of the enzyme and mediates the 
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wrapping of ~140 bp of DNA in a right-handed manner around the entire enzyme (Liu 
& Wang, 1978a). 
 
Figure 1.12: Domain organisation of type IIA topoisomerases based upon 
sequence comparison and homology (Bates & Maxwell, 2005). 
Type IIA topoisomerases have functional domains that are conserved among 
the members and are present in type IA and IIB topoisomerases (Figure 1.13). For 
example the 5Y-CAP DNA and Toprim cleavage domain is present in  type IA, IIA 
and IIB topoisomerases (Corbett & Berger, 2004). This domain has a winged-helix 
fold and possesses the active–site tyrosine, which binds to the 5´ end of the cleaved 
DNA in the case of type II topos. 
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Figure 1.13: Conserved functional domains in type II topoisomerases. The 
GHKL domain (yellow), transducer (orange), Toprim (red) and 5Y-CAP (green) are 
the conserved domains (Corbett & Berger, 2004). 
The Toprim (topoisomerase-primase) domain is approximately 100 amino 
acids and has two conserved motifs, one containing glutamate and other containing 
two conserved aspartates (DxD). The glutamate is essential for strand joining by 
topoisomerases and may act as a general base in nucleotide polymerisation by 
primases. The aspartates coordinate the Mg2+ and are important for the activity of the 
enzyme (Aravind et al., 1998). The GHKL domain is important for the ATPase 
activity of type II topoisomerases. It is called GHKL due to its presence in DNA 
gyrase, Hsp90, CheA-family histidine kinases and MutL (Dutta & Inouye, 2000, 
Corbett & Berger, 2004). In type II topos, ATP- binding causes dimerisation of the 
  
Chapter 1 
 
41 
 
GHKL domains.  The N-terminal arm from one GHKL domain reaches across the 
dimer interface and makes contacts with the ATP lid of the partner GHKL domain. 
 
1.4.9 ATP hydrolysis by type II topoisomerases 
DNA gyrase hyrolyzes ATP to perform DNA supercoiling, which is a 
energetically unfavourable process. On the other hand, other type II topoisomerases 
that only relax DNA supercoils also hydrolyzes ATP.  Relaxation of supercoiled DNA 
is an energetically favourable process and hence it should not require ATP. It is 
proposed that ATP hydrolysis may be used to simplify distributions of DNA 
topoisomers below thermodynamic equilibrium levels (Rybenkov et al., 1997), but the 
energy required for this process is low (Stuchinskaya et al., 2009).  A recent study 
related to topological simplification due to type II topoisomerases has shown that 
topological simplification is not altered by reducing the free energy available from 
ATP hydrolysis (varying ADP:ATP ratio) and it may be an evolutionary effect with no 
adaptive significance (Stuchinskaya et al., 2009).  It has also been proposed that the 
major role of ATP hydrolysis in the type II topoisomerase reaction is to enable the 
controlled separation of strong protein-protein interfaces. This prevents the formation 
of potential cytotoxic double-stranded breaks in DNA (Bates et al., 2010). 
1.4.10 Mechanism of type IIA topoisomerases 
  Type IIA topoisomerases follow a two-gate mechanism for maintaining DNA 
topology (Figure 1.14). The reaction starts with the creation of a double- stranded 
break in DNA, which is called the gate segment or G segment, through which another 
DNA duplex is passed. The double-stranded break is created through nucleophilic 
attack of the DNA backbone and the formation of covalent bonds between the active 
site tyrosine in each monomer with the 5´-phosphates of the DNA strands (Roca, 1995, 
Roca & Wang, 1992). The broken ends of the G segment then makes a way for the 
intact DNA duplex (transported segment or T segment) to be passed through the gap. 
This is brought about by conformational changes, which are induced by ATP binding. 
These conformational changes are transmitted across the enzyme which results in the 
capture of the T segment, closure of the N-gate, separation of the broken ends of the G 
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segment and closing of the C gate (Wang, 1998). After the passage of the T segment, 
the G segment is religated and the C-terminal gate opens to allow the T segment to exit 
the enzyme. When the G and T segments are located, on the same DNA molecule then 
either change in the level of supercoiling or knotting/ unkotting of DNA takes place 
(Roca, 1995, Tse et al., 1980). On the contrary if the G and T segments are located on 
different DNA molecules then it leads to catenation/ decatenation of two DNA 
molecules (Roca, 1995). DNA relaxation takes place by reverse strand passage 
mechanism in DNA gyrase only. In this mechanism, the T segment enters through the 
opening at the C-gate; passes through the transient break in the G segment and exits 
through the open ATP-operated clamp (Williams & Maxwell, 1999b, Williams & 
Maxwell, 1999a).  
 
Figure 1.14: Two-gate mechanism for type II A topoisomerase (Dong & Berger, 
2007). 
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Figure 1.15: Crystal structures of different domains of E. coli DNA gyrase.  
Structures have been solved for the (A) N-terminal (Morais Cabral et al., 1997) and 
(B) C-terminal domains of  E. coli GyrA (Ruthenburg et al., 2005) as well as for the 
(C) N-terminal domain of E. coli GyrB (Brino et al., 2000, Wigley et al., 1991) and 
the (D) E. coli GyrBA-fusion (Schoeffler et al., 2010). Structures were redrawn with 
PyMOL 1.01. 
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1.5 DNA gyrase  
1.5.1 Introduction 
DNA gyrase is a type IIA topoisomerase, which introduces negative supercoils 
into closed-circular DNA (Gellert et al., 1976). DNA gyrases are found in all 
prokaryotes and in eukaryotes such as Plasmodium falciparum, Plasmodium vivax and 
Arabidopsis thaliana.  E. coli DNA gyrase was the first type II topoisomerase to be 
discovered (Gellert et al., 1976). The enzyme maintains the homeostatic balance of 
chromosomal superhelical density by catalysing the introduction of negative 
supercoiling into DNA, a prerequisite for replication and transcription, and relaxes 
positive supercoils generated ahead of the transcription complex. The DNA 
supercoiling mechanism involves transient breakage and resealing of both strands of 
DNA. It also catalyses catenation and decatenation of DNA rings, and knotting and 
unknotting of duplex DNA, but this activity is weaker in comparision to topo IV. 
E. coli DNA gyrase is composed of two subunits of GyrA and two subunits of 
GyrB. The molecular weights of E. coli GyrA and GyrB are 97-kDa and 90-kDa 
respectively (Wang, 1985). The E. coli DNA gyrase domain boundaries have been 
well defined and characterised. GyrA is divided into a 64-kDa N-terminal domain 
(breakage-reunion domain) that contains the QRDR (Quinolone-resistance determining 
region), and a 33-kDa C-terminal domain around which the DNA is wrapped (Reece & 
Maxwell, 1989). The N-terminal domain forms a DNA-binding saddle known as the 
DNA breakage-reunion domain. It also forms a large 30-Ǻ cavity that can 
accommodate a DNA duplex. The GyrA C-terminus adopts a β-propeller fold and is 
largely basic around the outside suggesting the involvement of the domain in DNA 
wrapping (Corbett & Berger, 2004, Liu & Wang, 1978a). GyrB is divided into a 43-
kDa N-terminal ATPase domain (aminocoumarin interaction site) (Wigley et al., 1991) 
and a 47-kDa C-terminal domain (Brown et al., 1979, Gellert et al., 1979, Adachi et 
al., 1987) that interacts with GyrA and DNA. E. coli DNA gyrase has a 170 amino 
acid insertion within the C-terminal domain, in comparison to other bacterial DNA 
gyrase (M. tuberculosis) and type IIA topoisomerases. This insertion is important for 
the DNA binding capabilities of E. coli DNA gyrase (Chatterji et al., 2000). Recently 
  
Chapter 1 
 
45 
 
it has been established that the insertion is important for DNA binding and 
communication between different functional domains (Schoeffler et al., 2010). The 
crystal structures for different domains of E. coli gyrase subunits are available as 
shown in the Figure 1.15. 
M. tuberculosis DNA gyrase is a validated target for anti-tubercular drug 
discovery, because its inhibition results in mycobactericidal activity (Mdluli & Ma, 
2007). Inhibitors of this enzyme are also active against non-replicating, persistent 
mycobacterium, which may play a role in shortening the duration of TB therapy. The 
M. tuberculosis DNA gyrase genes have been cloned in E. coli (Madhusudan et al., 
1994, Takiff et al., 1994). Based on the sequencing data and genome analysis, M. 
tuberculosis genes encoding DNA gyrase were identified as a gyrB-gyrA contig in 
which gyrA and gyrB encode the A and B subunits, respectively; they are organized as 
a bicistronic unit. The gyrA gene is located 34 nucleotides downstream of gyrB. Both 
the genes are transcribed from the promoter elements located upstream of gyrB coding 
sequence.  
Like E. coli DNA gyrase, M. tuberculosis DNA gyrase is an A2B2 tetramer. 
GyrA is ~97-kDa and 838 amino acids, while GyrB is ~72-kDa and 714 amino acids. 
The N-terminal domain of GyrB harbours the ATPase activity; the C-terminal domain 
of GyrB is the domain that interacts with GyrA and forms a complex capable of 
catalyzing DNA breakage and reunion. The N-terminal domain of GyrA is the 
catalytic centre of gyrase, which harbours the DNA cleavage–reunion activity, and the 
C-terminal domain of GyrA is involved in binding and wrapping the DNA.  Recent 
research shows that Y577, R691 and R745 are among the key DNA-binding residues 
in the C-terminal domain of M. tuberculosis GyrA, and that the  third blade of the 
GyrA C-terminal domain is the main DNA-binding region (Huang et al., 2006). The 
pairwise comparisons of the gyrase proteins from M. tuberculosis and M. smegmatis 
showed that GyrA of M. smegmatis shares 88.5% identity and 93.9% similarity with 
that of M. tuberculosis at the amino acid level. M. smegmatis GyrB is also highly 
homologous (86% amino acid sequence identity) to M. tuberculosis GyrB protein. 
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 There are two structural differences between E. coli and M. tuberculosis 
DNA gyrase. There is an insertion of 170 amino acids within the Toprim fold of  
E. coli GyrB that is not present in M. tuberculosis. In order to understand the 
significance of this insertion, a crystal structure has been solved (PDB code: 3NUH) 
for this insert sequence along with the DNA binding and cleavage core of E. coli 
gyrase (Schoeffler et al., 2010). The insert adopts a novel fold that contacts the 
associated GyrA subunit (Figure 1.15, D). Mutagenesis experiments involving the 
deletion of this insert sequence affect DNA supercoiling and relaxation by ~25 fold 
with a less severe impact on DNA cleavage. The insert was also shown to be 
important for DNA binding and DNA-dependent stimulation of ATPase activity. 
Although the modelling studies do not indicate direct contacts between the insert and 
DNA, it is proposed that the insert stabilises the DNA gate of gyrase in a 
conformation that favours G-segment binding and also acts as a relay between the 
DNA gate and either the ATP- or C-gate to communicate conformational signals. 
This study has led to further refinement of the strand passage model for DNA gyrase 
having the insert. Recently there have been several crystal structures of different 
domains of M. tuberculosis DNA gyrase. Crystal structures of GyrA N-terminus 
(PDB code: 3ILW; 3IFZ), GyrB C-terminus (PDB code: 2ZJT) and Toprim domain 
(PDB code: 3IGO) are available as shown in the Figure 1.17. Functional, 
biophysical and structural studies of the M. tuberculosis catalytic DNA gyrase 
reaction core (Toprim and the breakage-reunion domains) have also been performed 
(Piton et al., 2010). The structure of GyrA N-terminal domain (GyrA59) (PDB code: 
3ILW) is similar to E. coli GyrA59 (PDB code: 1AB4) with 44% sequence identity 
and 1.27Ǻ rmsd. The difference between the two proteins is in the loop containing 
helices α3 and α4 (Gly88-Ala92). The position of this loop in M. tuberculosis 
GyrA59 (an important region involved in acquiring quinolone-resistance mutation) is 
different from its location in E. coli GyrA NTD (Tretter et al., 2010).  
The crystal structure of GyrB C-terminus from 485-714 residues (PDB code: 
2ZJT), indicated by GyrB´, has a crab-shape organisation and consists of a tail and a 
Toprim domain (Fu et al., 2009). It is a dimer in the asymmetric unit and shows a 
pair of negatively charged antenna (R614/K639) on the top and an amphiphilic 
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surface (R534/R589 and D554/E555) on the bottom, which are conserved in 
sequence in prokaryotic topo II enzymes. This crystal structure has been helpful to 
study the possible way of T-segment navigation from the N gate to the DNA gate of 
DNA gyrase. It has been suggested that GyrB´ binds the G-segment of DNA through 
the two pairs of amphiphilic residues on the bottom and the positively charged 
antenna interact with DNA duplex (T-segment). Mutational studies have 
demonstrated that the negatively charged residues on the tail groove are essential for 
the T-segment transport. A sluice-like model (Figure: 1.16) was proposed to explain 
the T- segment navigation. According to the model, once the T-segment is captured 
by the N-gate and docked in the opened groove, strong charge-charge repulsion 
occur between the phosphate groups on the DNA backbone and the negatively 
charged residues present on the groove bottom (Figure 1.16). This repulsive force 
may generate torsion on the Toprim dimer, which results in the opening of GyrB´ 
dimer.  Besides the electrostatic tension, the model also takes into account the energy 
from ATP hydrolysis to open the GyrB´ dimer. It is suggested that the ATP 
hydrolysis may provide energy for switching GyrB´ from a closed to an open state, 
and electrostatic repulsion may be responsible for the opening of Toprim domain (Fu 
et al., 2009). 
 
Figure 1.16: Electrostatic map of the GyrB' dimer and DNA duplex showing the 
sluice like model for T-segment navigation involving strong charge-charge 
repulsion (Fu et al., 2009). 
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 Figure 1.17: Crystal structures of different domains of M. tuberculosis DNA gyrase. (A) Crystal structure of M. tuberculosis 
GyrA59 (Tretter et al., 2010) ,(B) Toprim domain and (C) M. tuberculosis GyrB C-terminal domain (GyrB´) (Fu et al., 2009). 3ILW and 
3IGO were redrawn with PyMOL 1.01.  
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1.5.2 DNA gyrase strand passage mechanism  
The DNA gyrase follows the general mechanism of type II topoisomerases for 
strand passage. A double-stranded break is made in the G segment and the T segment 
(another duplex) is passed through the G segment, followed by religation of the broken 
ends of the G segment. Each cycle of strand passage changes the linking number of 
DNA by two (Brown et al., 1979). A  characteristic feature of strand passage in DNA 
gyrase is  the wrapping of approximately 140 bp DNA around the C-terminal domain 
of the GyrA subunits, presenting the T segment to the ATP-operated clamp 
(Champoux, 2001). 
1.5.3 DNA wrapping by DNA gyrase 
DNA gyrase can catalyse DNA supercoiling due it unique carpability to wrap a 
segment of DNA (which contains the G segment) around the enzyme in such a way as 
to present a T segment to the ATP-operated clamp (Heddle et al., 2004, Reece & 
Maxwell, 1991, Liu & Wang, 1978a). The wrapping function residues (‘GyrA-box’ 
motif) reside in the C-terminal domain of GyrA which has a β-propeller fold 
(Ruthenburg et al., 2005, Corbett et al., 2004) (Figure 1.18 A,B).  It has been 
demonstrated in previous studies that an E. coli GyrA C-terminal truncation mutant 
lacks supercoiling activity while retaining the relaxation activity due to the loss of the 
DNA-wrapping domain (Kampranis & Maxwell, 1996). The DNA wrapping around 
the GyrA C-terminal domain is positive in nature (Kampranis et al., 1999a). Similarly, 
the GyrA C-terminal domain is essential to M. tuberculosis DNA gyrase. Site-directed 
mutagenesis experiments have shown that Y577, R691 and R745 are among the key 
DNA-binding residues in M. tuberculosis GyrA-CTD, and that the third blade of the 
GyrA-CTD is the main DNA-binding region in M. tuberculosis DNA gyrase. The 
substitutions of Y577A, D669A, R691A, R745A and G729W led to the loss of 
supercoiling and relaxation activities, with little effect on the drug-dependent DNA 
cleavage & decatenation activities. There was also no effect on the ATPase activity 
(Huang et al., 2006). 
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A recent crystal structure of Xanthomonas campestris GyrA C-terminal domain 
(Figure 1.18B) (PDB code: 3L6V) and site-directed mutageneis experiments have 
revealed that the conserved β-strand bearing proline contributes directly to gyrase’s 
negative supercoiling activity (Hsieh et al., 2010). 
 
Figure 1.18: Crystal structures of GyrA C-terminal domain. (A) Crystal structure 
of Borrelia burgdorferi GyrA C-terminal domain (PDB code: 1SUU) (Corbett et al., 
2004) and (B) Crystal structure of Xanthomonas campestris GyrA C-terminal domain 
(PDB code: 3L6V) (Hsieh et al., 2010). 
1.5.4 DNA cleavage-religation reaction by DNA gyrase 
Studies with   E. coli   DNA gyrase have demonstrated the involvement of both 
gyrase subunits in the cleavage-religation reaction. In the case of GyrA, the cleavage-
religation reaction involves the formation of a 5'-phosphotyrosine intermediate and 
residues Arg 32, Arg 47, His 78 and His 80 cooperate with the active-site tyrosine 
residue on the opposite subunit of the GyrA dimer during the cleavage-religation 
reaction. These residues affect only the DNA cleavage reaction (Hockings & Maxwell, 
2002). Glu424, Asp498, Asp500 and Asp 502 in GyrB have been proposed to 
coordinate Mg2+ for the cleavage-religation reaction. Studies involving the role of 
GyrB in the cleavage-religation reaction provided evidence to support the idea that 
cleavage of each DNA strand involves two or more metal ions. The two metal-ion 
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mechanism for DNA cleavage by DNA gyrase involves polarisation of tyrosine by 
Mg2+, which undergoes deprotonation by His 78 or His 80 of GyrA. The tyrosine 
residue attacks the phosphate group of DNA and forms a negatively charged 
pentacovalent phosphate intermediate that is stabilised by two metal ions (Mg 2+).  
The 3'-bridging oxygen atom is stabilised by Mg 2+ to make a 3'-oxyanion that 
results into 3'-hydroxyl group by an unidentified acidic group (Figure 1.19) (Noble & 
Maxwell, 2002). It also has been shown by biophysical and thermal stability 
experiments that DNA is required for the effective two-site coordination of divalent 
ions (Sissi et al., 2008). 
 
Figure 1.19: The two-metal ion mechanism for cleavage-religation reaction 
(Noble & Maxwell, 2002). 
 
 
  
Chapter 1 
 
52 
 
 1.5.5 ATP hydrolysis by DNA gyrase 
Another characteristic feature of DNA gyrase in comparison to other type II 
topoisomerases is the ATP-dependent DNA supercoiling and ATP-independent 
relaxation activity. The GyrB subunit has the ATP-binding site and ATP/ADPNP 
causes the subunits to dimerise. A crystal structure for the 43-kD N-terminal GyrB 
fragment complexed with ADPNP (PDB code: 1EI1) (Brino et al., 2000, Wigley et al., 
1991)  shows the dimerisation of the GyrB N-terminal domain. The significance of 
ATP hydrolysis is clear: DNA gyrase is capable of introducing negative DNA 
supercoils, which is an energetically unfavourable process.  
 
Figure 1.20: Interaction between GyrB24 and ATP showing hydrogen-bonds 
with different residues (Oblak et al., 2007). 
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The important residues involved in ATP binding (Figure 1.20) based on the  crystal 
structure of 43-kDa N-terminal GyrB fragment complex with ADPNP (PDB code: 
1EI1) are as follows (Maxwell & Lawson, 2003): 
1. Glu42 behaves as a catalytic base and removes a proton from water promoting 
nucleophilic attack on the γ-phophate of ATP (Jackson & Maxwell, 1993). 
2.  His38 stabilises Glu-42 and Lys337 forms hydrogen bonds with the ATP 
molecule (Jackson & Maxwell, 1993, Smith & Maxwell, 1998). 
3. Lys103 forms a salt bridge to the β-phosphate of the ATP molecule (Wigley et 
al., 1991) and Asn46 forms a hydrogen bond with the ATP molecule and helps 
coordinate the Mg2+  (Wigley et al., 1991). 
Water molecules also play an important role and form a H-bond network 
with the adenine ring of ATP, and residues Asp73, Gly77 and Thr165. Pro79 and 
Lys103 have been suggested to be required for coupling of ATP hydrolysis to 
DNA supercoiling activity (Gross et al., 2003). The crystal structure of the ParE43-
ADPNP (PDB code: 1S16) is similar to the crystal structure of GyrB43-ADPNP 
complex (PDB code: 1EI1) and upon superimposition of the ADPNP structures 
both the ParE and GyrB ATP-binding sites are nearly identical, as the positions of 
the majority of essential residues for ATP binding and hydrolysis are conserved. 
The only difference is presence of Met74 rather that Ile78 found in GyrB. This 
difference is important in terms of the novobiocin potency for topo IV and DNA 
gyrase. Novobiocin is a 5-10-fold less potent inhibitor of  E. coli topo IV compared 
to E. coli DNA gyrase (Bellon et al., 2004). Mutation of Met74 in ParE to Ile 
increases the potency of novobiocin by 18-fold compared to the wild-type enzyme. 
Vice-versa in GyrB, resulted in a 22-fold decrease in novobiocin affinity (Oblak et 
al., 2007). 
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1.5.6 DNA gyrase in eukaryotes 
DNA gyrase is also found in eukaryotes such as Plasmodium falciparum, 
Plasmodium vivax and Arabidopsis thaliana. Plasmodium falciparum, has both 
subunits A (PfGyrA) and B (PfGyrB) that are targeted to the apicoplast (Dar et al., 
2007). These subunits are also present in P.  vivax.  Full length PfGyrB shows intrinsic 
ATPase activity in the absence of PfGyrA or DNA.  Heterologous expression of 
PfGyrA is difficult due to the presence of asparagines and lysine-rich-repeat regions 
and the unusual codon usage in Plasmodium (Dar et al., 2009). In Arabidopsis 
thaliana, four putative gyrase subunit genes were identified, out of which one is 
homologous to the GyrA subunit and the other three are homologous to the GyrB 
subunits (Wall et al., 2004). One of the GyrB homologues has been shown recently not 
to be a gyrase subunit (Evans-Roberts et al., 2010). 
1.6 Type IIB topoisomerases 
 Topoisomerase VI belongs to the type IIB topoisomerase family and it was 
first discovered in Sulfolobus shibatae (Bergerat et al., 1997). Type IIB 
topoisomerases catalyse ATP-dependent relaxation of negatively or positively 
supercoiled DNA with a preference for decatenation over relaxation (Buhler et al., 
2001, Corbett & Berger, 2004). Topo VI, like bacterial topoisomerases consists of 
two subunits and functions as an A2B2 heterotetramer. Both type IIA and type IIB 
topoisomerases have descended from a common ancestor (Corbett & Berger, 2003). 
Topo VI has no obvious homology to other type II topoisomerase except for 
the ATPase domain (Bergerat et al., 1997). Sequence alignment has shown that the 
conserved Toprim fold found in type IA and type IIA topoisomerase is also present in 
the subunit A of topo VI (Aravind et al. 1998). The striking difference between type 
IIA and IIB topoisomerases is the lack of a cavity for the T-segment and therefore it is 
likely that the strand passage mechanism is different. The subunit A of topo VI is 
homologous to the eukaryotic meiotic recombination factor, Spo11, which catalyses 
double-strand breaks during meiosis (Keeney et al., 1997).  However, Spo11 does not 
rejoin the double-strand breaks and it does not have an equivalent of the B subunit. 
The B subunit  has the characteristic transducer and GHKL domains (Corbett & 
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Berger, 2003) (Figure 1.21, A). A complete structure of topoVI from Methanosarcina 
mazei with 4.0 Ǻ resolution is now available. The structure shows a 220-kDa 
heterotetramer with‘twin-gate’ architecture (Figure 1.21, B). 
  
 
Figure 1.21: Crystal structure of topo VI. (A) Structure of complete topo VI (PDB 
code: 2Q2E) (Corbett et al., 2007) (B) topo VI-B (PDB code: 1MX0) (Corbett & 
Berger, 2003). 
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1.7 DNA gyrase inhibitors 
Since DNA gyrase is the only topoisomerase that can catalyse the introduction 
of negative supercoils into DNA, it has been exploited as a drug target. It has been 
possible to develop inhibitors that inactivate gyrase without substantially affecting its 
human counterpart, topo II (Gatto et al., 1999). DNA gyrase is the target of the 
fluoroquinolones (eg.ofloxacin, ciprofloxacin, sparfloxacin, moxifloxacin, 
gatifloxacin), aminocoumarins (novobiocin, clorobiocin), simocyclinones (eg. 
simocyclinone D8), cyclothialidines, CcdB and microcin B17 (Figure 1.22). 
 
Figure 1.22: The DNA gyrase reaction and sites of action of gyrase inhibitors 
(Nakada et al., 1994). 
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1.7.1 Fluoroquinolones 
Fluoroquinolones (7-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acids) 
(Figure 1.23) have few toxic side effects, good pharmacokinetic properties and 
potent activity against Gram-positive, Gram-negative and mycobacterial strains. 
Norfloxacin was the first of a new generation of fluoroquinolone antibacterial. They 
bind reversibly to the enzyme-DNA complex and stabilize the covalent enzyme 
tyrosyl-DNA phosphate ester, which is normally a transient intermediate in the 
topoisomerase reaction. Hydrolysis of this linkage leads to the accumulation of 
double-stranded DNA fragments and is the bactericidal consequence of 
fluoroquinolone treatment. Fluoroquinolones are being used in cases of MDR-TB 
and have a great potential for shortening treatment duration and improving therapy of 
TB-HIV co-infections. Recently a low-resolution crystal structures (4 Ǻ) of cleavage  
complexes formed by the S. pneumoniae 55-kD ParC breakage-reunion and 30-kD 
ParE Toprim domains of topoisomerase IV stabilized by moxifloxacin and 
clinafloxacin (Figure 1.24) have provided insights into the fluoroquinolone 
mechanism of action (Laponogov et al., 2009). The structures reveal that the 
fluoroquinolones intercalate at the bent gate DNA, stacked against DNA bases and 
are present in the drug-stabilised cleavage complex as shown in the Figure 1.25. 
They intercalate in the gap between the -1 and +1 nucleotide pairs of the cleaved 
DNA bound to topo IV.  
Studies in the past have identified consensus sequences for fluoroquinolone-
mediated DNA cleavage by Gram-negative and Gram-positive type II 
topoisomerases. Wild type and mutated consensus sequences showed the following 
features: 
 (1) Gn/Cn-rich sequences at and around the cleavage site are hot spots for 
quinolone-mediated strand breaks. 
(2) Symmetry of the target sequence is important for cleavage. 
(3) In case of S. pneumoniae, A and T at position -2 and +6 are cleavage 
determinants. 
 (4) The consensus sequence adopts a heteronomous A/B conformation (Richter et 
al., 2007).  
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In the crystal structure the C-7 substituent of the quinolone interacts with 
DNA base pairs while the 3-carboxyl group contacts S79 (equivalent to positions 83 
in E. coli GyrA) and is close to S80 (A84 of GyrA). Formation of a Mg2+- bridge is 
important for drug binding due to the Mg2+- dependence of complex formation (Sissi 
et al., 2001). Figure 1.25 also shows the residues in ParC (S79, D83) that are 
responsible for drug resistance upon mutation. Similarly, in the case of ParE, the 
residues (E474, E475, R456 and D435) responsible for drug-resistance are located 
within the Toprim domain and are close to the intercalated drug. 
 
Figure 1.23: Structures of Flurooquinolones (Drlica et al., 2008). 
 
   However, the existing DNA intercalation model has its limitations. It cannot 
explain the effects of certain amino acid substitutions and drug structure variations. For 
example the putative interaction of the C-7 substituent with position 81 as described 
above and the drugs substituent at position 1 and 8 that alter both the antimicrobial 
activity and drug-target binding constant (Barnard & Maxwell, 2001). Thus, quinolone 
binding is a multi-step process that involves at least two steps before and after the 
DNA cleavage (Critchlow & Maxwell, 1996, Marians & Hiasa, 1997).  
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A Crystal structure with a resolution of 3.35 Ǻ of S. aureus DNA gyrase in 
complex with fluoroquinolone and DNA is also available (2XCT) (Bax et al., 2010). 
This structure provides insights into how DNA is cleaved by type IIA topoisomerases 
and the role of the metal-binding Toprim domains in catalysis (Figure 1.26). 
 
Figure 1.24: Crystal structure of the topo IV-DNA-moxifloxacin complex. 
 Front (A) and top views (B) of topo IV ParC55 (blue) and ParE30 (yellow) protein 
complex with the G-segment DNA (green) and moxifloxacin (red) (Laponogov et al., 
2009). A & B both are represented in space-filling and ball-and-stick models. 
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 Figure 1.25: Quinolone-topo IV cleavage complex.  
(A) The DNA G-segment is in green with numbers indicating the backbone position 
relative to the cleavage point. (B) Top view of the cleaved G-segment DNA molecule 
(green) attached to the Y118 with intercalated moxifloxacin molecules (red) 
(Laponogov et al., 2009). 
 Figure 1.26: S. aureus DNA gyrase in complex with ciprofloxacin and DNA 
(dimer in an asymmetric unit) (2XCT) (Bax et al., 2010). Arrows point to 
ciprofloxacin molecules (spheres).    
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At the cellular level, it was proposed that the irreversible collision of 
replication forks with quinolone-mediated complexes is the primary reason for cell 
death (Khodursky & Cozzarelli, 1998). Reactive oxygen species such as hydroxyl 
radicals also play an important role in amplification of lethality due to quinolones. The 
hydroxyl radicals are generated via the Fenton reaction due to iron-misregulation 
following gyrase poisoning due to quinolones. The iron misregulation occurs due to 
superoxide-mediated oxidation of iron-sulfur clusters (Dwyer et al., 2007). There is 
also a difference in the lethality of different generations of quinolones under different 
conditions. For example, first-generation compounds such as nalidixic acids are not 
lethal in the presence of chloramphenicol or during anaerobic growth. On the other 
hand, ciprofloxacin, a third generation compound kills under both conditions but 
requires higher concentration during anaerobiosis. In the case of M. tuberculosis, 
moxifloxacin is more active when chloramphenicol is added (Malik & Drlica, 2006). 
Fluoroquinolones are effective in killing bacteria in the presence of chloramphenicol, 
when the lethal chromosome fragmentation due to quinolones requires on-going 
protein synthesis. Chloramphenicol blocks the formation of lesions. The connection 
between cleaved complex destabilisaiton and chloramphenicol-insensitive killing also 
provides information about the effects of quinolone structure. For example, the N-1 
cyclopropyl group is probably important for cleaved complex destabilisation, since this 
moiety is the only difference between ciprofloxacin and norfloxacin. Ciprofloxacin 
kills in the presence of chloramphenicoal and norfloxacin does not (Drlica et al., 
2008). Besides chloramphenicol, Lon protease may be involved in the repair of lethal 
lesions due to quinolones. Lon protease has been shown to have a role in chromosome 
maintenance when studying the survival of bacteria at high quinolone concentration 
(Crumplin & Smith, 1975). 
Despite the lethal actions of fluoroquinolones, resistance to fluoroquinolone is 
acquired by genetic variations that reduce drug concentration or reduce the affinity of 
the compounds for its target. The drug concentration plays an important role in 
determining if non-target or target alleles are selected for mutation. In the case of 
mycobacteria, mutations in the non-target alleles have been observed due to initial low 
drug concentrations (Zhou et al., 2000). Thus, the effect of drug concentration on the 
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mutation has led to the coining of a term called the ‘mutant selection window’which is 
a drug concentration range that is above the minimum inhibitory concentration (MIC) 
but below mutant prevention concentration (MPC) (Drlica, 2003). MIC is the lowest or 
minimum concentration of drug that blocks the growth of the majority of drug-
susceptible cells. MPC (Smith et al., 2003) on the other hand is the drug concentration 
that blocks the growth of the least susceptible, single-step mutant. Above this 
concentration, cell growth required the presence of two or more resistance mutations. 
In other words, MPC is the MIC of the least susceptible single-step mutant (Smith et 
al., 2003). 
QRDR mutations have been the principle factor behind fluoroquinolone 
resistance. The quinolone-resistance-determining region (QRDR) is the region that 
contains those amino acids whose mutation leads to quinolone resistance. GyrA amino 
acids changes that result in resistance to fluoroquinolone are predominantly in the 
QRDR. The presence of a single mutation in the QRDR usually results in low-level 
resistance to fluoroquinolone; to obtain high levels of resistance, additional mutations 
in GyrA are required. The QRDR (Piton et al., 2010) of M. tuberculosis is similar to 
those from other organisms. It is located at the highly conserved N-terminal region of 
GyrA, and the mutations associated with fluoroquinolone resistance in clinical isolates 
of M. tuberculosis are located in codons equivalent to those in gyrA genes from 
fluoroquinolone-resistant mutants from other bacteria (Goswitz et al., 1992, Hopewell 
et al., 1990, Yoshida et al., 1990). Laboratory generated quinolone-resistant mutants of 
M. tuberculosis usually have single missense mutations in gyrA for low-level 
resistance, and two mutations in gyrA, or one mutation in gyrA and one in gyrB for 
high level resistance (Kocagoz et al., 1996). The regions of gyrB that encode common 
mutations that lead to resistance to coumarins and quinolones are also highly 
conserved between M. tuberculosis and other bacteria (Takiff et al., 1994). A study 
analyzing mutations in both gyrA and gyrB associated with quinolone resistance 
identified a novel N510D mutation in gyrB that was also associated with quinolone 
resistance. This study also found that while strains that carry the novel GyrA T80A 
mutations were slightly resistant to quinolones, several isolates carrying a combination 
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of GyrA T80A plus A90G mutations were hypersusceptible to quinolones (Aubry et 
al., 2006b).  
Another study investigated the enzymatic efficiency and quinolone sensitivity 
of M. tuberculosis GyrA carrying a mutation at position G88 (Matrat et al., 2006). G88 
in M. tuberculosis GyrA corresponds to G81 in E. coli.  The residue is predicted to be 
involved in the quinolone-binding site. This study clearly established that GyrA G88C 
and G88A mutations conferred resistance to fluoroquinolones in M. tuberculosis by 
decreasing gyrase inhibition. This study further found that quinolones that do not have 
an R7 ring or fluorine in R6, minimum inhibitory concentrations (MICs) were similar 
for the G88A mutants and the H37Rv strain. IC50s for the mutant enzymes with both 
the G88C and G88A were also similar to the IC50 for the wild-type enzyme.  
M. tuberculosis GyrA protein contains an alanine at the position homologous to serine 
83 in the E. coli enzyme. Substitution at this position to a hydrophobic residue leads to 
drug resistance as in case of S83W (Guillemin et al., 1998, Guillemin et al., 1999). 
However, the most common mutations in fluoroquinolone resistant M. tuberculosis 
clinical isolates are still due to substitutions at codons 90 and 94 of gyrA, whose E. coli 
equivalents are also resistance determinants. A list of mutations in DNA gyrase 
subunits conferring resistance to fluoroquinolone in E. coli and M. tuberculosis are 
summarised in Table 1.2. 
Besides spontaneous mutation in the target gene, three forms of plasmid-
mediated quinolone resistance have also been identified. These are Qnr (Martinez-
Martinez et al., 1998), Aac(6´)-Ib-cr  (Robicsek et al., 2006b)  and QepA (Yamane et 
al., 2008). Of the three, Qnr appears to have the most activity, followed by QepA and 
Aac(6´)-Ib-cr.  Qnr increases MIC up to 250- fold, while QepA and Aac(6´)-Ib-cr 
increase MIC by 10-fold (Perichon et al., 2007) and 4-fold respectively (Robicsek et 
al., 2006b). Qnr will be discussed in brief here. 
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DNA gyrase subunits E. coli M. tuberculosis 
GyrA Ser-83→Leu; 
Ser-83→Trp; 
Asp-87→Asn; 
Gly-81→Cys; 
Ala-84→Pro; 
Ala-67→Ser; 
Gln-106→His. 
Thr-80→ Ala;  
Gly-88→Cys;    
Asp-89→ Asn; 
Ala-90 → Val;  
Ser-91→ Pro; 
Asp-94→ Ala 
Asp-94→ Asn, 
Asp-94→His, 
Asp-94→Gly,  
Asp-94→ Tyr. 
GyrB Asp-426→ Asn; 
Lys-447→ Glu. 
 
Asn-533→Thr; 
Asn-510→Asp. 
Table 1.2: Mutations in the DNA gyrase subunit conferring resistance to 
fluoroquinolone (Takiff et al., 1994, Von Groll et al., 2009, Yoshida et al., 1990, 
Kocagoz et al., 1996, Yoshida et al., 1991). 
Qnr was discovered in a strain of K. pneumoniae exhibiting resistance to 
fluoroquinolone and 13 other agents (Martinez-Martinez et al., 1998). QnrA is a 218 
amino acid protein that belongs to a large family characterised by pentapeptide repeats. 
A Qnr homologue, MfpA found in mycobacteria has provided insights into how gyrase 
is protected from quinolones (Hegde et al., 2005, Montero et al., 2001). The three-
dimensional structure of MfpA revealed that it is a dimer and appears to be a DNA 
mimic (Figure 1.27). It has size, shape and electrostatic similarity to B-form DNA 
(Hegde et al., 2005). 
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Figure 1.27: MfpA, Qnr homologue found in M. tuberculosis. (A) Molecular 
model of MfpA bound to E. coli GyrA59. (B) MfpA dimer showing its similarity to B-
DNA (Hegde et al., 2005). 
    In general, Qnr proteins lower quinolone binding to DNA complexes formed 
with gyrase or topo IV (Tran et al., 2005b) and reverse quinolone-mediated inhibition 
of the gyrase supercoiling activity (Tran et al., 2005a). It is likely that Qnr acts by 
altering the DNA-binding properties of gyrase rather than by competitive binding to a 
quinolone interaction site (Tran et al., 2005a). qnr is expect to cause a serious 
resistance problems due to following two reasons: 
1. Firstly, often plasmids having a QnrA determinant also carry genes that 
provide resistance to other anti-bacterials such as chloramphenicol and 
sulphonamides (Nordmann & Poirel, 2005).  
2. Qnr-expressing plasmids are widely distributed (Nordmann & Poirel, 2005). 
  
Chapter 1 
 
66 
 
     QepA and Aac(6´)-Ib-cr  has not been extensively studied in comparisons to 
Qnr. Aac(6´)-Ib-cr adds an acetyl substituent on the nitrogen atom of the C-7 
piperazinyl ring (Robicsek et al., 2006b),  but it has no effect on quinolones such as 
levofloxacin and gemifloxacin lacking piperazinyl nitrogen (Robicsek et al., 2006a). 
The QepA efflux pump was found in a clinical isolated of E. coli in 2006. QepA 
increases the MIC for fluoroquinolones such as ciprofloxacin by 10-fold (Perichon et 
al., 2007).  
Thus, although quinolones continue to be an important class of antimicrobial 
agent, bacterial resistance is increasing (Boyd et al., 2008). 
1.7.2 Aminocoumarins  
Aminocoumarin are naturally occurring products of Streptomyces species that 
share common structural features: a 3-amino-4, 7-dihydroxycoumarin structure, an L-
noviosyl sugar and an aromatic acyl component attached to the amino group of the 
aminocoumarin moiety. Novobiocin, coumermycin A1 and clorobiocin are the three 
naturally-occurring aminocoumarins produced by S. spheroides, S. rishiriensis and S. 
roseochromogenes, respectively (Pojer et al., 2002). The difference in clorobiocin and 
novobiocin is the substitution of the methyl group at the 8´ position of the coumarin 
ring with chlorine atom and a 5-methyl-pyrrole-2-carboxyl group substitutes the 
carbamoyl group at the 3´ position of the noviose. Coumermycin A1 has coumarin 
rings attached to the either side of a pyrrole group; a substituted sugar is attached to 
each of the coumarin rings, and a pyrrole group is attached to each noviose sugar 
(Figure 1.28).  
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Figure 1.28: The three main naturally-ocurring aminocoumarins: Novobiocin, 
clorobiocin, and coumermycin A1 (Oblak et al., 2007).  
  Aminocoumarin drugs act by competitively inhibiting the ATPase activity of 
GyrB (Gormley et al., 1996, Maxwell, 1997). The interactions of aminocoumarin with 
E. coli DNA gyrase is extremely well characterised.  Crystal structures of novobiocin 
and clorobiocin (PDB code: 1KZN) in complex with the  GyrB  N- terminus (GyrB24) 
(Holdgate et al., 1997, Lafitte et al., 2002, Maxwell & Lawson, 2003, Lewis et al., 
1996) and Thermus thermophilus  GyrB43 complexed with novobiocin  (PDB code: 
1KIJ ) (Lamour et al., 2002) are available. The crystal structures clearly show an 
overlap in the binding site of ATP and the aminocoumarin. In the case of novobiocin 
the binding site of the noviose sugar and the adenine ring of the ATP/ADPNP 
molecule overlap (Figure 1.29). 
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Figure 1.29: Overlap of the novobiocin (green) and ADPNP (red) binding site at 
E. coli GyrB N-terminus (GyrB24). 
   Novobiocin is licensed for the treatment of infections by some Gram-positive 
organisms and has been shown to be able to enhance the cytotoxic activities of the 
anti-tumour drugs etopside and teniposide (Maxwell & Lawson, 2003). Despite the 
fact that aminocoumarins are potent inhibitors of DNA gyrase, due to their poor 
solubility, high toxicity and ineffectiveness against Gram-negative bacteria they have 
limited potential as drugs. The aminocoumarins are ineffective against Gram-negative 
due to the problem with antibiotic uptake across the bacterial outer membrane (Chusri 
et al., 2009). Novobiocins under the trade name albamycin and cathomycin have been 
withdrawn. 
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1.7.3 Simocyclinones 
     Simocyclinones are a class of new antibiotics that were isolated from 
Streptomyces antibioticus TÜ 6040 (Holzenkampfer et al., 2002, Theobald et al., 
2000, Schimana et al., 2000). Simocyclinone has an aminocoumarin ring but in 
contrast to other aminocoumarin antibiotics, it does not contain an L-noviosyl sugar 
at the 7-OH of the aminocoumarin ring; another sugar, D-olivose, is attached to the 
acyl moiety (which is a tetraene dicarboxylic acid) by an ester bond. This D-olivose 
is glycosidically linked to an angucyclic polyketide. The main simocyclinone 
produced by Streptomyces antibioticus TÜ 6040 is simocyclinone D8 (Figure 1.30, 
B).  In addition to simocyclinone D8, 13 other polyketide containing compounds 
have been isolated from Streptomyces antibioticus TÜ 6040 (Theobald et al., 2000). 
These simocyclinones can be grouped into four classes (A-D) depending upon their 
structure. These classes are defined by the presence of different functional groups in 
polyketide (R1), D-olivose (R2), coumarin (R3) parts. The production of different 
proportions of simocyclinones can be affected by the media composition and 
fermentation conditions (Schimana et al., 2001) (Theobald et al., 2000). 
Characterisation and cloning of the simocyclinone D8 biosynthetic gene cluster has 
revealed 49 open reading frames that code for genes responsible for the synthesis of 
the four distinct parts of simocyclinone D8 (Trefzer et al., 2002). 
  Simocyclinone D8 has weak inhibitory activity only against Gram-positive 
bacteria (Schimana et al., 2000).  Wild-type E. coli and other Gram-negative bacteria 
are resistant to simocyclinones because the compounds cannot penetrate the outer 
membrane (Schimana et al., 2000). In a recent study (Edwards et al., 2009), E. coli 
strain (NR698) was used to isolate simocyclinone-resistant mutants because it carries 
an in-frame deletion in the imp (increased membrane permeability) gene (Ruiz et al., 
2005) and is sensitive to simocyclinone. It has also been suggested that efflux pumps 
such as the AcrB multidrug efflux pump may be responsible for the ineffectiveness 
of simocyclinones against Gram-negative bacteria (Oppegard et al., 2009). In the 
producing organism, it is suggested that regulation at the level of TetR repressor 
SimR and a proton dependent transporter SimX may be responsible for the resistance 
mechanism and thus preventing suicide of the producer (Le et al., 2009). 
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Simocyclinone D8 can also inhibit human topoisomerase II with an IC50 of 100 µM, 
more potent than etoposide with an IC50 of 400 µM (Sadiq et al., 2010). 
 
 
Figure 1.30: Simocyclinone D8 binds to GyrA59. Crystal structure (PDB code: 
2WL2) of Simocyclinone D8-GyrA59 complex (A: top panel). Structure of 
Simocyclinone D8 showing the polyketide and coumarin moieties (B: bottom panel) 
(Edwards et al., 2009). 
  Studies in the past involving simocyclinone D8  with E. coli DNA gyrase 
suggested that simocyclinones inhibit an early stage of the gyrase catalytic cycle by 
interacting with the N-terminal domain of GyrA and  preventing binding of the 
enzyme to DNA (Flatman et al., 2005). The recent crystal structure of the complex 
between the N-terminal domain of E. coli GyrA (GyrA59) and simocyclinone D8 
identified the binding site for the molecule and provides information about the 
mechanism of action (Edwards et al., 2009). The structure revealed two distinct 
binding sites for simocyclinone D8 within each GyrA59 monomer, one for the 
aminocoumarin moiety and one for the polyketide moiety. In the crystal structure 
(Figure 1.30, A), two GyrA59 dimer are non-covalently crosslinked by four 
simocyclinone D8 molecules. Each drug molecule binds the aminocoumarin-binding 
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site of a GyrA59 monomer of one dimer and the polyketide-binding site of a GyrA59 
monomer of another dimer. 
Analysis of the GyrA59-simocyclinone D8 complex revealed that the 
distance between the aminocoumarin-and polyketide-binding sites is equal to the 
length of the tetraene chain which links the aminocoumarin and polyketide moieties 
of simocyclinone D8. This has led to the proposal that simocyclinone D8 is able to 
adopt an alternative configuration where it stretches between the two sites within the 
same GyrA monomer. Nano-ESI MS data has revealed that simocyclinone D8 binds 
GyrA59 in a cooperative manner, with the binding of one molecule promoting the 
binding of a second (Edwards, 2009). Both ends of the simocyclinone D8 molecule 
are required for the positive cooperative binding. The simocyclinone D8 fragments, 
MGD8N2A (lacks the polyketide moiety) and simocyclinone C4 (lacks the 
aminocoumarin moiety) do not display positive cooperativity. 
Besides the N-terminal domain of  the GyrA subunit, a binding site for the 
drug has also been identified in the C-terminal domain of GyrB (GyrB47) (Sissi et 
al., 2010). It is suggested that these two distinct sites in both the subunits could 
cooperate in the reconstituted enzyme. The exact location for the binding of drug 
within GyrB47 is not known, but it is likely that interaction could be at the protein-
protein interface.    
1.7.4 Cyclothialidine 
      Cyclothialidine (Figure 1.31, A) contains a unique 12-member lactone ring that 
is partly integrated into a pentapeptide chain. Cyclothialidine was isolated from 
Streptomyces filipinensis NR0484 and acts by competitively inhibiting the ATPase 
activity of the GyrB subunit (Nakada et al., 1993, Nakada et al., 1994). The 
compound was also active against DNA gyrase resistant to novobiocin, suggesting 
that its precise site of action might be different from that of novobiocin.  However, 
cyclothialidine does not show any growth inhibitory activity against bacterial cells. It 
may be due to permeability problems across the cytoplasmic membrane (Goetschi et 
al., 1993) Investigation involving the identification of active structural components 
have directed the synthesis of a number of new inhibitors that have shown in vitro 
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activity against gram-positive pathogens (Angehrn et al., 2004, Goetschi et al., 
1993). 
The crystal structure of GyrB24 complexed with a cyclothialidine 
(GR122222X) has been determined to 2.0-Å resolution (Lewis et al., 1996) (Figure 
1.31, B). The majority of the protein-ligand interactions are between the resorcinol 
ring of cyclothialidine and GyrB24. The drug lies in a hydrophobic pocket and 
makes a number of hydrogen bonds with the amino acids such as Asn46, Asp73 and 
Thr165. The drug binding-site does not lie in the ATP-binding pocket of GyrB but 
partially overlaps with that of ATP. The resorcinol ring occupies a position that 
prevents binding of the adenine ring. 
 
 
Figure 1.31: Cyclothialidine inhibits the ATPase activity of the GyrB subunit. 
(A) Chemical structure of cyclothialidine (Tse-Dinh, 2007). (B) Crystal structure of 
GyrB24 complexed with a cyclothialidine (GR122222X) (Lewis et al., 1996). 
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1.7.5 GSK299423 
   In a recent publication (Bax et al., 2010), GlaxoSmithKline reported the  2.1 
Ǻ crystal structure (Figure 1.32, A) of a novel inhibitor GSK299423 (Figure 1.32, B) 
in a pre-cleavage complex with S. aureus DNA gyrase and a 20-bp DNA duplex (PDB 
code: 2XCS). GSK299423 is 2,000 times more potent than ciprofloxacin for inhibition 
of S. aureus DNA gyrase supercoiling.  It has been suggested that the compound does 
not stabilise the cleavage complex rather it generated single-strand breaks. These 
single-strand breaks seem to be associated with covalent phosphotyrosyl-protein–DNA 
complex formation. However, the gel-based assays do not provide any evidence for the 
formation of single-stranded breaks. 
The binding site of the drug is distinct from but close to the fluoroquinolone 
binding site. GSK299423 binds midway between the two active sites, with the 
quinoline-carbonitrile group sitting in between the two central base pairs of the 
stretched DNA and the oxathiolo-pyridine group occupying the non-catalytic pocket 
that opens up between the two GyrA subunits. The pocket between the two GyrA 
subunits occupied by the oxathiolo-pyridine group is largely hydrophobic, with 
residues Ala 68, Gly 72, Met 75 and Met 121 making van der Waals interactions with 
the compound.  The crystal structure also provides structural evidence of a second 
metal-binding site involved in the Toprim domain nucleotidyl phosphotransferase. 
 The publication also reported a 3.35 Ǻ structure complex with ciprofloxacin, 
providing detailed structural insight into how DNA is cleaved by type IIA 
topoisomerases. Comparison of these two structures indicates that for DNA cleavage, 
the correct positioning of the catalytic tyrosine on the CAP domain with respect to the 
Toprim domain seems to be achieved by a rigid body-domain movement.  The GyrB 
Asp 512– GyrA Arg A33 ion pair was also proposed to act as a conformational switch 
to help communicate information about the state of cleavage of the DNA from the 
active sites to the rest of the protein. 
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Figure 1.32: GSK299423 a novel DNA gyrase inhibitor. (A) Crystal structure of 
GyrB27-A56 fusion protein in complex with DNA and GSK299423. GSK299423 is 
shown in yellow and DNA in green colour. (B) Structure of GSK299423 (Bax et al., 
2010).  
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1.7.6 CcdB  
   CcdB is component of the ccd toxin-antitoxin (TA) module encoded by the 
F plasmid. CcdB is the toxin and CcdA is the antitoxin (Bahassi et al., 1999). CcdB 
inhibits the catalytic reactions of gyrase by stabilization of the cleavage complex 
(Bernard et al., 1993). The GyrA C-terminal DNA-wrapping domain and the GyrB 
N-terminal ATPase domains are dispensable for CcdB’s action. Based on the 
structure of CcdB (PDB code: 3vub) (Loris et al., 1999) and its complex with the N-
terminal domain of GyrA (PDB code: 1x75) (Dao-Thi et al., 2005) a model for CcdB 
action was proposed. The model suggested that a dimeric CcdB binds within the 
cavity formed by the GyrA dimer, but only when the DNA gate is open. This places 
the three C-terminal residues of CcdB (Trp99, Gly100 and Ile101) which are critical 
to its toxicity (Bahassi et al., 1995), in close proximity to the GyrA Arg462 residue. 
When this residue is mutated, it confers resistance to CcdB (Bernard & Couturier, 
1992, Bernard et al., 1993). The structure of CcdB with a fragment of GyrA 
(GyrA14; PDB code: 1x75) shows a symmetric complex, with an asymmetric centre 
where the GyrA Arg462 residue stacks between the Trp99 residues of the CcdB 
monomers.  
  While CcdB poisons gyrase, CcdA actively dissociates CcdB-gyrase 
complexes by a process called rejuvenation. The CcdA:CcdB ratio modulates 
autorepression of the ccd operon. Recent crystal structures of CcdB with fragments 
of CcdA (PDB code: 3HPW & 3G7Z) have provided insights into the mechanism 
behind rejuvenation and regulation of expression (Figure 1.33). This mechanism is 
complex and autoregulatory (De Jonge et al., 2009). 
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Figure 1.33: CcdB with multiple interacting partners: CcdA and DNA gyrase. 
Representation of CcdB2:CcdA37-72 and GyrA592:CcdB2complexes. GyrA592 is shown 
in orange surface representation and GyrA142 in red. CcdB2:CcdA37-72complex is 
represented as Cα traces inside the cavity of GyrA59 (De Jonge et al., 2009). 
1.7.7 Microcin B17 
   Microcins are antibacterial peptides encoded by genes located on plasmids, 
or on the chromosome, along with their self-immunity factors, secretion proteins and 
the post-translational modification enzymes. They have molecular masses below 10-
kD and are produced mainly by enterobacteria. They are ribosomally synthesised as 
precursors and further modified enzymatically. They are secreted under conditions of 
nutrient depletion. Fourteen microcins have been reported so far, among which only 
seven have been characterised and Microcin B17 is among the well characterised 
microcins (Duquesne et al., 2007). 
    Microcin B17 (MccB17) is a post-translationally-modified 43-amino acid 
peptide produced by strains of E. coli containing the plasmid-borne mccB17 operon. 
MccB17 results from the 69 amino acid McbA precursor that is modified by the 
mcbB, C and D gene products (Mcc synthetase). The genes mcbE and mcbF encode 
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two proteins involved in MccB17 secretion and self-immunity while the product of 
mcbG offers complete self-immunity (Garrido et al., 1988) (Figure 1.34, A). Serine 
and cysteine residues react with the carbonyl group of the preceding glycines to 
produce thiazole or oxazole rings. Thus MccB17 contains four oxazole and four 
thiazole rings; two thiazole and oxazole rings are in tandem as bis-heterocycles 
(Figure 1.34, B). The effect of MccB17 on bacteria is to arrest DNA replication and 
to induce the SOS response (Herrero & Moreno, 1986). It has been shown to target 
bacterial DNA gyrase by the isolation of a resistant mutant in the gyrB gene (Vizan 
et al., 1991). MccB17 has been reported to display potent bactericidal activity against 
a wide range of gram-negative bacteria including Escherichia, Klebsiella, 
Salmonella, Shigella and Pseudomonas (Duquesne et al., 2007). 
 
 
Figure 1.34: MccB17 chemical structure and gene cluster. (A) Different genes 
involved in MccB17 synthesis, modification and self-immunity in the gene cluster. (B) 
Structure of mature MccB17 having thiazole, oxazoles and bis-heterocycles 
(Duquesne et al., 2007). 
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MccB17 stabilises the gyrase-DNA covalent complex and this is responsible 
for its toxicity (Heddle et al., 2001).  It slows down both the DNA supercoiling and 
relaxation reactions of gyrase and can stabilise the covalent complex between the 
enzyme and DNA with and without ATP (Pierrat & Maxwell, 2003). With relaxed 
DNA as a substrate, MccB17 can stabilise a cleavage complex weakly in the absence 
of ATP but more efficiently in the presence of nucleotide. The peptide can stabilise a 
cleavage complex more efficiently in the absence of ATP if the DNA substrate is 
negatively supercoiled; this suggests that it is acting at an enzyme conformation, 
which arises either when ATP is being hydrolysed during the supercoiling cycle or 
during the ATP-dependent relaxation of supercoiled DNA. Inhibition of supercoiling 
and relaxation by MccB17 is due to the reduction of the rate of strand-passage by 
MccB17 (Pierrat & Maxwell, 2003). MccB17 interacts with the N-terminal domain 
of GyrA, the C-terminal domain of GyrB and/or DNA, exploiting an enzyme 
conformation that occurs during the topoisomerase cycle. Thus MccB17 has potential 
to guide the design of effective antibacterial by identify the active components of this 
peptide and using them as templates. 
 
1.8 Other proteinaceous inhibitors 
Other DNA gyrase inhibitors that have been discovered are either enzymes or 
proteins such MurI and YacG or small molecules like QPT-1. Glutamate racemase 
(MurI) catalyses the conversion of L-glutamate to D-glutamate. D-glutamate is an 
important component of the bacterial cell wall. It has been found that besides the 
catalytic activity of E. coli MurI, it also inhibits DNA gyrase in the presence of the 
peptidoglycan precursor. The requirement of the peptidoglycan precursor is not 
obligatory for the inhibitory activity of MurI, as out of two MurI in B. subtilis one 
inhibits DNA gyrase in absence of the precursor and M. tuberculosis MurI inhibits in 
the absence of the precursor. M. tuberculosis has a single gene for MurI and it 
inhibits DNA gyrase activity. The inhibitory activity of MurI is not species-specific 
rather it is enzyme-specific as topo I is not inhibited by it. MurI inhibitory activity is 
due to its selective binding to the GyrA subunit, which affects DNA binding. 
Although MurI inhibits DNA gyrase activity, Mur I protects M. smegmatis against 
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the action of ciprofloxacin. This indicates that MurI may be a survival strategy used 
by the cell to safeguard DNA gyrase. It can also have physiological role of 
preventing excessive supercoiling (Sengupta & Nagaraja, 2008a, Sengupta et al., 
2008, Sengupta et al., 2006). 
Similarly, other endogenous proteins in E. coli such as YacG and GyrI have 
DNA gyrase inhibitory activity. The GyrI protein was the first identified 
chromosomally nucleoide-encoded regulatory factor of E. coli DNA gyrase. It 
inhibits the supercoiling activity of DNA gyrase and overexpression and antisense 
expression of the gyrI gene-induced filamentous cell growth and suppressed cell 
proliferation (Nakanishi et al., 1998).  GyrI  binds to the gyrase holoenzyme with 
higher affinity than to either GyrA or GyrB alone (Nakanishi et al., 2002). Besides 
its inhibitory activity, it has also been shown to provide limited protection against the 
quinolones (Chatterji et al., 2003). 
 YacG is encoded by E. coli and has a zinc-finger motif.  It inhibits all the 
activities of DNA gyrase by preventing DNA binding.  It binds to the carboxy- 
terminal domain of GyrB.  Topo I and topo IV are not inhibited by YacG (Sengupta 
& Nagaraja, 2008b). 
 There are certain pentapeptide repeat proteins such as MfpA and QnrB4, 
which inhibit DNA gyrase activity. MfpA as described previously is present in M. 
tuberculosis (Hegde et al., 2005), while QnrB4 is encoded by a plasmid borne in 
enterobacteria. MfpA is more effective in inhibiting M. tuberculosis DNA gyrase 
activity in comparison to the inhibitory activity of QnrB4 against E. coli DNA 
gyrase. Both the proteins are involved in resistance to fluoroquinolone, but the 
QnrB4 activity is species specific (Merens et al., 2009). 
Besides the endogenous DNA gyrase inhibitors, the conventional high-
throughput screening of chemical libraries has discovered inhibitors such as QPT-1 
(Miller et al., 2008), which has activity against a broad spectrum of pathogenic and 
antibiotic-resistant bacteria. The molecule was non-toxic and targeted the β subunit 
of bacterial type II topoisomerase. An introduction to the novel DNA gyrase 
inhibitors discovered in this project is given in Chapter 4. 
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1.9 Aim of the project 
The aim of this Ph.D. project was to establish a fundamental understanding of  
M. tuberculosis DNA gyrase and explore it as a target for novel inhibitors. 
Bioinformatics analysis revealed some interesting features about the enzyme such as 
the presence of a putative Ca2+- binding site, which was investigated by biochemical 
and biophysical techniques. Further investigation of the enzyme lead to the discovery 
of naphthoquinones, aaptamines and quinolines as new classes of DNA gyrase 
inhibitors. 
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Chapter 2: Materials & Methods 
 
2.1 Bacteriology 
Different strains of Escherichia coli (E. coli), Mycobacterium smegmatis (M. 
smegmatis), growth medium and plasmids were used for microbiology and molecular 
biology experiments. 
2.1.1 E. coli and M. smegmatis strains 
The following E. coli and M. smegmatis strains listed in Table 2.1 were used in this 
study. 
 Strain Genotype 
BL21 E. coli  F– ompT hsdSB(rB –  mB –) gal dcm 
BL21 (DE3) pLysS E. coli 
  
F– ompT hsdSB(rB –  mB –) gal dcm (DE3) pLysS 
(CamR) 
Top 10 chemically 
competent E. coli  
 
 
F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 
∆lacΧ74 recA1 araD139 ∆(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG λ- 
DH5α chemically 
competent E. coli  
 
 
F- φ80lacZ∆M15 ∆(lacZYA-argF)U169 deoR recA1 
endA1 hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 
relA1 λ- 
M. smegmatis mc2155 wild-type 
Table 2.1: The list of  E. coli and M. smegmatis strains used in the study. 
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2.1.2 Media and antibiotics 
E. coli and M. smegmatis growth medium 
Luria-Bertani (LB) medium was used for the growth of different strains of  
E. coli in liquid media. The liquid media was used for growing transformed colonies 
for plasmid propagation and for protein expression. The autoclaved liquid medium 
after preparation was stored at room temperature. The recipe for the medium is as 
follows: 
 
The solid medium was prepared by adding 15 gm of agar (OXOID) to the LB 
medium before autoclaving it. 
7H9-Tw medium was used for the growth of pure cultures of mycobacteria.  
 
7H9-Tw medium: BD Middlebrook 7H9 broth base  4.7 g 
 
Glycerol 2 ml 
 
20% (v/v) Tween 80 (final 
concentration of 0.05% v/v) 
5 ml 
 
BD oleic albumin dextrose catalase 
(OADC) enrichment   
100 ml 
 
 Water 900 ml 
 
Note: Mix well and filter sterilize the medium before adding Tween 80 and ODAC.
Luria-Bertani (LB) medium: Tryptone (OXOID) 10 g 
 
Yeast extract  (OXOID) 5 g 
 
NaCl 10g 
 
Water 1L 
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7H10 agar plates were used for mycobacteria by including appropriate antibiotics in 
the medium. The media was prepared as follows: 
 
7H10 agar plates: Middlebrook 7H10 medium  19 g 
 
60% glycerol (v/v) 8.4  ml 
 
OADC  enrichment media  100 ml 
 
Water 900 ml 
 
Note:  Autoclave after adding 60% glycerol (v/v). On cooling media to ~50°C, add 
ODAC. 
SuperBroth was used for growing cells for large-scale preparation of pBR322. 
SuperBroth: Tryptone 4.8 g 
 
Yeast Extract 9.6 g 
 
Glycerol 2.0 ml 
 
Phosphate Buffer 40 ml 
 
Water 360 ml 
A stock solution of 100 mg/ml of Ampicillin in water was prepared in milli-Q 
water and added to solid/liquid medium to a final concentration of 100 µg/ml.  
Chloramphenicol at 30 mg/ml was prepared in 100% ethanol and added to solid/ 
liquid medium to a final concentration of 30 µg/ml. 50 mg/ml Streptomycin was 
prepared in Milli-Q water and added to solid medium to a final concentration of 20 
µg/ml.  
2.1.3 Preparation of electrocompetent M. smegmatis cells 
A starting culture of M. smegmatis was grown overnight in 7H9-Tw liquid 
medium overnight at 37°C with shaking at 100 rpm. 1 ml from the overnight cultures 
was used as seed inoculums for 100 ml cultures. This culture was grown for nearly 
24 hr until the OD at 600 nm is between 0.8 -1.0. The grown cells were incubated on 
ice for 90 min before centrifuging at 2700 g for 10 min at 4°C. The pellets were 
resuspended in a volume of 10% (w/v) glycerol and washed with successive smaller 
amounts of 20 ml, 10 ml and 5 ml. Finally, the pellets were suspended in 1 ml of 
10% (w/v) glycerol and stored at -80°C in 200 µl aliquots. 
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2.1.4 Preparation of chemically competent E. coli cells 
In order to prepare chemically competent E. coli cells, a single colony was 
used to inoculate 5 ml LB containing the required antibiotics from a LB agar plate 
streaked from a glycerol stock and incubated overnight at 37°C. 1 ml of the 
overnight culture was used to inoculate 100 ml LB containing the required 
antibiotics. The culture was incubated at 37°C, shaking at 220 rpm, until an OD600 = 
0.6 was achieved. The cells were then incubated on ice for 10 min before being 
harvested by centrifugation at 3,500 × g. The pellets after centrifugation were 
resuspended in 20 ml of 100 mM calcium chloride (4°C) and incubated on ice for 20 
min.  Finally, the cells were centrifuged at 3,500 × g, harvested and resuspended in 
2.4 ml 100 mM calcium chloride with 20% glycerol. The cells were frozen with 
liquid nitrogen and stored at - 80°C in aliquots of 50 µl. 
2.1.5 Transformation 
Transformation of chemically competent E. coli 
2 µl of plasmid (~100 ng/µl) was added to 50 µl of competent cells and 
incubated on ice for 30 min followed by heat shock at 42°C for 30 sec. After heat 
shock the transformed cells were again incubated on ice for 2 min. 250 µl of LB was 
added and incubated at 37°C for 1 hr before plating them on the solid medium. 
 Electroporation of M. smegmatis  
Electrocompetent M. smegmatis cells were thawed on ice and 1 µg of plasmid  
was added. The transformed cells were incubated on ice for 10 min. After the 
incubation, 200 µl of transformed cells were transferred to a chilled electroporation 
cuvette. Electroporation was carried out at 1000 Ω resistance, 2.5 kV voltage, and 25 
µF capacitance followed by incubation on ice for 10 min. The cells were then 
transferred to 5 ml 7H9-Tw medium in a sterile universal tube and recovered at 37ºC 
for at least 2 hours. After the incubation, the cells were spun down by centrifugation 
for 10 min. The sedimented cells were re-suspended in 100 µl 7H9-Tw medium and 
serial diluted up to 10-6. Finally 100 µl of each dilution was plated on 7H10 agar 
plates and incubated at 37°C for two days. 
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2.2 Molecular biology methods 
2.2.1 Oligonucleotides 
Table 2.2: PCR primers for generating PCR products that were cloned into vectors. Oligonucleotides for gene cloning and for site-
directed mutagenesis were supplied by Sigma-genosys. 
 
 
Vector Forward Primer Reverse Primer 
pET-20gyrB N∆40 
5′ATCGTGCATATGGCTGCCCAGAAA
AAGAAGG3′ 
5′AAGCTTCTCGAGGACATCCAGGAA
CCGAACATC3′ 
pSM-128gyrBval 
5′AGTACTCAC GTCGATCGGC 
CCAGAACAAGGCGC3′ 
5′CCCGGGCACGATCCGAATACTCTC
CTCAGGG3′ 
pSM-128gyrBmeth 
5′AGTACTCAC GTCGATCGGC 
CCAGAACAAGGCGC3′ 
 
5′CCCGGGCATCTAACCGCGCCGTGC3
′ 
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Mutant Forward Primer Reverse Primer 
GyrA-D504A 5’  GGCCGACGGAGCCGTCAGCGACG  3’ 
 
5’  CGTCGCTGACGGCTCCGTCGGCC  3’ 
 
GyrA-E514A 5’  TTGATCGCCCGCGCGGACGTCGTTGTC  3’ 5’  GACAACGACGTCCGCGCGGGCGATCAA  3’ 
GyrA- 
E508AD509A 
5'-
GACGTCAGCGACGCGGCTTTGATCGCCCGC-3' 
 
5'-
GCGGGCGATCAAAGCCGCGTCGCTGACGTC-3' 
 
   Table 0.1: Oligonucleotides designed in order to introduce mutations into expression plasmid pET20-gyrA (Huang et al., 2006). 
 
 
       
       
       
       
       
  
          Table 2.4: Oligonucleotide for RT-PCR (reverse transcription-polymerase chain reaction). 
 
Primers Sequence 
Forward primer (F-1.1) 5’ CACGGCGCGGTTAGATGGGTAA3’  
Forward primer (F-1.2) 5’TGGGTAAAAACGAGGCCAGAAGATC3’ 
Forward primer (F-2) 5’CGACTCAACCGCATGCACGCA3’ 
Forward primer (F-3) 5’CCAGAAAAAGAAGGCCCAAG3’ 
Reverse primer (R) 5’ATAACCGGCCATCGCCTCGT3’ 
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2.2.2 Preparation of supercoiled and relaxed pBR322* 
Supercoiled and relaxed pBR322* were used as substrates in the DNA relaxation 
and supercoiling assays. pBR322* has a point mutation to increase its copy number. 
The nucleotide change is G➝T point mutation at bp 3074 (Boros et al., 1984). A 
brief protocol (Sambrook et al., 1989) for the large scale preparation of supercoiled 
pBR322*  is as follows: 
1. 6 × 400 ml super broth cultures containing 50-100 µg/ml ampicillin grown 
for up to 2 days were centrifuged at 6000 rpm for 10 min in Beckman 
polycarbonate pots. 
2. Pellets from two pots were pooled and resuspended in 48 ml of 1× 
SOLUTION I (10 × 500 mM glucose, 250 mM Tris pH 7.5, 100 mM EDTA) 
followed by addition of 12 ml of 10 mg/ml lysozyme. 
3. 120 ml of SOLUTION II (0.2 M NaOH, 1% SDS) was added and stirred well 
after incubation for 10 min at room temperature. 
4.  The pellets suspended in SOLUTION II were incubated on ice for 10 min 
and then chilled SOLUTION III was added and stirred well. 
5.  The pellets suspended in SOLUTION III (0.24 gm/ml sodium acetate, 0.11 
gm/ml acetic acid) were incubated on ice for 25 min and then centrifuged at 
6000 rpm for 5 min at 4°C. 
6.  The supernatant was collected in fresh Beckman pots and 150 ml of 
isopropanol was added. After isopropanol addition, the solution was again 
centrifuged at 8000 rpm for 5-10 min at 20 °C. 
7.  The pellets (total 6 pellets) were redissolved in 28 ml TE (10 mM Tris-HCl, 
pH 7.5 1 mM EDTA) in a pre-weighed 50 ml falcon tube. 1.019 gm of CsCl 
and 0.11 ml of 10 mg/ml ethidium bromide solution were added per gram of 
sample. The mixture was pippetted into Sorvall Ultra Crimp tubes up to the 
neck. 
8. The sealed tubes were centrifuged in a StepSaver rotor in a Sorvall Ultra 
centrifuge overnight at 45000 rpm.  
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9. Next day, the lower band was taken out with a wide bore needle and was 
centrifuged overnight in the presence of CsCl and ethidium bromide at 
45,000 rpm.  
10.   Next day, the band was removed and extracted 3-5 times with 25 ml of 
water-saturated butanol until all ethidium bromide was removed.    
11.  An equal volume of water and 2 volumes of isopropanol were added and left 
at room temperature for DNA to precipitate for a minimum of 2 hrs in Corex 
tubes. 
12.  The Corex tubes were centrifuged at 7500 rpm for 30 min and ethanol 
precipitated overnight at - 20°C. Finally the pellet was resuspended in TE and 
quantitated.   
Relaxed pBR was prepared by relaxing the supercoiled DNA using chicken 
erythrocyte topoisomerase I followed by phenol extraction and ethanol precipitation 
(Trask & Muller, 1983). 
 
2.2.3 Plasmid DNA purification 
Plasmid DNA was purified using the Qiaprep spin miniprep kit (Qiagen) following 
the manufacturer’s recommended protocol. 
 
2.2.4 DNA concentration determination 
DNA concentration was determined using a BioPhotometer (Eppendorf) by 
measuring the A260 of a sample diluted in milli-Q water (1 µl sample + 49 µl milli-Q 
water). 
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2.2.5 PCR and cloning 
pET20-gyrBN40∆ cloning  
A typical 50 µl PCR reaction mixture to amplify gyrB40N∆ consisted of: 
 
 Forward primer 10 µM 1.0 µl 
Reverse primer 10 µM 1.0 µl 
pET20-gyrB (68 ng/µl) 0.5 µl 
dNTP ( 1.25 mM) 8.0 µl 
Promega Pfu10× buffer  5.0 µl 
Promega Pfu (2–3u/µl) 1.0 µl 
DMSO (100%) 2.5  µl 
Water 31 µl 
The details of the oligonucleotide used in the PCR are provided in section 2.2.1. 
Table 2.5 shows the thermocycler program used. 
The amplified gyrBN40∆ was cloned (blunt-end cloning) into TOPO® 
cloning vector by following the protocol recommended for Invitrogen TOPO® 
cloning kit. The clone was verified by sequencing and then restriction digested with 
NdeI and XhoI (New England Biolabs) for cloning the digested gyrB40N∆ insert 
into the NdeI and XhoI digested pET20. The final stage of cloning into pET20 was 
performed using the ClonableTM Ligation kit (Novagen). 
pSM128-gyrBmeth & pSM128-gyrBval cloning 
A typical 20 µl PCR reaction mixture to amplify gyrB40N∆ consisted of: 
Forward primer 10 µM 1 µl 
Reverse primer 10 µM 1 µl 
pET20-gyrB (68 ng/µl) 1 µl 
dNTP ( 1.25 mM) 3.2 µl 
Promega Pfu10× buffer 2.0 µl 
Promega Pfu (2–3u/µl) 0. 1 µl 
DMSO (100%) 2.0 µl 
Water 9.7 µl 
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The details of the oligonucleotide used in the PCR are provided in section 2.2.1. 
Table 2.5 shows the thermocycler program used. 
Step Temperature (°C) Time (min) Description 
1 94 2 Denaturation 
2 94 1 Denaturation 
3 55 1 Primer annealing 
4 72 0.25 Extension 
5 - - Loop to step 2 
( 35 times) 
6 72 10 Ensure complete 
extension 
Table 2.5: Typical thermocycler program used for amplifying sequences for 
promoter analysis. Reactions were carried out using a PTC-200 thermal cycler (MJ 
Research). 
The PCR amplified products were cloned (blunt-end cloning) into pGMT®- 
Teasy vector (Promega) with primers containing the ScaI sites. Finally the pGMT®- 
Teasy clones containing the inserts were digested with ScaI (New England Biolabs) 
and sub-cloned into pSM128 vector to generate pSM128-gyrBmeth & pSM128-
gyrBval. 
2.2.6 Site-directed mutagenesis 
PCR was used to introduce mutations into DNA through site-directed 
mutagenesis. The Stratagene QuickChange® Lightning kit was used for site-directed 
mutagenesis. A typical 50 µl reaction contained: 
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Forward primer 14 µM 1 µl 
Reverse primer 14 µM 1 µl 
pET20-gyrA (185 ng/µl) 0.5 µl 
dNTP  1 µl 
10 × reaction buffer 5.0 µl 
Quick Solution reagent 1.5 µl 
Water 40 µl 
Finally 1 µl QuickChange Lightning Enzyme was added to the PCR mix. Table 2.6 
shows a typical thermocycler program used. 
Step Temperature (°C) Time (min) Description 
1 95 2 Denaturation 
2 95 0.3 Denaturation 
3 60 0.16 Primer annealing 
4 68 0.5 /kb Extension 
5 - - Loop to step 2 
( 18 times) 
6 68 5 Ensure complete 
extension 
Table 2.6: Typical thermocycler program used for side-directed mutagenesis. 
Reactions were carried out using a PTC-200 thermal cycler (MJ Research). 
Following the PCR, 2 µl DpnI provided in the kit was added to the reaction.  
The reaction was incubated at 37ºC for 5 min followed by transformation into E. coli 
TOP 10 cells. The transformed cells were plated out on LB media containing the 
required antibiotics. Plasmid DNA was isolated from minipreps that were set up from 
a single colony and were verified by DNA sequencing. 
 
 
 
 
  
Chapter 2 
 
92 
 
2.2.7 RT-PCR (reverse-transcriptase) 
The master mix for the PCR included Promega GoTaq PCR master mix and 
10% DMSO. The typical thermocycler program that was used for RT-PCR is shown 
in Table 2.7: 
 
Step Temperature (°C) Time (min) Description 
1. 94 2 Denaturation 
2. 94 0.5 Denaturation 
3. 56 0.5 Primer annealing 
4. 72 1 Extension 
5. - - Loop to step 2 
( 25 times) 
Table 2.7: Typical thermocycler program used for RT-PCR. 
2.2.8 Agarose gel electrophoresis 
Agarose gel electrophoresis is a routine technique employed in the project for 
the detection and topological separation of DNA. In most of the cases 1% agarose 
gels were prepared by dissolving agarose (SIGMA-ALDRICH) in TAE (40 mM 
Tris-acetate (pH 7.5), 20 mM sodium acetate, 2 mM EDTA) and heating in a 
microwave. The dissolved agarose was allowed to cool to lukewarm and then poured 
into a gel mould with an inserted comb. The gel was allowed to set followed by 
submerging it in a horizontal electrophoresis tank filled with TAE buffer. The DNA 
samples were prepared by mixing them with an equal volume of 2×STEB  
(40% sucrose, 100 mM Tris- HCl (pH 8), 1 mM EDTA, and 0.5 µg/ml bromophenol 
blue). Gels were run at 20-85 V and stained by soaking in TAE buffer containing 2 
µg/ml of ethidium bromide (200 µg/ml) for 10 minutes. Destaining was performed 
for 10 min in TAE buffer containing no ethidium bromide. Processed gels were 
visualized by ultraviolet transilluminator and photographed using the GeneGenius 
Bio-imaging system (Syngene). 
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2.2.9 DNA sequencing 
DNA sequencing reactions were carried out using the BigDye v3.1 kit (Applied 
Biosciences). A typical 10 µl reaction consisted of: 
 
Sequencing primer (2 µM) 1 µl 
Big dye buffer 1.5 µl 
Big dye  v3.1 1 µl 
Template DNA (100 ng/µl) 1-2 µl 
Total 10 µl 
 
Table 2.8 shows a typical thermocycler program used. 
Step Temperature (°C) Time (min) Description 
1 96 1 Denaturation 
2 96 0.5 Denaturation 
3 45 0.25 Primer annealing 
4 60 4 Extension 
5 - - Loop to step 2 
( 29 times) 
Table 2.8: Typical thermocycler program used DNA sequencing. 
Reactions were carried out using a PTC-200 thermal cycler (MJ Research). 
Once the DNA sequencing reaction had been performed, the samples were 
submitted to the John Innes Genome Laboratory for analysis. Results were generated 
in the form of text files and .abi chromatogram trace files. Vector NTI was used to 
analyse the sequencing data. 
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2.3 Protein Methods 
2.3.1 Purification of   M.  tuberculosis DNA gyrase and mutants 
  M. tuberculosis GyrA and the double (GyrA E508A, D509A) and quadruple 
mutants (GyrA D504A, E508A, D509A, E514A) were  expressed and purified 
according to the previously published protocol with slight modifications (Huang et 
al., 2006). The expression plasmids were transformed into E. coli BL21 (DE3) 
pLysS and a 12 ml overnight culture of the cells was used to inoculate each 1 L 
culture of LB, containing 100 µg/ ml ampicillin and 30 µg/ ml chloramphenicol. The 
cells were grown at 37°C to an OD600 = 0.4 -0.6. 
 Once the culture had reached the required cell density, protein expression was 
induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final 
concentrations of 0.4 mM and the culture was left shaking for 4 hr at 37°C. The cells 
were harvested by centrifugation at 7000 rpm for 15 min using a SLC-6000 rotor  
(Sorvall). The harvested cells were resuspended in Binding Buffer (20 mM Tris–HCl 
pH 7.9, 500 mM NaCl and 5 mM imidazole).  
The cells were lysed by French press and a complete EDTA-free protease-
inhibitor cocktail tablet (Roche) was added before thawing the cells. The cell debris 
was removed by centrifugation at 84,000× g for 60 min. The supernatant was then 
purified using a HisTrap HP IMAC 5 ml column (Amersham Bioscience, USA) 
equilibrated with the Binding Buffer. The column was washed initially with Washing 
Buffer (20 mM Tris–HCl pH 7.9, 500 mM NaCl and 60 mM imidazole). The his-
tagged protein was eluted with Elution Buffer (20 mM Tris–HCl pH 7.9, 500 mM 
NaCl and 500 mM imidazole) with an imidazole gradient from 60 mM to 500 mM. 
The peak fractions were pooled based on their purity, analysed using SDS-PAGE and 
then dialysed in Storing Buffer (50 mM Tris–HCl pH 7.9, 30% glycerol and 5 mM 
dithiothreitol). The protein were concentrated in Amicon Ultra-4 (< 5 ml) columns 
and then stored at -20°C. 
 The same protocol was used for purifying GyrB and GyrB N40∆, except the 
final concentration of IPTG was 1 mM IPTG during induction. 
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2.3.2 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
was used to separate, identify and check the quality of proteins of different molecular 
mass. A 12.5% polyacrylamide resolving gel with a 4% polyacrylamide stacking gel 
was used. The composition of the gel is shown in Table 2.9. 
 
Component Resolving 
gel  
Stacking gel 
Polyacrylamide (37.5:1 acrylamide : bis) 
(Severn Biotech Ltd.) 
12.5 % 4.0% 
SDS (W/V) 0.1% 0.1% 
Tris.HCl (pH 8.8) 375 mM - 
Tris.HCl (pH 6.8) - 125 mM 
(N,N,N’,N’-tetramethylethylenediamine (Sigma) 0.1% 0.1% 
Ammonium  persulphate  (Sigma) 0.1% 0.1% 
Table 2.9: Composition of resolving and stacking gels of a 12.5 % SDS-PAGE. 
Samples for SDS-PAGE analysis were prepared by the addition of an equal 
volume of SAB (0.125 M Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 10% β-
mercaptoethanol and 0.002% bromophenol blue) and boiling for 5 min. Then gels 
were loaded with the samples along with a suitable molecular weight ladder. Gels 
were run partially submerged in running buffer (25 mM Tris-HCl, 192 mM glycine 
and 0.1% SDS) at constant voltage of 90 V through the stacking gel and 150 V 
through  the  resolving gel. Gels were run using a Mini-Protean II electrophoresis 
system (Bio-Rad) and stained by soaking in Instant Blue Coomassie stain 
(Expedeon) for 30 min. Gels were visualised using a GeneGenius Bio-Imaging 
system (Syngene). 
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2.3.3 Dialysis 
Dialysis was carried out overnight in a large volume of buffer (2 L) at 4°C. 
The use of dialysis equipment varied depending upon the volume of the protein 
solution: 
 
10- 500 µl Slide-A-Lyzer MINI Dialysis Units, 10K MWCO (Thermo Scientific) 
 
 
>3 ml SnakeSkin Dialysis Tubing, 10K MWCO (Thermo Scientific) 
 
Purified proteins were dialysed in Storing Buffer (50 mM Tris–HCl pH 7.9, 
30% glycerol and 5 mM dithiothreitol). Where experiments involved EGTA dialysis, 
protein was dialysed in Storing Buffer containing 1 mM EGTA. 
Similarly, for protein refolding experiments, protein was first dialysed in  
Buffer A (50 mM Tris-HCl pH 7.5, 100 mM KCl, 2 mM DTT, 8 M Guanidine 
hydrochloride, 1 mM EDTA) at 37°C for 3 hrs. Then the protein was dialysed in 
Buffer B (50 mM Tris-HCl pH 7.5, 100 mM KCl, 2 mM DTT, 8 M Urea, 1 mM 
EDTA, 10% glycerol) at 4°C overnight. The next day the protein sample was 
dialysed in EB buffer (50 mM Tris-HCl pH 7.5, 100 mM KCl, 2 mM DTT, 1 mM 
EDTA, 10% glycerol) to remove the denaturing agents and for protein refolding. In 
Chapter 3 where protein samples were refolded in the presence of EGTA, all the 
three buffers (A, B, EB) had 1 mM EGTA. For this experiment, a big pool of protein 
was split into two parts, which was then refolded in the presence and absence of 1 
mM EGTA as outlined below in the flowchart (Figure 2.1). This protocol was a 
modified version of the protein refolding protocol that was used for recombining 
DNA gyrase subunits for transactivation experiment (Hockings & Maxwell, 2002).  
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Figure 2.1: Flowchart for the protein refolding experiment. 
 
2.3.4 Protein concentration 
Protein samples were concentrated in Amicon Ultra-4 (< 5 ml) columns with 
10-kDa molecular weight cut offs. The protein solution to be concentrated was 
applied to the reservoir of the concentrator and then centrifuged at 4000 rpm at 4°C 
until the protein solution had reached the desired volume. In the case of protein 
samples with a small volume, the samples were concentrated with 10-kDa molecular 
weight centrifugal concentrators. 
 
2.3.5 Protein concentration determination 
The protein concentration was determined using the Bradford method 
(Bradford, 1976). Bradford reagent was prepared by adding 100 mg of Coomassie 
Brilliant Blue G to 50 ml of 95% (v/v) ethanol plus 100 ml of 85% (v/v) phosphoric 
acid and made up to one litre with milli-Q water. The reagent was filtered before 
storing it in a brown bottle covered with a foil. For protein estimation, 2 µl of protein 
sample was diluted to 100 µl with milli-Q water followed by the addition of 900 µl 
Bradford reagent. Sample was then incubated at room temperature for 5 min before 
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taking the absorbance at 595 nm on a BioPhotometer (Eppendorf). The blank 
solution consisted of 100 µl milli-Q water with 900 µl Bradford reagent. The protein 
concentration was determined through a comparison of the absorbance of the protein 
sample against a calibration curve constructed from BSA standards. 
2.3.6 Limited Proteolysis 
 Limited proteolysis experiments were performed to study the effect of 
ligands (Ca2+, diospyrin) on the digestion profile of DNA gyrase. These experiments 
reflected conformational changes in the protein induced by the ligand. 
 6 µM GyrA was incubated with 3 mM Ca2+ at 25°C for 1 hr before 
incubating it with 1.8 µg/ml of trypsin at 37°C in a total reaction mixture of 55 µl.  5 
µl aliquots were collected at different time points (1, 2, 5, 10, 30, 60 and 120 min) 
and the digestion was stopped by boiling the samples in sample application buffer 
(SAB). The samples were run on a 12% SDS-PAGE gel to visualise the difference in 
the digestion profile. 
4 µM gyrase subunits were incubated with 100 µM diospyrin at 25°C for 60 
min before incubating it with trypsin at 37°C in a total reaction mixture of 55 µl. 5 µl 
aliquots were collected at different time points and the digestion was stopped by 
boiling the samples in sample application buffer (SAB). The samples were run on a 
12% SDS-PAGE gel. 
2.3.7 Electroblotting & Edman sequencing 
100- 200 pmol of each protein sample was run in triplicates on a  NuPAGE 
10% Bis-Tris Gels (Invitrogen) and then blotted onto a PVDF membrane using 
CAPS buffer (10 mM CAPS, pH 11 with or without the inclusion of 10% methanol). 
For electroblotting, PVDF membrane was prepared by immersion in HPLC 
grade methanol for 20 sec followed by equilibration in transfer buffer for 10 min.  A 
gel/ PVDF/ blotting paper sandwich as for Western blotting is prepared and semi-dry 
blot under 1-3 mA/cm2 for 45 min-1.5 hr was performed. After blotting, the PVDF 
membrane was immediately washed with water twice with 10 min shaking. The 
membrane was stained with 0.1% Coomassie Blue R250 in 50% methanol for 5 min 
and destained with several changes, 2-5 min each of 30-50% methanol. Finally, the 
membrane was washed in water and air-dryed and stored at -20°C before sending it 
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for Edman sequencing. The Edman sequencing was done in collaboration with  
Dr. Mike. A. Weldon at PNAC facility, Dept. of Biochemistry, Cambridge. 
N-terminal protein sequencing is achieved by Edman reactions. In this 
process, the N-terminal amino acid reacts with PITC (phenylisothiocyanate) to form 
a phenylthiocarbamyl (PTC) protein. The PTC protein is then cleaved with 
trifluoroacetic acid, resulting in the formation of an intermediate anilinothiazolinone 
(ATZ). This intermediate is converted to the more stable phenylthiohydantoin (PTH) 
amino acid derivative and subsequently separated by HPLC. The HPLC fractions are 
compared against a standard, and identified by the sequencer software. 
An essential requirement of this technique is that the protein should be at 
least 80% pure. It is also important the N-termini of the protein is not blocked. Many 
proteins may be blocked at the N-terminus by modification during manipulation and 
purification. Modifications include formyl groups, acetyl groups, and pyroglutamic 
acid residues acquired during handling steps and exposure to poor quality grade 
reagents. Depending upon the nature of the modification, some N-terminal blocking 
groups can be removed with mild acid treatment. Failing this "quick fix" the standard 
solution is to carry out chemical or enzymatic cleavages followed by HPLC 
purification. 
2.3.8 Peptide mass fingerprinting by Orbitrap mass spectrometer 
Peptide mass fingerprinting was performed on a LTQ-OrbitrapTM mass 
spectrometer (Thermo Fisher Scientific Inc) in collaboration with John Innes Centre 
Proteomics Shared facility.  
 The sample was in-gel digested with trypsin (Promega) according to 
the standard procedures and the peptides were extracted with 5% formic acid. 
Aliquots of the extract were loaded onto a Trap column (C18 PepMapTM , Dionex) 
which was then switched in-line to an analytical column (BEH C18, 1.7 µm, Waters, 
75 µm × 120 mm, self-packed). Peptides were separated and eluted with a gradient of 
5-40% acetonitrile in water/ 0.1% formic acid at a rate of 1% min-1. 
The mass spectrometer was operated in positive ion mode at a capillary 
temperature of 200°C. The source voltage and focusing voltages were tuned for the 
transmission of MRFA peptide (m/z 524) (Sigma-Aldrich, St. Louis, MO). Data- 
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dependent analysis was carried out in oribtrap-IT parallel mode using CID 
fragmentation on the five most abundant ions in each cycle. The collision energy was 
35%, an isolation width of 2 was used, and for phosphopeptide analysis multistage 
activation was enabled. The orbitrap was run with a resolution of 30,000 over the MS 
range from m/z 350 to m/z 2000 and an MS target of 106 and 1 s maximum scan 
time. The MS2 was triggered by a minimal signal of 2000 with an AGC target of 
3x104 ions and 150 ms scan time.  For selection of 2+ and 3+ charged precursors, 
charge state and monoisotopic precursor selection was used. Dynamic exclusion was 
set to 1 count and 30 s exclusion time with an exclusion mass window of ±20 ppm. 
MS scans were saved in profile mode while MSMS scans were saved in centroid 
mode. 
Peaklists from tandem mass spectra were extracted by BioWorks version 
3.3.1 (Thermo Fisher Scientific Inc). The resulting peaklist file was used for a 
database search using Mascot Server 2.2 (Matrix Science, London, UK, in-house) on 
all bacterial sequences of the SPtrEMBL database (June 2008). Searches were 
performed with a parent ion mass tolerance of 5.0 ppm and a fragment ion mass 
tolerance of 0.60 Da.  Iodoacetamide derivative of cysteine was specified as a fixed 
modification, and oxidation of methionine was specified as a variable modification. 
Trypsin was designated as the protease and up to three missed cleavages were 
allowed. 
2.3.9 Circular dichroism 
Circular dichroism experiments were carried out in collaboration with Mrs. 
Fiona Husband (Institute of Food Research, Norwich, UK.).  
 Circular dichroism is a useful technique for rapid determination of the 
secondary structure and folding properties of proteins. Figure 2.2 displays the 
circular dichroism spectra of different secondary structure elements of protein. The 
most widely used application of protein CD spectra is to determine whether an 
expressed, purified protein is folded, or if a mutation has affected its conformation or 
stability (Greenfield, 2006b). For example in my research project, circular dichroism 
was used to confirm that the mutations in the putative Ca2+ -binding site have not 
misfolded GyrA. The technique relies upon the differential absorption of left-handed 
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and right-handed circularly polarised light by secondary structure elements (i.e.α-
helix/β-sheet/β-turn). CD has the advantage that measurements can be taken for 
multiple samples containing ≤20 µg of proteins in physiological buffers. The 
limitation of the technique is that it does not provide the residue-specific information 
that can only be obtained by X-ray crystallography or NMR. 
Protein was dialysed in 20 mM HEPES buffer pH 7.5. Far-UV (180-260 nm) 
CD spectra were recorded at 20°C using a J-715, Rev. 1.00 spectropolarimeter 
(JASCO Corp.) using  a 0.1 mm path length cell. Spectra were the average of 3 
accumulations at 100 nm. min-1 and 0.5 nm resolution. 
 
 
Figure 2.2: CD spectra of poly-L-lysine at pH 11.1 and placental collagen.  
Poly-L-lysine: α-helical (black), antiparallel β-sheet (red) conformations, extended 
conformation at pH 5.7 (green). Placental collagen in its native triple-helical (blue) 
and its denatured form (cyan) (Greenfield, 2006a). 
 
  
Chapter 2 
 
102 
 
2.4 Enzyme assays 
2.4.l  DNA supercoiling, relaxation, and decatenation assays 
 A typical supercoiling assay (30 µl) containing a range of gyrase 
concentrations and 0.5 µg of relaxed pBR322 in Supercoiling Assay Buffer (40 mM 
Tris-HCl pH 7.9, 25 mM KCl, 4 mM DTT, 0.1 mg/ml tRNA, 100 mM  potassium 
glutamate, 0.36 mg/ml BSA, 6 mM magnessium acetate, 2 mM spermidine and 1 
mM ATP ). Reactions were incubated at 37°C for 60 min in a waterbath. After the 
incubation time, DNA was prepared for electrophoresis by addition of an equal 
volume of chloroform-isoamylacohol mixture (24:1), brief vortexing, centrifugation 
(13,000 rpm for 5 min) and addition of 30 µl STEB (40% sucrose, 100 mM Tris- 
HCl (pH 8), 1 mM EDTA, and 0.5 µg/ml bromophenol blue). The products were 
analysed on a 1% (W/V) agarose gels running at 20 V overnight. The gels were 
stained with an ethidium bromide solution (2 µg/ml). 
DNA relaxation assays were performed in a similar way, except they were 
performed in the absence of ATP and spermidine. The substrate for this reaction was 
supercoiled pBR322.  
A typical decatenation assay (30 µl) containing a range of  gyrase 
concentrations and 200 ng kDNA in Decatenation Assay Buffer (40 mM Tris-HCl 
pH 7.9, 25 mM KCl, 4 mM DTT, 100 mM  potassium glutamate, 0.36 mg/ml BSA, 6 
mM magnesium acetate and 1 mM ATP). Reactions were incubated at 37°C for 60 
min in a water bath, and the DNA was analysed as described above. 
2.4.2 DNA wrapping assay 
For DNA wrapping experiments, the DNA relaxation assay was scaled up to 
60 µl. After incubation at 37°C for 60 min, the reaction was divided into two halves. 
The reaction was stopped in one-half with 2 × STEB and the other half of the 
reaction was incubated with 2 µl of wheat germ topo I (2–10 u/µl) at 37ºC for 30 
min. The reaction was stopped with 3 µl 2% SDS, 0.2 µl proteinase K (20 mg/ml) 
and 2 × STEB. The DNA was extracted with chloroform: isoamyl alcohol (24:1). 
The products were analysed on a 1% (W/V) gels running at 20 V overnight and 
stained with ethidium bromide solution (2 µg/ml). 
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2.4.3 Promoter activity assay (β-galactosidase activity assay) 
This assay was performed to verify if there are any promoter elements in the 
region, which code for an additional 40 amino acids at the GyrB N-terminus. This 
assay provides an advantage for studying mycobacterial promoters as mycobacteria 
do not naturally produce β-galactosidase and therefore no background enzyme 
activity is present. The assay is based on the conversion of ortho-nitrophenyl-β-D-
galactopyranoside (OPNG) to ortho-nitrophenol (ONP) by β-galactosidase, which is 
only expressed in the presence of an active promoter. 
In this method, cell extracts were prepared and the protein concentration was 
determined. The cell free extracts were prepared by centrifuging liquid cultures at 
2500- 3000×g for 10 min at room temperature. The pelleted cells were washed with 
the original culture volume of 10 mM Tris-HCl pH 8 and resuspended in 1 ml of 10 
mM Tris-HCl pH 8. The resuspended cells were transferred to a lysing Matrix B tube  
(Q-BIOGENE) and transferred to a FastPrep™ (Q-BIOGENE). The cells were lysed 
at a speed 6.0 for 30 sec and centrifuged at 1600×g for 5 min. The cell-free extracts 
were then transferred to a sterile 1.5 ml tube. 
For the assay, three Falcon 2054 polystyrene tubes containing 900 µl of Z-
buffer (60 mM Na2HPO4, 40 mM Na2PO4, 10 mM KCl and 1 mM MgSO4) were 
taken. As a negative control 100 µl sterile distilled water was added to one of the 
tubes and to the other two tubes 100 µl of two different cell-free extracts were added. 
The tubes were then incubated for 5 min at 37°C followed by addition of 200 µl of 
ONPG solution to start the reaction. The reaction was then incubated for up to 90 
min at 37°C. Finally, 500 µl of 1 M NaHCO3 was added to each tube to stop the 
reaction. The contents of the tube were emptied into a cuvette and the optical density 
was measured at 420 nm. Z-buffer was used as blank. The β-galactosidase activity 
was calculated using the following formula and reported in Miller units: 
(OD420 x 1.7) / (t x v x p x 0.0045) 
Where t = reaction time (min), v = volume of cell free extract (ml) and p = total 
protein concentration (mg/ml). 
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2.5 Biophysical techniques 
2.5.1 ICP-AES 
ICP-AES (Inductively coupled plasma atomic emission spectroscopy) was 
used to determine the concentration of divalent ions (Mg2+ & Ca2+) in the protein 
sample. ICP-AES experiments were performed in collaboration with Mr. Graham 
Chilvers (University of East Anglia, UK). 
ICP-AES is an analytical technique used for the detection of metals or cations 
in food, environmental or biological samples. It is a type of emission spectroscopy 
that uses the inductively coupled plasma to produce excited atoms and ions that emit 
electromagnetic radiation at wavelengths characteristic of a particular element. The 
intensity of this emission is indicative of the element within the sample. 
The basic principle of the instrument is that when an aerosol of an analyte is 
passed through argon gas plasma, the matrix is broken down and elements in that 
plasma are excited.  The electrons will jump to higher energy states in order to 
preserve the equilibrium. As the elements move to a cooler part of the plasma, the 
electrons will relax back to the ground state, giving off a photon, which is uniquely 
related to its parent element. There are two types of electron emission used in ICP 
emission spectroscopy: atomic and ionic emissions. Atomic emissions are electrons 
that have been excited from the ground state, to relax and emit a photon of 
characteristic wavelength. Ionic emissions are caused by electrons that have been 
excited from the atomic orbits into such a higher energy state they are no longer part 
of that atom and therefore the atom is ionised. Alkaline earth elements (Ca, Mg etc) 
are easily ionized, so ionic emission wavelengths are most intense, and for non-
metals (S, P etc) and metalloids (As, Se, etc) atomic emission wavelengths are the 
most intense. 
The instrument consists of the sample introduction system that transports the 
analytes of interest to the argon plasma that causes the sample to undergo desolvation 
and excitation resulting in emission of characteristic radiation. The spectrometer 
separates the radiation of interest and the detection system measures the intensity of 
the selected radiation and compares it to the known intensity of analyte standards for 
quantitative determination (Figure 2.3).  
  
 
Figure 2.3: Illustration of ICP
(Ref:http://www.balticuniv.uu.se/environmentalscience/ch12/chapter12_g.htm)
The protein samples in the storing buffer with appropriate buffer controls 
were analysed on Varian Vista Pro ICP
following settings listed in
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2.5.2 Nano-ESI MS 
In our experiments to study diospyrin interactions with different DNA gyrase 
subunits, nano-ESI MS (nanoflow electrospray ionization mass spectrometry) was 
used. These experiments were performed in collaboration with Dr. Adam Mckay 
(University College London, UK.). 
There is an advantage in using nano-ESI MS over conventional electrospray 
ionization mass spectrometry (ESI-MS). Conventional ESI-MS is not suitable for 
studying large non-covalent protein complexes, which can be disrupted due to high 
curtain gas flow rates and spray heating which are required for the evaporation of the 
sample droplets. Nanoflow electrospray ionization was initially developed to 
overcome the limitation of low salt tolerance and large sample volume associated 
with ESI. The main development of this technique was the use of gold-coated 
borosilicated capillaries, with tip orifice diameters of around 1-4 µM. This allowed 
lower flow rates of 20 nl/mim for the production of smaller droplets with a diameter 
of <200 nm, in comparison to standard electrospray ionization which requires flow 
rates of 1- 10 µl/min and produces droplets of 10 µm diameter. Due to smaller 
droplet size high curtain gas flow rates and heating is no longer required for 
evaporation and this helps to maintain non-covalent complexes. Figure 2.4 shows a 
schematic representation of the Electrospray ionisation process. 
In this study protein (M. tuberculosis GyrA, M. tuberculosis GyrB, E. coli 
GyrB43, E. coli GyrB47) were buffer exchanged into 250 mM ammonium acetate at 
pH 7.5 using mini gel filtration columns (Bio-Rad). A 13 mM stock solution of 
diospyrin was prepared in 100% DMSO. All the drug dilutions were prepared from 
this stock and added to the protein solution to give a final DMSO concentration of 
not more than 10%. Gold-coated borosilicate capillaries were used to load 2-3 µl of 
the protein-drug samples.  Ions were generated by nanoflow electrospray ionisation  
with a capillary voltage of 1.2-1.6 V. Spectra were recorded on a Synapt™ High 
Definition Mass Spectrometry™ (HDMS™) Q-TOF mass spectrometer (Waters, 
Manchester, UK) modified for high mass operation. Spectra were externally 
calibrated using 33 mg/ml cesium iodide. 
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Figure 2.4: Electrospray ionisation process. 
An electric field is applied between the capillary and the counter-electrode. The 
protein solutions emerge from the capillary forming a Taylor cone, which give rise to 
charged droplets. The charged droplets move along the electric field towards the 
mass spectrometer and solvent evaporates from the droplets, which leads to fission of 
charged droplets into naked charge ions, which enter the mass spectrometer. 
(Ref:http://www.chm.bris.ac.uk/ms/theory/esi-ionisation.html). 
 
2.5.3 BIAcore 
Surface plasmon resonance (SPR) allows molecular interactions (e.g. 
protein–protein, protein–small molecule interactions) to be monitored in real-time. 
The technique involves sample injection over a sensor surface, onto which a potential 
interacting partner has been immobilised. The interaction between the injected 
sample and immobilised partner on the sensor chip changes the mass at the surface. 
This in turn alters the refractive index at the interface between the sensor surface and 
the solution. The sensogram recorded during these interactions trace the association 
and dissociation of complexes. This data can also provide kinetic information about 
the system. SPR was used to analyse the binding of diospyrin to gyrase subunits. 
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Surface plasmon resonance experiments were performed using a Biacore 
T100 instrument (Biacore AB, Uppsala, Sweden) at 25°C.  Protein was immobilised 
on a CM5 sensor chip (BIAcore) via amine coupling in immobilisation buffer (10 
mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA and 0.05% P20 surfactant). The 
immobilisation process included activation of the surface carboxyl groups by 
injecting 1:1 mixture of N-hydroxysuccinimide (0.1 M) and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (0.4 M) across the surface of the chip at 5-10 µl/ 
min.  Protein dialysed and diluted in 10 mM sodium acetate (pH 4.5) was injected 
across the surface of the chip until a response of 4000 to 6000 response unit was 
reached. The active esters were deactivated by injection of 1 M ethanolamine/ HCl 
pH 8.0.  
Kinetic experiments were performed at 25°C in Running Buffer (35 mM 
Tris-HCl pH 7.5, 24 mM KCl, 4 mM MgCl2, 5 mM DTT, 6.5 % glycerol and 0.02% 
P20 surfactant).  The flow rate was set at 30 µl/min.  Various concentrations of 
diospyrin prepared in the Running Buffer were injected over the immobilised 
proteins, and the association phase was observed for 210 s. After the end of the 
injection, the flow was switched back to drug-free buffer and the dissociation phase 
was observed for 240 s. At the end of the dissociation phase, the surface was re-
generated. Several conditions recommended by the manufacturers were tried. The 
conditions were either ineffective or they affected the chip surface. The best 
regeneration condition that could be achieved was with 40 mM NaOH and 0.5% P20 
but this affected the chip surface to a certain extent. The data was analysed by 
BIAevaluation software. 
2.5.4 Protein crystallography 
Crystallisation trials were carried out by vapour diffusion in a sitting-drop 
format with 96-well MRC plates (Molecular Dimensions) using a variety of screens 
such as Hampton Research, Molecular Dimension and Qiagen. A Tecan robot and a 
nanodrop robot were used to set up crystallisation screens. Drops consisted of 1 µl 
protein solution (with and without drug) and 1 µl precipitant solution. Crystallisation 
screens were usually set up with a protein concentration of 5-10 mg/ml. Screens were 
stored at 20 °C. 
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Any hits obtained from the screens were optimised by hanging drop vapour 
diffusion in a 24 well VDX plates (Molecular Dimensions). Different ratios of 
protein solution (with and without drug) and reservoir solutions were placed on a 
plastic coverslip which was then suspended and sealed with vacuum grease over a 
well containing 1 ml of reservoir solution. 
E. coli GyrB24 + 1 mM Novobiocin + 1 mM Diospyrin crystals soaked in the 
cryoprotectant (450 µl PEG550 MME (50%) + 100 µl 1M MME pH 6.5) were 
mounted for X-ray data collection using Cryoloops (Hampton Research). X-ray data 
was collected in-house by mounting crystals on the goniostat and flashcooled to 100 
K in a stream of gaseous nitrogen produced by an X-Stream cyrocooler (Rigaku-
MSC). Diffraction data were collected using a Mar 345 image-plate detector 
(MarResearch). Initial diffraction images were taken at 0° and 90° to assess the 
quality of the diffraction and estimate resolution. The diffraction data was processed 
using software such as MOSFLM (Leslie, 2006), PHRASER (McCoy et al., 2007) 
and COOT (Emsley & Cowtan, 2004) to check the presence of diospyrin in the 
diffraction data.  
2.6 Bioinformatics software  
2.6.1 Clustal W and MUSCLE 
Clustal W is a general purpose multiple sequence alignment program for 
DNA or proteins. It calculates the best match for the selected sequences, and aligns 
them so that the identities, similarities and differences between the sequences can be 
seen. It also generates cladograms or phylograms, which are useful for studying 
evolutionary relationship between sequences. This information is very useful in 
designing experiments to test and modify the function of specific proteins and in 
identifying new members of protein families. Clustal W2 (Larkin et al., 2007) is 
available from the EBI website. 
MUSCLE (Edgar, 2004a, Edgar, 2004b)  is another program for creating 
multiple sequence alignment of amino acids or nucleotide sequences. It is predicted 
to be faster and more accurate than ClustalW. The algorithm of this tool works by 
first generating a tree by a method called as k-mer clustering based on the number of 
sub-sequences that two sequences have in common. In the second step, the tree is 
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used to construct progressive alignment. From the multiple alignments, a pair-wise 
identity of each pair of sequences is computed. This gives a new distance matrix 
from which a new tree is estimated and thus it leads to improvement of multiple 
sequence alignment. The tool uses several iterations of tree and sequence alignment 
refinement. 
2.6.2 PSIPRED 
PSIPRED (Jones, 1999) is a protein structure prediction server developed by 
the Bioinformatics group at UCL Department of Computer Science. It is a server that 
aggregates several structure prediction methods into one location. Several prediction 
methods such as PSIPRED v3.0, MEMSAT3 & MEMSAT-SVM, pGenTHREADER 
and pDOMTHREADER are available as choice for the user. The input single letter 
amino acid code is submitted via the server and the results are sent via email. 
2.6.3 PROSITE 
PROSITE (Gasteiger et al., 2003) is a web-based tool available from the 
ExPASy Proteomics Server. The tool identifies and predicts structural and functional 
patterns for a protein sequence. These predictions are based on the patterns and 
profiles specific for more than a thousand protein families and domains stored in the 
database. Each of these signatures comes with documentation providing background 
information on the structure and function of these proteins. PROSITE is 
complemented by ProRule. ProRule is a collection of rules based on profiles and 
patterns, which provides additional information about functionally and structurally 
critical amino acids. 
2.6.4 Phyre and BioInfoBank MetaServer 
Phyre (Kelley & Sternberg, 2009) is a protein homology/analogy recognition 
server maintained by the bioinformatics group at Imperial College London. Phyre 
generates models that are produced based on finding a sequence alignment to a 
known structure, copying the coordinates and relabeling the residues according to the 
sequence provided by the user. The tool uses profiles generated by PSI-Blast for both 
the sequence provided by the user and the sequences of the known structures. This 
enables the tool to detect remotely homologous structures. Phyre performs a profile-
profile matching algorithm together with predicted secondary structure matching. 
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While modelling insertions or deletions, Phyre makes changes to the backbone of the 
known structure / template. 
BioInfoBank MetaServer (Ginalski et al., 2003) is a structure prediction 
server that provides access to various fold recognition, function prediction and local 
structure prediction methods. Amino acids are deposited to the sever with a reference 
name for the job and an e-mail address. All results of fold recognition server are 
translated into uniform formats and they can be viewed on the web page. The 
information extracted from the raw output of the servers includes the PDB codes of 
the hits, the alignment and the similarity scores specific for every server. The Meta 
Server is coupled to consensus servers that provide jury predictions based on the 
results collected from other services. 
2.6.5 Insight II  
Insight II is a comprehensive graphic molecular modelling program from 
Accelrys. With the aid of other programs such as CHARMm, Insight II can be used 
to virtually build or manipulate any class of molecule or molecular system. It has 
several applications such as molecular docking, superimposition, molecular orbital 
calculations, conformational search using molecular mechanics and dynamics and 
dynamic simulation.  Insight II was used to model M. tuberculosis GyrA. 
2.6.6 AutoDock Vina 1.0.2 
AutoDock Vina is a new open-source program for drug discovery, molecular 
docking and virtual screening. It has been designed and implemented by Dr. Oleg 
Trott at The Scripps Research Institute. For its input and output, Vina uses the 
PDBQT molecular structure file format. PDBQT files can be generated and viewed 
using MGLTools. It can be run as standalone software on Windows XP, Linux, and 
Mac operating systems. Several auxiliary software programs such as MGL Tools, 
PyMOL can be useful in docking and virtual screening with AutoDock Vina. Auto- 
Dock Vina was used for virtually screening at the putative Ca2+-binding site in GyrA.  
 
 
 
 
  
Chapter 2 
 
112 
 
2.6.7 Discovery Studio 2.5.5 
Discovery Studio is a life science modelling and simulation suite of 
applications focused on optimizing the drug discovery process from Accelrys. It can 
be used to investigate and test hypothesis in silico prior to experimental 
implementation using its life science modelling and simulation tools. The system 
requirement for the software is Windows 2003 and higher versions, Red Hat® 
Enterprise Linux® 4.0 and SUSE® Linux Enterprise 10. LibDock protocol is 
available in Discovery Studio 2.5.5 for virtual docking experiments.  The protocol 
uses protein site features referred to as HotSpots. HotSpots consist of two types: 
polar and apolar. A polar hotspot is preferred by a polar ligand atom (hydrogen bond 
donor or acceptor). An apolar atom (a carbon atom) prefers an apolar HotSpot. The 
receptor HotSpot file is calculated prior to the docking procedure. The rigid ligand 
poses are placed into the active site and HotSpots are matched as triplets. The poses 
are pruned and a final optimization step is performed before the poses are scored. 
Libdock was used for the in-silico docking of diospyrin onto the M. tuberculosis 
GyrB43 model. 
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Chapter 3: Unique features of M. tuberculosis   
DNA gyrase 
 
 
 
Bacterial DNA gyrase is one of the proven targets for antibacterial 
chemotherapy (Maxwell, 1997). It is a type II DNA topoisomerase found in all 
bacteria. Most of our current information is related to the enzyme from 
 E. coli, a Gram-negative bacterium, with limited information about the DNA 
gyrase from Mycobacterium tuberculosis, a Gram-positive bacterium. Although 
there is similarity between the DNA gyrase from these two bacteria, there are 
also key differences, which can be exploited for identifying new drug molecules 
for tuberculosis. Keeping this in mind, bioinformatics analysis was performed 
which led to the identification of unique features of M. tuberculosis DNA gyrase:  
A. Prediction of the presence of 40 additional amino acids at the GyrB N-
terminus. 
B. The presence of a predicted putative Ca2+-binding site in M. tuberculosis 
GyrA subunit. 
 
 
 
 
 
 
 
 
 
 
  
Chapter 3  
 
114 
 
3.1 Purification of M. tuberculosis DNA gyrase 
Mycobacterium tuberculosis GyrA and GyrB subunit were over-expressed 
and purified using the expression plasmids pET20-gyrA and pET20-gyrB (Huang et 
al., 2006) respectively transformed in BL21 (DE3) pLysS cells as described in the 
Materials and Methods section. On average, 1 mg of purified protein was obtained 
from a 1 L culture. The molecular weights of purified GyrA and GyrB subunits with 
C-terminal histidine tags are 93-kDa and 79-kDa respectively. The quality of the 
purified enzyme was assessed by SDS-PAGE (Figure 3.1) and assays were 
performed to test the enzyme activity. The purified GyrA and GyrB subunits 
exhibited DNA supercoiling, relaxation and decatenation activity (Figure 3.2). The 
protocol for the expression and purification of the wild-type protein was also used for 
the expression and purification of GyrB40N∆ and GyrA proteins with mutation in 
the Ca2+ -binding site. 
 
Figure 3.1: SDS-PAGE (12%) of DNA gyrase subunits purified by affinity 
chromatography. The left panel (A) shows different fractions (represented by 
numbers) of GyrA and the right panel (B) shows different fractions of GyrB purified 
from a His Trap HP IMAC 5 ml column. 
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Figure 3.2: Enzyme activity of purified M. tuberculosis DNA gyrase. The left 
panel (A) shows the supercoiling activity and the right panel (B) shows the 
relaxation activity of purified DNA gyrase subunits mixed in equimolar 
concentration. A range of concentrations of A2B2 were incubated with 0.5 µg relaxed 
pBR322 in the presence of ATP & spermidine for the supercoiling assay (A) and 0.5 
µg supercoiled pBR322 in the absence of ATP and spermidine for the relaxation 
assay. NC: nicked circular DNA, R: relaxed topoisomers, SC: supercoiled DNA. 
3.2 Bioinformatics analysis of M. tuberculosis 
DNA gyrase 
Bioinformatics analysis was performed for both the subunits of M. 
tuberculosis DNA gyrase to identify any unique structural features of the enzyme in 
comparision to other well-studied bacterial DNA gyrase such as E. coli DNA gyrase. 
The first stage of the analysis involved multiple sequence alignment using ClustalW 
1.83 followed by advance homology modelling and docking studies. 
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3.3 M. tuberculosis GyrB promoter analysis 
There are structural differences between the M. tuberculosis GyrB and E. coli 
GyrB subunits and these have been investigated. For example, E. coli GyrB has a 
large insertion closer to the carboxy-terminus which is absent in M. tuberculosis 
GyrB (Schoeffler et al., 2010, Madhusudan & Nagaraja, 1995). In order to identify 
other structural differences, multiple sequence alignment was performed between the  
M. tuberculosis GyrB and other bacterial GyrB sequences using ClustalW 1.83. 
 The multiple sequence alignment indicated the presence of 40 amino acids at 
the N-terminus of GyrB subunit as shown in Figure 3.3. 
 
Figure 3.3: Multiple sequence alignment of bacterial GyrB using ClustalW 1.83 
(Larkin et al., 2007). The 40 additional amino acids at the N-terminus of  
M. tuberculosis GyrB is enclosed in a rectangle. 
The N-terminus of GyrB is involved in ATP binding and hydrolysis (Ali et 
al., 1993). Therefore, it was important to investigate if there is any effect of these 
additional 40 additional amino acids on the DNA gyrase activity.  
Besides this, there is also a discrepancy between the M. tuberculosis GyrB 
sequences retrieved from different databases. For example, in the case of NCBI code 
CAB02426 for M. tuberculosis H37Rv GyrB, the 40 additional amino acids are 
present in the sequence starting with amino acids MGKNEARRSA. While the same 
protein cross-referenced in UniProtKB/Swiss-Prot as P0C5C5, lacks these additional 
amino acids and the sequence starts with MAAQKKKAQD. But for other  
M. tuberculosis strains, such as M. tuberculosis T92 in UniProtKB/Swiss-Prot, the  
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GyrB sequence (UniProtKB/Swiss-Prot: D5XPA3) has 40 additional amino acids 
and starts with MGKNEARRSA. Similarly, in case of M. bovis AF2122/97 both the 
NCBI (CAD92867) and UniProtKB/Swiss-Prot (Q7U312) indicates the presence of 
an additional 40 amino acids at the GyrB N-terminus. 
Due to these discrepancies in the exact start of GyrB between different 
sequences and databases, it was important to determine the exact start site of GyrB 
and if there is any significance of these additional 40 amino acids on the activity of 
the enzyme. As we know from previous work (Unniraman et al., 2002) on  
M. tuberculosis gyrase, the genes encoding the two subunits are present next to each 
other in the genome, with gyrB upstream of gyrA. As a result, the primary transcript 
is dicistronic and in addition to the principle promoter, there are multiple weaker 
promoters that appear to fine-tune transcription. Thus in this study it will also be 
interesting to investigate if there are any promoter elements within these 40 amino 
acids of M. tuberculosis GyrB. The investigation was done at the level of promoter, 
RNA and protein by promoter analysis, RT-PCR (reverse transcriptase-PCR) and 
mutation studies respectively. The work on promoter analysis and RT-PCR was done 
in collaboration with Dr. Amanda Brown and Prof. Tanya Parish (Barts & the 
London, Queen Mary's School of Medicine and Dentistry, London). 
 
3.3.1 RT-PCR for M. tuberculosis GyrB transcript 
 The first stage of the study involved RT-PCR to determine if the transcript 
includes the sequence corresponding to the additional 40 amino acids on the GyrB N-
terminus. Based on the M. tuberculosis codon usage (Andersson & Sharp, 1996) and 
the Shine-Dalgarno consensus sequence (Agarwal et al., 2006), the putative 
ribosome-binding site (RBS) is probably present in the sequence corresponding to 
the addition 40 amino acids as shown in the sequence below. 
.> Intergenomic sequence: 4997- 5243 
cac gtcgatcggc ccagaacaag gcgctccggt cccggcctga gagcctcgag gacgaagcgg 
atccgtatgc cggacgtcgg gacgcaccag gaagaaagat gtccgacgca cggcgcggtt agatg 
ggtaa aaacgaggcc agaagatcgg ccctggcgcc cgatcacggt acagtggtgt gcgaccccct 
gcggcgactc aaccgcatgc acgcaacccc tgaggagagt attcggatcg tg 
// 
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The putative ribosome-binding site (RBS) is underlined and boldfaced. The promoter 
elements are only in bold. 
The following sets of nested primers were designed for RT-PCR as shown in the 
Figure 3.4: 
1. Forward primer (F-1.1): upstream near the start of the region corresponding 
to the additional 40 amino acids at position 5109 bp. 
2. Forward primer (F-1.2): at the start of the region corresponding to the 
additional 40 amino acids at position 5123 bp. 
3. Forward primer (F-2): in the middle of the region corresponding to the 40 
amino acids at position 5195 bp. 
4. Forward primer (F-3): 5 bp after at the end of 40 amino acids at position 5247 
bp. 
5. Reverse primer (R): at position 5433 bp. 
The sequence of the primers and the RT- PCR conditions are described in the 
Materials and Methods section. Before performing RT-PCR, RNA prepared from 
the crude extract of M. tuberculosis cells was divided into two batches for making 
cDNA. In one of the batch reaction mixture 1 µl of Superscript II reverse 
transcriptase was added (cDNA+RT). The other batch included all of the components 
apart from reverse transcriptase (cDNA-RT). cDNA-RT acts as a control to show 
that the product amplified in the cDNA+RT is due to RNA reverse transcribed from 
cDNA rather than genomic DNA contamination. Another control without the 
template was included to show that there is no DNA contamination and a control to 
show that the PCR is working. 
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Figure 3.4: RT- PCR for M. tuberculosis GyrB transcripts. (A)Cartoon 
representation of the position of RT-PCR primers. (B)The RT-PCR products obtained 
with different primers (F-1.1, F-1.2, F-2, F-3, and R). cDNA+RT are the test samples 
with the template cDNA and reverse transcriptase. cDNA-RT lacks reverse 
transcriptase; gDNA (genomic DNA) is a positive control; blank contains all the 
ingredients except template to show that there is no DNA contamination. L-1 kb: 
Promega- cat # G5711 DNA ladder. 
As shown in the Figure 3.4, PCR products are obtained with all the primers 
(F-1.1, F-1.2, F-2, F-3) both including and excluding the 40 bp region; although the 
bands obtained with F-1.1, F-1.2 are weaker than the bands due to the other two 
primers. No PCR products are present in the cDNA-RT control, which shows that the 
bands in cDNA+RT are due to PCR products of cDNA. The gDNA control clearly 
demonstrates that the PCR conditions were optimal and the blank control shows that 
A. 
B. 
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there is no DNA contamination in the starting material. The bands in the blank and 
cDNA-RT may be due to primer-dimer. 
 This RT-PCR experiment clearly demonstrates that the region corresponding 
to the 40 amino acids is also expressed in the transcripts (F-1.2, F-2). This was also 
verified by sequencing the RT-PCR products. 
3.3.2 Mass spectrometric analysis 
 After verifying that there are some species of transcript that code for 
the additional 40 amino acids, the next step of the investigation was to identify if 
these additional amino acids are present in the protein. Due to safety, issues and the 
amount of protein required for N-terminal sequencing it was not possible to isolate or 
over-express native GyrB from the crude extract of M. tuberculosis cells. However, it 
was feasible to verify if these 40 amino acids are present in heterologous expression 
of the protein in E. coli  before generating a deletion mutant. The deletion mutant 
was generated to see if there is any effect of this mutation on the enzyme activity. 
The GyrB band from an SDS-PAGE was submitted to the John Innes 
Proteomics facility for Orbitrap analysis. As shown in the Figure 3.5, the mass 
spectrometric analysis indicates that the 40 additional amino acids are present in the  
M. tuberculosis GyrB over-expressed in E. coli. We expect the presence of 40 
additional amino acids in the over-expressed M. tuberculosis GyrB because the 
pET20 vector has its own ribosomal-binding site (RBS). This experiment only 
confirmed the expression of 40 additional amino acids.  
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Figure 3.5: Orbitrap analysis of M. tuberculosis GyrB over-expressed in E. coli 
BL21 indicates the presence of 40 additional amino acids (enclosed in the 
rectangle). Observed peptides are indicated in red. 
3.3.3 GyrB N40∆ deletion mutant 
 The GyrB N40∆ deletion mutant was constructed using PCR by amplifying 
the GyrB sequence excluding the region coding for the additional 40 amino acids, 
and the amplified PCR product was cloned into pET-20 as described in the 
Materials and Methods section. The plasmid referred as pET-20- GyrB N40∆ was 
verified by big dye sequencing and the deletion mutant was expressed in E. coli 
BL21 (DE3) pLysS. Since the protein was his-tagged, it was purified by affinity 
chromatography (HisTrap HP IMAC 5 ml columns). The protein was also further 
purified by gel filtration (Superdex 200 pg; 16/60) for setting up crystallisation 
screens as shown in Figure 3.6.  
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Figure 3.6: Different fractions of GyrBN40∆ deletion mutant purified by 
HisTrap HP IMAC 5 ml and Superdex 200 pg; 16/60 column. The alignment of 
sequencing data from the start of the sequence in pET-20-GyrBN40∆ (bottom) and 
GyrBN40∆ sequence (top) is shown. The sequence does not start with the codon ATG 
as in pET-20- GyrB. The unshaded part of the sequence data is the vector sequence. 
The supercoiling, relaxation and decatenation activity of the purified GyrB 
N40∆ deletion mutant was compared with GyrB WT. As shown in the Figure 3.7& 
Figure 3.8, there was no effect of the deletion on the activity of the enzyme. This 
demonstrates that the presence or absence of 40 amino acids at the N-terminus of  M. 
tuberculosis GyrB has no effect on the enzyme activity.  
 
 
 
 
 
  
Chapter 3  
 
123 
 
 
 
Figure 3.7: Effect of GyrBN40∆ on the decatenation activity of M. tuberculosis 
DNA gyrase. There is no difference between the decatenation activity of the GyrB 
WT (A) and GyrB N40∆ mutant (B). The assay was done at a range of concentrations 
of DNA gyrase. kDNA is trapped in the gel well, while dkDNA 
(decatenated minicircles) migrates faster than kDNA as indicated by the bands in the 
picture. 
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Figure 3.8: Effect of GyrB N40∆ on the supercoiling and relaxation activity of  
M. tuberculosis DNA gyrase. There is little or no difference between the 
supercoiling (A & B) and relaxation activity (C & D) of the GyrB WT and GyrB 
N40∆ mutant. NC: nicked circular DNA, R: relaxed topoisomers, SC: supercoiled 
DNA. 
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3.3.4 Promoter analysis 
Based on the above observations, it seems that there is no functional 
significance to the 40 amino acids at the N-terminus of GyrB, but at the 
transcriptome level two RNA species with and without the region expressing the 40 
amino acids are found. Due to experimental limitations, investigation into the native 
GyrB from M. tuberculosis was not possible. The question therefore still exists what 
is the significance of the sequence encoding these additional amino acids and should 
they be included in the sequence for GyrB? In previous work (Unniraman et al., 
2002) on M. tuberculosis DNA gyrase promoters, putative promoter elements 
referred to as PB1 are predicted to be located upstream of the gyrB gene in addition to 
several other promoters that appear to fine-tune transcription. Interestingly these 
promoter elements were predicted to lie in the same region as that coding for the 
additional 40 amino acids, as shown in the Figure 3.9. 
 
Figure 3.9: Promoters of M. tuberculosis DNA gyrase. (A) The relative position of 
different promoters with respect to gyrB and gyrA genes. PB1 is predicted to be the 
primary gyr promoter, while PA and PR are weak promoter elements and have been 
predicted to be regulatory in function. (B) Sequence of the putative promoter 
elements. Promoter elements of PB1 that are present in the region coding 40 amino 
acids at the N-terminus are indicated in bold (Unniraman et al., 2002). 
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PB1 shows extensive conservation with Pgyr, the promoter driving the gyr 
genes of M. smegmatis, indicating that they are evolutionarily related. The other 
promoters are weak and may have a regulatory role; for example PA, located 
upstream of gyrA gene is weaker than PB1. PR overlaps PB1 and its function is also 
regulatory. When this sequence was analysed by Artemis software (Rutherford et al., 
2000), TCGGCC and TACAGT were identified as the -35 and -10  sequences as 
shown in Figure 3.10. The result was the same as predicted before (Unniraman et 
al., 2002). 
 
 Figure 3.10: Screen capture of Artemis analysis of gyr promoter elements (-35 
and -10) (http://www.sanger.ac.uk/resources/software/artemis/). As indicated by 
arrows the promoter elements are present in the region encoding the predicted 40 
amino acids at the N-terminus of GyrB.  
 Therefore, it was decided to do promoter analysis using the vector pSM128. 
pSM128 is a promoter-less lacZ fusion vector that is routinely used for the analysis 
of mycobacterial promoters (Jain et al., 2005, Haydel et al., 2002, Parish et al., 2001) 
and also been used to conduct rapid antimycobacterial drug screening (Srivastava et 
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al., 1997) and screen for potential vaccine strains (Kumar et al., 1998). Any 
sequences that are predicted to have promoter elements can be cloned into pSM128 
and analysed for promoter activity. This system provides an advantage for studying 
mycobacterial promoters as mycobacterium do not naturally produce β-galactosidase 
and therefore no background enzyme activity is present. 
The following two plasmids were generated for the analysis:  
1. pSM-128-Met: cloning 125 bp upstream of the predicted start site (4997-5125 
bp; Met (atg) into pSM128. The sequence cloned into the plasmid is as 
follows: 
> Met: 4997-5125 bp 
cac gtcgatcggc ccagaacaag gcgctccggt cccggcctga gagcctcgag gacgaagcgg 
atccgtatgc cggacgtcgg gacgcaccag gaagaaagat gtccgacgca cggcgcggtt ag atg 
// 
 
2. pSM-128-Val: cloning the region from pSM-128-Met till the end of 40 amino 
acids ending with Val (gtg) into pSM128. The sequence cloned into the 
plasmid is as follows: 
.> Intergenomic sequence Val: 4997- 5243 
cac gtcgatcggc ccagaacaag gcgctccggt cccggcctga gagcctcgag gacgaagcgg 
atccgtatgc cggacgtcgg gacgcaccag gaagaaagat gtccgacgca cggcgcggtt agatg 
ggtaa aaacgaggcc agaagatcgg ccctggcgcc cgatcacggt acagtggtgt gcgaccccct 
gcggcgactc aaccgcatgc acgcaacccc tgaggagagt attcggatcg tg 
// 
These plasmids were then transformed into M. smegmatis mc2-155 by 
electroporation. The crude extract of the transformed cells was used to assay the 
promoter activity by recording the formation a soluble yellow product at 410 nm. 
This product is formed by conversion of the substrate nitrophenyl-β-D-
galactopyranoside (ONPG) to o-nitrophenol (ONP) by β-galactosidase. The detailed 
procedure for the assay is provided in the Materials and Methods.  
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Figure 3.11:  Colonies of M. smegmatis mc2-155 obtained by transformation of the cells 
with pSM-128, pSM-128-Met and pSM-128-Val plasmids. The colonies transformed with 
pSM-128 (A), with pSM-128-Met (B) and and pSM-128-Val (C) are colourless, light blue and 
dark blue respectively.
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M. smegmatis mc2-155 containing pSM-128-Val gave blue colonies in 
comparison to colonies transformed with pSM-128-Met, as shown in the Figure 
3.11. This indicated the possibility of promoter activity with pSM-128-Val. The 
crude extract from the transformed cells were assayed for active promoter activity by 
recording the formation a soluble yellow product, o-nitrophenol (ONP) at 410 nm. 
As expected, the results (Figure 3.12) of the assay using cell crude extracts showed 
at least 10 times more β-galactosidase activity with pSM-128-Val in comparison to 
pSM-128-Met. The background activity in the crude extract of pSM-128 
transformants was low in comparison to pSM-128-Met transformants. 
 
 
 
Figure 3.12: β-galactosidase activity recorded from the crude extract of M. 
smegmatis mc2-155 cells transformed with pSM-128, pSM-128-Val and pSM-
128-Met respectively. β-galactosidase activity will only be observed in the crude 
extracts of the cells transformed with pSM-128 plasmid having active promoter 
elements. β-galactosidase expression regulated by the active promoter leads to 
formation of a soluble yellow product o-nitrophenol (ONP) from nitrophenyl-β-D-
galactopyranoside (ONPG). The activity was recorded on a spectrometer at 410 nm. 
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Thus, these experiments further confirm the prediction of the presence of 
promoter elements in the region corresponding to the predicted 40 amino acids at the 
GyrB N-terminus. The data indicate that the real start codon for  
M. tuberculosis GyrB is GTG (Val).  This is the first report that demonstrates that the 
additional 40 amino acids at the GyrB N-terminus, recorded by several databases 
such as NCBI and UniProtKB/Swiss-Prot does not have a functional significance and 
it may be an annotation discrepancy. At present, I have not been able to identify the 
reason for the existence of two transcript species. Future work in identifying the 
regulation and coordination of multiple promoters and primary promoter may 
provide clue. At present, we are limited by the little information we have about the 
transcription and translation of M. tuberculosis DNA gyrase gene in-vivo. These 
studies in future will be helpful for answering basic questions about mycobacterial 
growth and metabolism that will have impact on designing effective drugs for TB.  
3.4 A putative Ca2+ -binding site in DNA gyrase 
M. tuberculosis is very different in its physiology and lifestyle from the well-
studied model organism E. coli. These differences also exist in terms of their 
topoisomerases. Topo IV (a type II topoisomerase) is absent in M. tuberculosis 
unlike E. coli (Aubry et al., 2004). M. tuberculosis DNA gyrase is also efficient in 
relaxation and decatenation activity in comparison to E. coli gyrase. It is logical to 
attribute the efficient relaxation and decatenation of M. tuberculosis DNA gyrase to 
the absence of topo IV (Figure 3.13). This led to the investigation of differences 
between M. tuberculosis DNA gyrase and other bacterial DNA gyrase at the 
sequence level.   
Multiple sequence alignment was performed for M. tuberculosis GyrA and 
other bacterial GyrA using ClustalW 1.83 default parameters (Larkin et al., 2007).  
As shown in the multiple sequence alignment (Figure 3.14), there is a characteristic 
Ca2+-binding sequence in M. tuberculosis GyrA: 504DVSDEDLIAREDV516. 
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Figure 3.13: DNA gyrase is the only typeII topoisomerase in M. tuberculosis, 
and is efficient in supercoiling, relaxation and decatenation.  
 
Figure 3.14: Multiple sequence alignment of bacterial GyrA using ClustalW 
1.83 (Larkin et al., 2007). The characteristic Ca2+-binding sequence present in  
M. tuberculosis DNA GyrA aligned with other bacterial GyrA is enclosed in the 
rectangle. The putative Ca2+-binding sequence fits with loop and PS00018 pattern. 
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Further analysis of M. tuberculosis GyrA by PROSITE at EXPASY 
(Gasteiger et al., 2003); indicated that the sequence ‘504 DVSDEDLIAREDV 516’ 
is a potential EF-hand-like calcium binding domain. 
Based on the sequence alignment (Figure 3.15), sequences homologous to 
the putative Ca2+- binding site are also found in the closely related Mycobacterium 
bovis, Brucella melitensis and Corynebacterium diphtheriae. Interestingly B. 
melitensis and C. diphtheriae are human pathogens, and C. diphtheriae lacks topo 
IV. This indicates that the presence of the Ca2+- binding site in GyrA may have some 
correlation with the dual role that DNA gyrase has to play in the absence of topo IV. 
The significance of gyrase in the absence of topo IV is also evident from the fact that 
in the absence of topo IV, mutations in gyrA gene confer quinolone resistance (Payot 
et al., 2002, Sierra et al., 2005).  
 
 
Figure 3.15: Multiples sequence alignment for GyrA from B. melitensis,  
M. tuberculosis and C. diphtheriae. The sequence of the putative Ca2+- binding site 
is enclosed in a square. 
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3.4.1 EF-hand Ca2+ - binding domain 
The EF-hand proteins have a characteristic helix-loop-helix Ca2+-binding 
motif and they constitute one of the largest protein families involved in numerous 
biological processes. There are now 66 subfamilies for this protein (Kawasaki et al., 
1998, Kretsinger & Nockolds, 1973, Ravasi et al., 2004). EF-hands are divided into 
two major groups: the canonical EF-hand (calmodulin and prokaryotic calerythrin) 
(Figure 3.16) and the pseudo EF-hands, exclusively found in the N-termini of S100 
and S100-like proteins (Figure 3.16). The major difference between the two groups 
lies in the Ca2+-binding loop: the 12-residue canonical EF-had loop binds Ca2+ 
mainly via side chain carboxylates or carbonyls, which are denoted by loop sequence 
position: 1, 3, 5, 12; whereas the psuedo EF-hand loop is 14-residues with positions 
1, 4, 5 and 9 coordinating the Ca2+ (Figure 3.18). Water molecules may also be 
involved in coordinating Ca2+. Among all the structures reported for Ca2+ - binding 
proteins, the majority of EF-hand motifs are paired; proteins with odd numbers of 
EF-hands are coupled through homo-or heterodimerization (Hunter & Chazin, 1998, 
Grabarek, 2006, Ravulapalli et al., 2005). The situation is similar in the case of M. 
tuberculosis GyrA, the single EF-hand-like Ca2+-binding site is paired as M. 
tuberculosis GyrA59 (N-terminal) exists as a dimer (Tretter et al., 2010). Although 
the crystal structure (PDB code: 3ILW) does not include the putative Ca2+ -binding 
site. This pairing enables communication and many EF-hands show positive 
cooperativity. 
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Figure 3.16: The two major groups of EF-hands: (A) Canonical EF-hand 
domain from Saccharopolyspora erythraea (PDB code: 1nya) and (B) Pusedo-
canonical EF-hand from CalbindinD9K (PDB code: 1b1 g). The protein has both 
the N-terminal psuedo EF-hand Ca2+-binding ligand (blue) and the C-terminal 
canonical EF-hand (green) (Zhou et al., 2006). The red spheres represent the Ca2+ 
atoms. 
Secondary structure prediction of M. tuberculosis GyrA by PSIPRED (Jones, 
1999) indicated that the predicted Ca2+- binding site is loop-helix-loop-strand as 
shown in Figure 3.17. This secondary structure prediction does not follow the 
textbook definition of an EF-hand (Gifford et al., 2007). There are examples of other 
bacterial proteins, which have different EF-hand secondary structrure patterns. The 
best examples of this are the periplasmic galactose-binding protein (Salmonella 
typhimurium; PDB code: 1gcg) (Vyas et al., 1987) and alginate-binding protein 
(Sphingomonas sp.; PDB code: 1kwh) (Mishima et al., 2003) (Figure 3.17). 
Prokaryotic EF-hand-like proteins are involved in Ca2+ signalling and 
homeostasis in bacteria (Michiels et al., 2002, Rigden et al., 2003, Rigden & 
Galperin, 2004, Yang, 2001). They contain flexible lengths of Ca2+-binding loops 
that differ from the EF-hand motifs but their coordination properties resemble those 
of classical EF-hand motifs. 
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A recent publication (Zhou et al., 2006) on an improved pattern search 
method for the identification of EF-hand and EF-like Ca2+-binding proteins  
predicted a Ca2+- binding site in a closely related species M. bovis. The signature 
sequence predicted to be a Ca2+- binding site in M. bovis GyrA (NCBI code: 
CAD92868) is also found in M. tuberculosis GyrA (NCBI code: CAB02427). This is 
an interesting fact as M. bovis has been reported to be a causative agent of 
tuberculosis in humans like M. tuberculosis (Jou et al., 2008). 
This method (Zhou et al., 2006) is based on a series of patterns that were 
generated from the metal-binding properties of currently available EF-hand proteins 
and the helical structural context around the Ca2+-binding loop. The pattern PS00018 
for predicting the canonical EF-hand sites (http://us.expasy.org/cgi-
bin/nicesite.pl?PS00018) were modified by allowing more choices (Glu, Gln and 
Ser) at position 1 (axis X) and adding constraints at the flanking helical regions. A 
modified pattern for the prediction of psuedo EF-hand sites was also generated by 
loosening the constraints at the C-terminal canonical EF-hand and including reserved 
residues in the N-terminal pseudo EF-hand, which were called eloopf, eloop, loopf, 
and loop. This new pattern in comparison to PS00303, significantly improved the 
predictive accuracy and sensitivity. Based on the sequence, the putative Ca2+-binding  
site in GyrA fits with the  loop and PS00018 pattern (Zhou et al., 2006).    
The loop pattern sequence is: 
 [DNS]-x-[DNS]-{FLIVWY}-[DNESTG]-[DNQGHRK]-{GP}-[LIVMC]-
[DENQSTAGC]-x (2)-[ED]. 
The PS00018 sequence is: 
 D-x-[DNS]-{ILVFYW}-[DENSTG]-[DNQGHRK]-{GP}-[LIVMC] 
[DENQSTAGC]-x (2) - [DE]-[LIVMFYW]. 
The pattern is represented by PROSITE PAttern. In this format, amino acids are 
represented by IUPAC one-letter codes, x for any amino acid, [ ] represents accepted 
amino acids, { } represents the amino acids that are not accepted, '-' separates the 
pattern element, and x (n) represents the n times repetition of an element. 
Thus, there is supporting bioinformatic evidence for the presence of EF-hand 
like Ca2+ - binding domain in M. tuberculosis GyrA.  
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Figure 3.17: The non-cannonical EF-hand Ca2+-binding sites. (A) Ca2+-binding 
site in periplasmic galactose-binding protein from Salmonella typhimurium; (PDB 
code: 1gcg) with a helix-loop-strand pattern (Mishima et al., 2003, Zhou et al., 
2006). (B) Secondary structure prediction of M. tuberculosis GyrA by PSIPRED 
(Jones, 1999) showing helix-loop-strand structure. 
A. 
B. 
  
Chapter 3  
 
137 
 
 
 
Figure 3.18: Illustration of differences between canonical and pseudo-EF hand. 
Consensus sequence of canonical EF-hand (A) and pseudo EF-hand (B) domains 
based on the prediction method. n: the hydrophobic residues within the flanking 
helices, #: the potential Ca2+ - binding ligands involving the main chain carbonyl 
groups (Zhou et al., 2006). 
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3.4.2 Model for the Ca2+- binding site 
Recently crystal structures for the N-terminal (PDB codes: 3ILW & 3IFZ) 
(Tretter et al., 2010) and C–terminal  domains (PDB code : 2ZJT) (Fu et al., 2009) of 
M. tuberculosis GyrA subunit has been solved. However, both the structures lack the 
putative Ca2+-binding site and there is no crystal structure for the complete M. 
tuberculosis GyrA subunit. In the absence of the crystal structures containing the 
putative Ca2+- binding site, molecular homology modelling was done using the 
package Insight II (Accelrys). This protein modelling work was done in collaboration 
with Dr Faridoon Yousafzai (Computational and Systems Biology, John Innes 
Centre). 
 To build a 3-D homology model of the M. tuberculosis GyrA subunit, 
suitable templates were searched for by using tools such as the Protein Homology/ 
Analogy Recognition Engine (Phyre) (Kelley & Sternberg, 2009) and the 
BioInfoBank Metaserver (Ginalski et al., 2003). The M. tuberculosis GyrA complete 
sequence was submitted to these search engines and E. coli ParC subunit (PDB code: 
1ZVU) (Corbett et al., 2005) was identified as the top hit from both the servers. The 
N-terminal domain of E. coli Par C subunit (PDB code: 1ZVU) and the C-terminal 
domain of Borrelia burgdorferi GyrA subunit (PDB code: 1SUU) (Corbett et al., 
2004) were used as templates to model respectively the N- and C-terminal domains 
of M. tuberculosis GyrA. Sequence alignment between the template and M. 
tuberculosis GyrA was performed. The alignment between the N-terminus of M. 
tuberculosis GyrA and the N-terminal domain of ParC subunit (PDB code: 
1ZVU) was kept the same as that generated by Phyre (Figure 3.19). The alignment 
between C-terminal domain of M. tuberculosis GyrA and the C-terminal domain of 
Borrelia burgdorferi (PDB code: 1SUU) was generated by MUSCLE (Edgar, 2004b, 
Edgar, 2004a) as shown in Figure 3.19.  For modelling the Ca2+- binding site, PDB 
search and sequence search tools such as BLAST were used to identify suitable 
templates. 
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Figure 3.19: Sequence alignment for M. tuberculosis GyrA. Alignment between 
the N- terminus of M. tuberculosis GyrA and the N-terminal domain of Par C subunit 
(A) generated by Phyre has 39% identity, 61% similarity and 3% gaps. The 
alignment between the M. tuberculosis GyrA C- terminus and the C-terminal domain 
of Borrelia burgdorferi (B) has 25% identity, 51% similarity and 8% gaps. 
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After generating the sequence alignment, the coordinates were transferred 
from the template proteins to the modelling protein and other structural entities such 
as loops were built using the programme Insight II (Accelrys). The final refined 
model was generated by removing bumps, resolving chirality, bond length and 
dihedral angles (Ω values). 
As discussed before, the predicted putative Ca2+-binding site in  
M. tuberculosis GyrA does not follow the standard helix-loop-helix definition. There 
are several other prokaryotic proteins having the Ca2+- binding sites that do not 
follow the canonical EF-hand motif pattern. From the PDB search two such proteins 
were identified: psychrophilic metalloprotease from Pseudoalteromonas (PDB code: 
1H71) (Aghajari et al., 2003) and metallo-protease from Pseudomonas aeruginosa 
(PDB id: 1KAP) (Baumann et al., 1993); both have sequences similar to the EF- 
hand Ca2+-binding site in a loop-loop-strand and a strand-loop-strand structural 
motifs. Initially 1H71 was used as a template to build the putative Ca2+- binding site 
in M. tuberculosis GyrA.  
The Ca2+-binding sites in the homology model and in 1H71 is shown in 
Figure 3.20. The sequence from D504-V516 was forced to adopt the same fold as 
that of the Ca2+-binding site in 1H71. Although the Ca2+-binding site for  
M. tuberculosis GyrA was developed, the structure failed to optimise due to the 
presence of un-resolved bumps in the structure. An alternative strategy was used to 
fit the Ca2+-binding site. While optimising the model including the Ca2+-binding site 
(modelled based on the template 1H71), the entire model was restrained except for 
the five residues on the each side of  the D504-V516 sequence to allow the N- and C- 
terminal domains to adopt suitable orientations relative to each other. This strategy 
was successful and the model was developed, which will be hereafter referred to as 
MtGyrA-1H71. In this model, the Ca2+ coordinated to 6 residues: D504 (side-chain-
O), S506 (side-chain-O), E508 (side-chain-O), L510 (backbone-O), A512 
(backbone-O) and E514 (side-chain-O) in an octahedral geometry. Although, the 
Ca2+ -binding fold is the same as that of template protein, the coordination sphere of 
Ca2+ is different. In the template protein 1H71, alternate residues D49, N51, D53, 
V55 and N57 are bonded to Ca2+, except the last residue N114 that is 56 amino acids 
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away from N57. The Ca2+ is coordinated by side chain atoms except V55 where the 
backbone oxygen is bonded to Ca2+. In the case of M. tuberculosis GyrA model, the 
Ca2+-binding site is composed of six alternating residues, four out of which provide 
side-chains while the other two L510 and A512; provide backbone oxygen atoms for 
Ca2+. 
 
Figure 3.20: Homology model of the M. tuberculosis GyrA Ca2+-binding site 
(MtGyrA-1H71) based on the psychrophilic metalloprotease from Pseudomonas 
sp. (PDB code: 1H71). The cartoon shows the Ca2+-binding site in 1H71 above the 
GyrA Ca2+-binding site for comparison.  
Another protein Staphylococcus aureus metalloproteinase (PDB id: 1BQB) 
(Banbula et al., 1998) having a Ca2+-binding site, was found to have the best 
sequence identity and similarity with the predicted Ca2+-binding site in M. 
tuberculosis DNA gyrase. This template was identified by searching PDB for 
structures having Ca2+ as a ligand (~4000 hits), followed by sequence searching 
D504-V516, which gave 790 hits. The combination of both these techniques along 
with the removal of sequences ≥ 90% identity, found 21 unique chains which were 
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individually examined for the best fit to the predicted Ca2+-binding sequence D504-
V516 in terms of sequence identity and similarity. Using the Staphylococcus aureus 
metalloproteinase (PDB id: 1BQB) as a template another model was generated and 
referred to as MtGyrA-1BQB (Figure 3.21). The template structure had 2 Ca2+ atoms 
in the loop corresponding to the predicted Ca2+ -binding loop of M. tuberculosis 
GyrA. Based on the template, 2 Ca2+ atoms were modelled in MtGyrA-1BQB. 
 
Figure 3.21: Homology model of M. tuberculosis GyrA Ca2+-binding site 
(MtGyrA-1BQB) based on Staphylococcus aureus metalloproteinase (PDB code: 
1BQB). One water molecule coordinates Ca2+-1 and three water molecules 
coordinate Ca2+-2 as represented by yellow and red balls. 
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Although there is 57% similarity and 71% sequence identity between the Ca2+ 
-binding loops of 1BQB and M. tuberculosis GyrA, there are differences in the 3-D 
environment of the Ca2+ atoms. The first difference is that in the case of M. 
tuberculosis GyrA, one of the Ca2+-coordinating residues is S506 but the 
corresponding residue in 1BQB is D179 that coordinates the two Ca2+ atoms. Second, 
in 1BQB, one of the calciums (referred as Ca2+-1) is attached to two water 
molecules, while in the case of MtGyrA-1BQB; it is attached to only one water 
molecule. This is due to E586 coordination in MtGyrA-1BQB, the corresponding 
residue D140 in 1BQB is at a different place and coordinates the other Ca2+ atom 
(referred as Ca2+-2). The Ca2+-2 atom in the case of 1BQB is coordinated to only one 
water molecule, while in case of MtGyrA-1BQB it needs 3 water molecules for an 
octahedral coordination (Figure 3.22). 
 The overall electrostatics of the Ca2+ -binding site is also different in both the 
proteins. 1BQB has six negatively charged (five Ca2+-coordinated and one non-
coordinated acidic residues) and no positively charged residue. On the other hand M. 
tuberculosis GyrA, has five negatively charged (four Ca2+ coordinated and one non-
coordinated acidic residues) and one positively charged residue. 
Due to the unique nature of the predicted Ca2+-binding site in M. tuberculosis 
GyrA, two models namely MtGyrA-1H71 and MtGyrA-1BQB were generated based 
on the metalloprotease from Pseudoalteromonas (PDB code: 1H71) and 
Staphylococcus aureus metalloproteinase (PDB id: 1BQB) respectively. In the 
absence of a complete crystal structure for M. tuberculosis GyrA it is difficult to 
predict which of the models is correct. Mutation studies in the Ca2+-binding site were 
designed to mutate acidic amino acids that have significant importance in 
coordinating Ca2+. For example the quadruple mutant (GyrA D504A, E508A, 
D509A, E514A) described in later sections involves mutation of two acidic residues 
(D504 and E508) from MtGyrA-1H71 and two acidic residues (E509, E514A) from 
MtGyrA-1BQB. E508 is an important acidic residue shown to coordinate Ca2+ in 
both the models. 
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Figure 3.22: Difference between the 3-D environments of the GyrA Ca2+ -
binding site and the Staphylococcus aureus metalloproteinase (PDB id: 1BQB) 
template. The cartoon shows the Ca2+-binding site in 1BQB above the GyrA Ca2+-
binding site for comparison. One water molecule coordinates Ca2+-1 and three water 
molecules coordinate Ca2+-2 as represented yellow and red balls. 
3.5 Conclusion 
DNA gyrase is a type II topoisomerase present in all prokaryotes and plants. 
 The enzyme has been well studied and characterised in E. coli, a Gram-negative 
bacteria, with limited information about the enzyme from pathogenic bacteria such as 
M. tuberculosis. Most of the studies done on M. tuberculosis DNA gyrase have been 
related to inhibitors such as floroquinolones (Aubry et al., 2004). Although the aim 
of my project is to identify novel inhibitors for M. tuberculosis DNA gyrase, it was 
also important to explore the unique characteristic of this enzyme. 
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Bioinformatics analysis was performed to compare M. tuberculosis DNA 
gyrase with other bacterial gyrases. Based on multiple sequence alignment of 
bacterial DNA gyrase, the following two unique features were identified in the  
M. tuberculosis DNA gyrase: 
1.  Prediction of the presence of an additional 40 amino acids at the M. 
tuberculosis GyrB N-terminus. 
2. Prediction of a unique EF-hand like Ca2+ - binding site in M. tuberculosis 
GyrA. 
Bioinformatics analysis predicted the presence of 40 additional amino acids 
on the N-terminus of M. tuberculosis GyrB in comparison to GyrB from other 
bacteria. Since the ATP–binding site is present at the N-terminus of GyrB, 
investigation about the function of these additional amino acids was important. There 
are also differences in the GyrB sequences retrieved from different databases. For 
example M. tuberculosis H37Rv GyrB sequence (NCBI code CAB02426) from 
NCBI has 40 additional amino acids at the GyrB N-terminus, which are absent from 
the same sequence cross-referenced in UniProtKB/Swiss-Prot (P0C5C5).  
The first stage of analysis involved nested RT-PCR with primers designed at 
different positions within and flanking the region encoding the 40 amino acids. The 
RT-PCR results indicated the presence of both the transcript species with and 
without the region encoding the 40 additional amino acids. Due to the inability to 
over-express the protein in M. tuberculosis, it was not possible to confirm the 
presence of these additional 40 amino acids on the N-terminus of native GyrB from 
M. tuberculosis. However, the presence of these amino acids was confirmed by mass 
fingerprinting of protein expressed in E. coli. In future C. glutamicum can also be 
used to express M. tuberculosis proteins. 
A deletion mutant, GyrB N40∆, was generated which had no effect on 
supercoiling, relaxation and decatenation activity of DNA gyrase. There was also no 
effect of the deletion mutation on the novobiocin-sensitivity of the enzyme. This 
indicates that there is no functional significance of these additional 40 amino acids 
on the GyrB N-terminus. Promoter analysis using pSM-128-Val (pSM-128 cloned 
with the sequence encoding the 40 additional amino acids) showed promoter activity 
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with the β-galactosidase assay. These experiments further confirmed the previous 
finding (Unniraman et al., 2002) that the promoter elements are present in the 
sequence encoding the 40 additional amino acids. Therefore, this work has identified 
the starting coding for M. tuberculosis GyrB, which is Val41 instead of Met1. In 
future work it will be interesting to investigate the presence of two transcript species. 
An EF-hand like Ca2+-binding site has never been reported in other DNA 
topoisomerases. A few publications based on the bioinformatics analysis have 
predicted the possibility of the presence of a Ca2+-binding site in DNA gyrase 
(Michiels et al., 2002, Zhou et al., 2006), but there has been no experimental 
evidence in support of the observation. In one publication (Zhou et al., 2006), a Ca2+ 
- binding site was predicted to be present in the M. bovis GyrA subunit. M. bovis is a 
closely-related species to M. tuberculosis and forms the part of M. tuberculosis 
complex (Frothingham, 1995). Interestingly the sequence that was predicted to be a 
Ca2+- binding site in  M. bovis is also present in M. tuberculosis DNA gyrase ‘504 
DVSDEDLIAREDV- 516’. Further characterisation of the M. tuberculosis GyrA by 
PROSITE at EXPASY also identified an EF-hand like Ca2+ - binding site. Another 
interesting fact is that a similar sequence is also found in the GyrA subunit of the 
Gram-positive bacterium Corynebacterium diphtheriae, which lacks topo IV, also 
absent in M. tuberculosis. Topo IV is another type II topoisomerase efficient in DNA 
relaxation and decatenation (Zechiedrich et al., 1997). Along with DNA gyrase, topo 
IV is present in most bacteria, like E. coli, and is the primary decatenase. 
Since there is no crystal structure for the complete M. tuberculosis GyrA, the 
first stage of the investigation involved homology modelling of GyrA. Two 
homology models were generated referred to as MtGyrA-1H71, based on the 
template metalloprotease from Pseudoalteromonas (PDB code: 1H71) and MtGyrA-
1BQB based on Staphylococcus aureus metalloproteinase (PDB id: 1BQB). The Ca2+ 
- binding site is present at the junction of N- and C-terminus domains of GyrA as 
shown in the Figure 3.23. Although the predicted Ca2+-binding site in GyrA is an 
EF-hand like binding site, it does not follow the standard helix-loop-helix pattern 
rather a loop-helix-loop-strand, there are examples of similar bacterial proteins that 
do not follow the standard helix-loop-helix pattern. For example periplasmic 
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galactose-binding protein from Salmonella typhimurium (PDB code: 1gcg) has a 
helix-loop-strand pattern (Mishima et al., 2003, Zhou et al., 2006). The Ca2+-binding 
site seems to follow the loop and PS00018 patterns. These patterns have been used 
for bioinformatics prediction of canonical EF-hand Ca2+ -binding sites (Zhou et al., 
2006). 
 
Figure 3.23: The predicted Ca2+ -binding site in between the N- and C-terminal 
domains of M. tuberculosis DNA gyrase. 
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Chapter 4:  Investigation of a putative Ca2+-
binding site in M. tuberculosis GyrA 
 
Bioinformatics analysis of M. tuberculosis GyrA (Chapter 3) revealed the 
presence of a unique putative Ca2+-binding site. Biochemical analysis to study 
the relevance of Ca2+ and site-directed mutagenesis experiments in support of 
the models (MtGyrA-1H71 and MtGyrA-1BQB) were performed. The 
biochemical analysis involved protein dialysis, protein refolding and limited 
proteolysis experiments. Weak relaxation activity was observed when GyrA was 
dialysed in 1 mM EGTA, which then could be regained by the addition of Ca2+. 
This effect was intense when GyrA was refolded in the presence of 1 mM 
EGTA, leading to the complete loss of relaxation activity with weak supercoiling 
activity. Limited proteolysis experiments done in the presence of Ca2+, 
demonstrated conformational change in the protein, which resulted in 
disappearance of a 47-kDa band.   
Mutations (D504A, E508A, D509A, E514A) in the putative Ca2+-binding 
site affected the supercoiling activity of the enzyme which led to incomplete 
supercoiling. Thus, these experiments demonstrate the significance of the Ca2+ 
and its binding site in GyrA. Due to the significance of the Ca2+-binding site, 
virtual screening was performed at this site to explore it further as a target site 
for novel inhibitors. 
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4.1 Bacterial DNA gyrase Ca2+ selectivity 
According to the bioinformatics analysis, the putative Ca2+- binding site is 
present in M. tuberculosis DNA gyrase but not in E. coli gyrase. This suggests that 
Ca2+ may have a specific role in the activity of M. tuberculosis DNA gyrase. From 
previous studies, we know that E. coli DNA gyrase can supercoil relaxed DNA when 
Ca2+ ion is substituted for Mg2+. Ca2+ also induces the formation of the cleavage 
complex in case of E. coli DNA gyrase (Reece & Maxwell, 1989). On the contrary, 
although M. tuberculosis DNA gyrase has the putative Ca2+- binding site, it shows 
little or no supercoiling in the presence of Ca2+ alone (Figure 4.1). Earlier 
characterisation studies done on this enzyme confirm this finding and also indicate 
the inability of the enzyme to relax supercoil DNA and induce cleavage formation in 
the presence of Ca2+ alone (Aubry et al., 2006a). 
 
Figure 4.1: E. coli and M. tuberculosis DNA gyrase supercoiling assay in the 
presence of 6 mM Mg2+ and Ca2+. NC: nicked Circular DNA, R: relaxed 
topoisomers, SC: supercoiled DNA. 
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An interesting observation was made when subunits of M. tuberculosis and E. 
coli DNA gyrase were mixed. M. tuberculosis GyrA when mixed with equimolar 
concentration of E. coli GyrB exhibited DNA supercoiling activity in the presence of 
6 mM Mg2+, whereas only weak supercoiling was observed in the case of vice versa 
(E. coli GyrA mixed with equimolar concentration of M. tuberculosis GyrB). The 
assay with equimolar concentration of M. tuberculosis GyrA and E. coli GyrB was 
repeated in the presence of 6 mM Ca2+.  In the presence of 6 mM Ca2+, no 
supercoiling activity was observed (Figure 4.2). This indicates that the ability of the 
Ca2+ to support DNA supercoiling depends on the presence of E. coli GyrA and M. 
tuberculosis GyrA cannot substitute it. 
 
Figure 4.2: Supercoiling assay of M. tuberculosis and E. coli hybrid enzyme in 
the presence of 6 mM Mg2+ and 6 mM Ca2+. NC: nicked Circular DNA, R: relaxed 
topoisomers, SC: supercoiled DNA. 
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The results of the experiment can be summarised as follows (Table 4.1): 
 
 
 
 
 
Table 4.1: Summary of supercoiling activity of wild-type and hybrid enzymes in 
the presence Mg2+ and Ca2+. +: activity observed; - : no activity; NT: not tested. 
Studies involving the use of hybrid enzymes have been performed in the past 
for X. albilineans (Hashimi et al., 2008), P. falciparum  (Dar et al., 2007, Dar et al., 
2009) and B. subtilis (Orr & Staudenbauer, 1982) DNA gyrase subunits in 
combination with E. coli DNA gyrase subunits. These studies have provided 
important information about activity of enzyme. In the case of X. albilineans (Xa), 
DNA gyrase shows 20- to 25-fold higher resistance than E. coli DNA (Ec) gyrase to 
albicidin. In order to test the hypothesis that the GyrA subunit confers albicidin 
resistance, hybrid enzyme (XaA+EcB) was reconstituted. The reconstituted hybrid 
enzyme (XaA+EcB) showed the same level of resistance as the native X. albilineans 
DNA gyrase (XaAB). Thus it implies that the GyrA subunit is the albicidin target. 
Similarly it was shown using the hybrid enzyme (XaA+EcB) that 
 X. albilineans GyrA subunit is associated with an inability to relax supercoiled DNA 
(Hashimi et al., 2008). In the case of P. falciparum, hybrid enzyme studies were 
carried out to investigate the importance of a 45-amino-acid residue insertion in the 
Toprim domain of P. falciparum GyrB (Pf GyrB) which is not present in prokaryotic 
DNA gyrase. No DNA cleavage and supercoiling activity was observed with the 45 
amino acid deletion mutant (Pf GyrB∆45) and E .coli GyrA indicating that the 45 
amino acid residues in the Toprim domain of PfGyrB has a role in DNA binding and 
cleavage (Dar et al., 2009).  
 
GyrA GyrB Mg2+ Ca2+ 
E. coli E .coli + + 
M. tuberculosis M. tuberculosis + - 
E. coli M. tuberculosis - NT 
M. tuberculosis E. coli + - 
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Similarly when the B. subtilis DNA gyrase subunits were purified for the first 
time, their activities were verified by reconstituting hybrid enzymes with E. coli 
DNA gyrase subunits (Orr & Staudenbauer, 1982). All these observations are 
summarised in Table 4.2. 
Supercoiling and relaxation assays were also performed for M. tuberculosis 
DNA gyrase in the presence of 4 mM Mg2+ and 1 mM Ca2+. The enzyme activity in 
the presence of this divalent mixture was similar to that in the presence of 4 mM 
Mg2+ alone. 
 
   Table 4.2: Summary of the activity of hybrid enzymes from different sources. 
 
 
 
 
  
GyrA GyrB Enzyme Activity / Effect  
X. albilineans E. coli Albicidin resistance similar to native  
X. albilineans DNA gyrase . 
X. albilineans E. coli No relaxation activity 
E. coli X. albilineans No supercoiling activity but 
relaxation activity observed. 
E. coli P. falciparum 
GyrB∆45 
No DNA cleavage or supercoiling 
activity. 
E. coli B. subtilis Supercoiling activity observed. 
B. subtilis E. coli No supercoiling activity observed. 
M. tuberculosis E. coli Supercoiling activity observed. 
E. coli M. tuberculosis No supercoiling activity observed. 
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4.2 Ca2+-assisted Mg2+- dependent enzyme 
According to the model MtGyrA-1BQB (Figure 3.22), there is the possibility 
of the presence of two Ca2+ in the predicted binding site. It was decided to see if there 
is any effect of Ca2+ chelation on the activity of the enzyme. Since EGTA is a 
specific chelator of Ca2+, it was decided to dialyse the M. tuberculosis GyrA subunit 
in the presence of 1 mM EGTA as described in Material and Methods. There was 
little effect of EGTA dialysis on the supercoiling and decatenation activity of the 
enzyme (Figure 4.3). EGTA dialysis affected the relaxation activity of the enzyme.   
The relaxation activity of the EGTA-dialysed sample was ~2-3 fold weaker 
than the relaxation activity of enzyme dialysed in the absence of EGTA (Figure 4.4, 
A&C). Interestingly, this weak relaxation activity due to EGTA dialysis was 
regained by the addition of 1 mM Ca2+ to the assay and it was similar to the 
relaxation activity of M. tuberculosis GyrA prior to EGTA dialysis (Figure 4.4, 
A&D). The final Ca2+ concentration in the assay was 1 mM and the EGTA 
concentration was 200 µM. 
Time-course experiments were performed to analyse the loss in relaxation 
activity due to the EGTA dialysis of GyrA wild-type. As shown in the Figure 4.5, 
weaker relaxation activity is observed for GyrA dialysed in EGTA at different time 
points in comparison to GyrA dialysed without EGTA. At 125 min and 180 min, we 
observe a ladder of topoisomers for the GyrA dialysed without EGTA; these 
topoisomers may be positive supercoiled and are not observed in GyrA dialysed in 
EGTA. The apparent difference in the rate of the relaxation reaction in the presence 
or absence of EGTA is ~2-3 folds, consistent with the results in Figure 4.4. 
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Figure 4.3: Effect of EGTA dialysis on the supercoiling and decatenation 
activity of M. tuberculosis DNA gyrase. The little effect of EGTA dialysis on the 
supercoiling activity (A) can be seen at 10 & 7 nM; while the effect on decatenation 
activity (B) can be seen at 0.12 µM and 60 nM. NC: nicked Circular DNA, R: 
relaxed topoisomers, SC: supercoiled DNA, dkDNA: decatenated DNA. 
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Figure 4.4: DNA relaxation assay in the presence and absence of 1 mM Ca2+. 
M. tuberculosis gyrase in the presence and absence of 1 mM Ca2+ (A, B); EGTA 
dialysed M. tuberculosis GyrA + GyrB in the presence and absence of 1 mM Ca2+ 
(C, D). Reduced relaxation activity due to EGTA dialysis (C) is regained by inclusion 
of 1 mM Ca2+ in the assay (D); as indicated by a similar topoisomerase pattern as 
seen in (A) & (B). NC: nicked Circular DNA, R: relaxed topoisomers, SC: 
supercoiled DNA. 
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Figure 4.5: Time-course experiment to demonstrate the difference in the 
relaxation activity of GyrA dialysed in the absence and presence of EGTA. The 
weaker relaxation activity of GyrA dialysed in EGTA is demonstrated by the 
topoisomer distribution. NC: nicked Circular DNA, R: relaxed topoisomers, SC: 
supercoiled DNA.  
 The observed effects on the relaxation activity of M. tuberculosis DNA 
gyrase enzyme due to EGTA dialysis prompted protein-refolding experiments in the 
presence of EGTA. This method is a harsh treatment for the protein to make sure that 
any tightly bound Ca2+ is removed during protein refolding in the presence of EGTA. 
In short, the purified M. tuberculosis GyrA pool was divided into two main fractions 
based on their dialysis in 1 mM EGTA.  Each of these fractions was further divided 
into two fractions. One fraction was denatured with guanidine hydrochloride/urea 
and refolded, while the other fraction was not refolded. The details of the protein 
refolding are described in detail in Material and Methods section.  
In order to ensure that Ca2+ contamination is not carried over from  
M. tuberculosis GyrB in the assay, the purified pool of M. tuberculosis GyrB was 
divided into two fractions. Each of the fractions was dialysed in the presence or 
absence of 1 mM EGTA; M. tuberculosis GyrB was not denatured and refolded 
unlike M. tuberculosis GyrA (Figure 4.6).  
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Figure 4.6: Experimental plan for protein refolding experiment.  
(A) Flow chart for M. tuberculosis GyrA refolding experiment. (B) Flow chart for  
M. tuberculosis GyrB EGTA dialysis. 
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The M. tuberculosis GyrA samples from the refolding experiment were 
analysed for Ca2+ and Mg2+ concentration by ICP-AES (Inductively coupled plasma 
atomic emission spectroscopy). The details of this ICP-AES technique are described 
in detail in the Materials and Method section. This method is useful for determining 
the concentration of trace elements like Ca2+ and Mg2+ (Table 4.3, Table 4.4). 
Although this technique is sensitive for detecting trace elements, it has its limitations.  
It is important to consider these limitations for experimental design and data analysis. 
 ICP-AES estimates the total concentration of divalent ions like Ca2+ and Mg2+ in the 
sample, but it does not provide any information about the amount of divalent ions 
bound to the protein sample alone. Data inconsistency can also be a problem due to 
external contamination. These can be common contaminants such as Ca2+ from 
glassware and plastic ware.  For example, the apparent Ca2+ concentration in the two 
buffers (B) as shown by asterisk is very different. This illustrates the potential 
difficulties with this method and it means that small differences in Ca2+ concentration 
are unreliable. 
Based on the Table 4.3, 50 µM of Ca2+ is associated with the native  
M. tuberculosis GyrA and the protein concentration is 10 µM per dimer. Therefore, ~ 
5 Ca2+ atoms are associated with the native protein dimer. This is consistent with the 
MtGyrA-1BQB model in terms of the presence of two Ca2+ per M. tuberculosis GyrA 
subunit or four Ca2+  per M. tuberculosis GyrA dimer.  
The difference in Ca2+concentration between the native and refolded protein 
is ~20 µM. Although the amount of Mg2+ is comparatively less in the samples, there 
is an increase in its concentration in the refolded sample. This may be due to 
contamination or that during the refolding process the putative Ca2+- binding site 
binds Mg2+, which is available in the buffer environment. This is not surprising as 
the calcium EF-hand binding sites shows affinity towards Mg2+  (Gifford et al., 2007) 
. 
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Table 4.3: ICP-AES Estimation of Ca2+and Mg2+ in native and refolded  
M. tuberculosis GyrA. These single measurements were recorded at 317 nm. 
 
When M. tuberculosis GyrA is dialysed and refolded in the presence of 
EGTA, there is decrease in the amount of Ca2+. There is a difference of 26 µM (A-E) 
between the Ca2+ concentration of protein dialysed with and without EGTA. This 
difference is comparatively less in case of protein refolded in the presence and 
absence of EGTA. It is 6 µM (A-E) which may be due to contamination or it may be 
the remaining free Ca2+ in the solution that cannot be further removed by EGTA 
chelation. Thus, EGTA treatment was effective in reducing the Ca2+ concentration in 
the sample. 
 
 
 
 
 
Protein Ca2+concentration 
Buffer  (B) ng/ml 
Ca2+concentration 
Protein (A) ng/ml 
A-B 
ng/ml 
1. GyrA native (2 mg/ml) 
~10 µM 
*453.98 2455.8 2001.82 
= 50  µM 
2. GyrA refolded (2 mg/ml) 
~10 µM 
*70.379 1324 1253.621 
= 31  µM 
Protein Mg2+concentration  
Buffer (D) ng/ml 
Mg2+concentration 
Protein (C) ng/ml 
C-D  
ng/ml 
1.  GyrA native (2 mg/ml) 
~10 µM 
7.7415 121.2 113.458 
= 4.6 µM 
2.  GyrA refolded (2 mg/ml) 
~10 µM 
5.777 321.76 315.983 
= 12 µM 
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Table 4.4: ICP-AES Estimation of Ca2+ and Mg2+ in M. tuberculosis GyrA 
dialysed or refolded in the presence of 1 mM EGTA. These single measurements 
were recorded at 317 nm. 
The samples analysed by ICP-AES were used for studying the effect of 
EGTA and refolding on the enzyme activity of the treated samples. DNA 
supercoiling, relaxation and decatenation assays were performed. The summary of 
the results are shown in Table 4.5. 
 
 
 
 
 
 
 
Protein Ca2+concentrationin 
Buffer  (F) ng/ml 
Ca2+concentration  
Protein (E) ng/ml 
E-F 
  ng/ml 
1.  GyrA native  
(2 mg/ml) ~10 µM 
95.615 1040.3 944.685 
=23 µM 
2.  GyrA refolded 
(1 mg/ml) ~5 µM 
81.461 1063.2 981.739 
=24 µM 
Protein Mg2+concentration 
Buffer (H) ng/ml 
Mg2+concentration 
Protein (G) ng/ml 
G-H 
 ng/ml 
1.  GyrA native  
(2 mg/ml) ~10 µM 
5.8249 35.29 29.4651 
= 1.2 µM 
2.  GyrA refolded 
(1 mg/ml) ~5 µM 
8.856 94.793 85.937 
= 3.5 µM 
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M. tuberculosis  
DNA gyrase 
Supercoiling 
activity 
Relaxation  
activity 
Decatenation 
 activity 
1. GyrA + GyrB +++ +++ +++ 
2. Refolded GyrA + GyrB +++ +++ +++ 
3. EGTA- dialysed GyrA 
+ EGTA-dialysed GyrB 
++ No activity ++ 
4. Refolded EGTA- dialysed 
GyrA+ EGTA -dialysed GyrB 
+ No activity No activity 
Table 4.5:  Summary table for the effect of EGTA dialysis and refolding on the 
enzyme activity. + represents ~ 3 fold difference in the enzyme activity. 
As shown in Figure 4.7 & Figure 4.8, there is no effect of refolding alone on 
the enzyme activity of M. tuberculosis GyrA (supercoiling, relaxation and 
decatenation). This suggests that the refolding procedure does not damage the protein 
and it acts as a control for the refolding done in the presence of 1 mM EGTA. 
Although the concentration of Ca2+ based on ICP-AES analysis is less in the refolded 
GyrA (31 µM) in comparison to the native protein (50 µM), there is no effect of this 
decrease in the Ca2+ concentration on the enzyme activity.  This may because in the 
absence of chelating agent such as EGTA there is an opportunity for the protein to 
acquire Ca2+ from the surrounding medium.   
In contrast to this, dialysis or refolding M. tuberculosis GyrA in the presence 
of 1 mM EGTA leads to complete loss of relaxation activity and weak supercoiling 
activity. The supercoiling activity is weakest when M. tuberculosis GyrA is refolded 
in the presence of 1 mM EGTA. This effect of weak supercoiling activity is similar 
to the effect of mutations in the Ca2+-binding site which will be discussed in the next 
section. Decatenation activity of GyrA dialysed in EGTA is weaker in comparison to 
GyrA dialysed in the absence of EGTA. While complete loss of decatenation activity 
is observed when GyrA is refolded in the presence of 1 mM EGTA. This experiment 
suggests that EGTA is effective in chelating Ca2+ from the protein, which has 
significant effect on the enzyme activity. The interesting observation is the complete 
loss of relaxation and decatenation activity while weak supercoiling activity is 
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retained. This indicates that the protein is not completely denatured and the 
observation is due to the specific effect of EGTA on the relaxation / decatenation 
reactions.  
 
Figure 4.7: Effect of protein refolding in the presence and absence of EGTA on 
the supercoiling and relaxation activity of DNA gyrase. Weak supercoiling 
activity (top panel) and loss of relaxation activity (bottom panel) due to dialysis or 
refolding of M. tuberculosis GyrA in the presence of 1 mM EGTA. NC: nicked 
Circular DNA, R: relaxed topoisomers, SC: supercoiled DNA. 
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The complete loss of relaxation and weak supercoiling activity due to EGTA 
dialysis in this experiment is different from the weak relaxation activity observed on 
EGTA dialysis in previous experiment. This may be due to difference is several 
factors such as protein batch, availability of Ca2+ for effective chelation by EGTA 
and external contamination due to Ca2+. However, the consistent observation in all 
the experiments is the effect of EGTA dialysis on the relaxation activity of  
M. tuberculosis DNA gyrase. 
 
Figure 4.8: Effect of protein refolding in the presence and absence of EGTA on 
the decatenation activity of DNA gyrase. dkDNA: decatenated DNA, SC: 
supercoiled DNA. 
4.3 SDM of the Ca2+-binding site 
Based on the M. tuberculosis GyrA model described previously, double 
(E508A, D509A) and quadruple mutants (D504A, E508A, D509A, E514A) were 
created in the putative Ca2+-binding site by site-directed mutagenesis. The acidic 
amino acids that were proposed to be directly involved in Ca2+-binding were mutated 
by site-directed mutagenesis to alanine as described in Materials and Methods. 
Some of the residues that were mutated are involved in Ca2+-binding in both 
MtGyrA-1H71 and MtGyrA-1BQB model. Residue D509 is involved in coordinating 
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Ca2+ only in MtGyrA-1BQB model and D504 is involved in coordinating Ca2+ in 
MtGyrA-1H71 model. The double mutation as shown in (Figure: 4.9) involved 
mutation of Glu 508 (GAG) to Ala (GCG) and Asp 509 (GAT) to Ala (GCT). In 
addition to the double mutation, two more mutations were introduced in the double 
mutant involving residues Asp 504 (GAC) and Glu 514 (GAG) to Ala (GCT) as 
shown in the Figure 4.9, Figure 4.10 & Figure 4.11.  
 
Figure 4.9: Double mutation in the Ca2+ - binding site: Glu508 to Ala and 
Asp509 to Ala. 
 
Figure 4.10: Quadruple mutation in the Ca2+-binding site: Glu508 to Ala; 
Asp509 to Ala; Asp 504 to Ala and Glu 514 to Ala. 
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Figure 4.11: Acidic amino-acids in MtGyrA-1H71 and MtGyrA-1BQB model 
that were mutated to alanine in side-directed mutagenesis experiments. 
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DNA gyrase activity assays (supercoiling, relaxation and decatenation) were 
performed to study the effect of double (GyrA E508A, D509A) and quadruple 
mutations (GyrA D504A, E508A, D509A, E514A) on the enzyme activity. There 
was no significant effect of double mutations (GyrA E508A, D509A) on the 
supercoiling activity of the enzyme. Weak supercoiling activity observed at 10 nM 
enzyme concentration in case of double mutant may be due to experimental error 
(Figure 4.12). While in case of the quadruple mutant (GyrA D504A, E508A, 
D509A, E514A) a significant effect was observed on the supercoiling activity of the 
enzyme in comparison to the wild-type. This is indicated by incomplete supercoiling 
as shown in Figure 4.12. This effect is even more marked when the supercoiling 
assay is performed in the buffer having magnesium chloride rather than magnesium 
acetate and without potassium glutamate as shown in the Figure 4.13. Interestingly 
no effect of the quadruple mutation (GyrA D504A, E508A, D509A, E514A) was 
observed on the relaxation (Figure 4.14) and decatenation activity (Figure 4.15) of 
the enzyme, though previous reports indicate a slight effect on the relaxation activity 
of the enzyme due to E514A mutations (Huang et al., 2006).  
Since there in little or no effect of the quadruple mutation (GyrA D504A, 
E508A, D509A, and E514A) on the decatenation activity of the enzyme, we assume 
that there will be no effect of the double mutation (GyrA E508A, D509A) on 
decatenation. From the assay, the significant observation is that the quadruple mutant 
(GyrA D504A, E508A, D509A, and E514A) is efficient in decatenation but it is not 
efficient in supercoiling DNA in comparison to the wild-type. This is evident from 
the observation that minicircles that are released from the megacircles during the 
decatenation reaction are supercoiled in case of the wild-type but not in case of 
quadruple mutant as shown in Figure 4.15. 
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Figure 4.12:  Effect of double (GyrA E508A, D509A) and quadruple mutations 
(GyrA D504A, E508A, D509A, E514A) on supercoiling activity. (A) Supercoiling 
activity of M. tuberculosis GyrA2B2. (B) Supercoiling activity of M. tuberculosis 
GyrA(E508A, D509A)2B2. (C) Supercoiling activity of M. tuberculosis GyrA (D504A, E508A, 
D509A, E514A)
2B2. NC: nicked Circular DNA, R: relaxed topoisomers, SC: supercoiled 
DNA. 
 
  
Chapter 4  
 
168 
 
   
 
 
 
Figure 4.13: Effect of quadruple mutations (GyrA D504A, E508A, D509A, 
E514A) on the supercoiling activity under different assay conditions. Little or no 
supercoiling is observed for the quadruple mutant (B) in comparison to the wild-type 
enzyme (A) in assay buffer having magnesium chloride and no potassium glutamate. 
The linear DNA is observed due to the sample treatment with SDS and proteinase K. 
This linear DNA is not observed with E. coli DNA gyrase as a positive control. 
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Figure 4.14: No significant effect of double (GyrA E508A, D509A) and 
quadruple mutations (GyrA D504A, E508A, D509A, E514A) on the relaxation 
activity. (A) Relaxation activity of M. tuberculosis GyrA2B2. (B) Relaxation activity 
of M. tuberculosis GyrA (E508A, D509A)
 2B2. (C) Relaxation activity of M. tuberculosis 
GyrA (D504A, E508A, D509A, E514A) 2B2 .NC: nicked Circular DNA, R: relaxed topoisomers, 
SC: supercoiled DNA.  
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 Figure 4.15: Decatenation activity of the wild-type and quadruple mutant.  
Efficient decatenation by (A) M. tuberculosis GyrA2B2; (B) M. tuberculosis  
GyrA2 (D504A, E508A, D509A, E514A)B2.  E. coli topo IV decatenation activity is shown as a 
positive control. SC: supercoiled DNA and dkDNA: decatenated DNA. 
Due to the weak supercoiling activity of the quadruple mutant (GyrA D504A, 
E508A, D509A, E514A), it was important to determine whether this was a specific 
effect due to the loss of Ca2+ or it was due to the protein misfolding.  
Circular dichroism (CD) was employed to verify whether or not the quadruple 
mutant was folded correctly. Far-UV (180-260 nm) CD spectra was collected for 
both the GyrA WT and GyrA D504A, E508A, D509A- E514A mutant as shown in 
Figure 4.16. 
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Figure 4.16: Far-UV (180-260 nm) CD spectra of wild-type GyrA and GyrA 
D504A, E508A, D509A, E514A. The spectra were recorded at 20ºC using a J-710 
spectropolarimeter (Jasco Ltd.). 
The CD spectra of the wild-type and mutant proteins look similar suggesting 
that the mutant is not misfolded. Although the CD spectra clearly demonstrates that 
the four mutations in the quadruple mutant have not drastically affected its folding, 
but this data cannot rule out the more subtle changes due to the loss of Ca2+  from the 
binding site, which may have an effect on the supercoiling activity of the enzyme. 
The weak supercoiling activity of the quadruple mutant (GyrAD504A, 
E508A, D509A, E514A) without any effect on the relaxation activity indicates that 
the mutation may have affected DNA wrapping. This is because DNA gyrase’s 
unique ability to catalyse DNA supercoiling is thought to derive from the wrapping 
of G segment around the enzyme in such a way as to present a T segment to the 
ATP-operated clamp. The wrapping function resides in the C-terminal domain of 
GyrA. 
It has been shown in previous studies that a E. coli GyrA C-terminal 
truncation mutant lacks supercoiling activity while retaining the relaxation activity 
due to the loss of the DNA-wrapping domain (Kampranis & Maxwell, 1996). The 
DNA wrapping assay is based on the principle that the DNA wrapping around the 
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GyrA C-terminal domain is positive in nature (Liu & Wang, 1978b, Kampranis et al., 
1999a, Liu & Wang, 1978a) and this can be demonstrated by using topo I. In a 
typical DNA wrapping assay, the DNA-gyrase complex is relaxed by topo I. Positive 
superhelical wrapping induces the formation of opposing negative crossovers in 
unconstrained regions of DNA that can be relaxed with topo I, while the positive 
supercoiled DNA around the wrapping domain, which is not accessible, cannot be 
relaxed with topo I. As a result, positively supercoiled DNA is produced after topo I 
relaxation of gyrase-DNA complexes. Similar experiments have also been performed 
in the past to investigate the DNA wrapping (Heddle et al., 2004, Williams et al., 
2001).  
As shown in Figure 4.17, positively supercoiled DNA is produced in case of 
wild-type GyrA after topo I treatment, which is not observed in case of quadruple 
mutant (D504A, E508A, D509A, E514A) indicating the effect of the mutations on 
DNA wrapping. This effect on wrapping could be due to the loss of Ca2+ at the Ca2+ -
binding site due to the mutations. It can be suggested that Ca2+ may be important for 
maintaining the structural integrity of the DNA wrapping domain via the Ca2+-
binding site.  
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Figure 4.17: The effect of quadruple mutation (D504A, E508A, D509A, and 
E514A) on DNA wrapping around GyrA. (A) The relaxation assay of the GyrA 
WT and the quadruple mutant (D504A, E508A, D509A, E514A) without relaxing it 
further with topo I. (B) The other half of the reaction treated with wheat germ  
topo I. 
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4.4 Effect of EGTA on the activity of mutants 
The quadruple mutation (GyrA D504A, E508A, D509A, and E514A) in the 
putative Ca2+-binding site affected the supercoiling activity of the enzyme.  
It was decided to study the effect of EGTA dialysis on the enzyme activity of the 
mutants.  
Little effect was observed on the supercoiling and relaxation activity of the 
double mutant (GyrA E508A, D509A)
 
and the quadruple mutant (GyrA D504A, 
E508A, D509A, E514A) when dialysed in the presence of 1 mM EGTA as shown in 
the Figure 4.18.  
Far-UV (180-260 nm) CD spectra were collected for both the GyrA WT and 
GyrA D504A, E508A, D509A, E514A mutant dialysed in 1mM EGTA as shown in 
the Figure 4.19. Although the spectra for the GyrA WT and GyrA D504A, E508A, 
D509A, E514A mutant do not appear identical, this is due to a protein concentration 
effect. Scaling the mutant spectra by the average difference to overlay with the 
spectra for the wild-type protein, we can see that the profiles of the plots are very 
similar, suggesting that both proteins are folded in the same configuration. 
Thus these experiments demonstrate the following observations: 
1. Weak supercoiling activity of the GyrA D504A, E508A, D509A, E514A mutant 
due to the effect of the mutations on DNA wrapping. 
2. EGTA dialysis affects the relaxation activity of the wild-type enzyme which can 
be regained by adding Ca2+. 
3. Protein refolding in presence of EGTA affects the supercoiling and relaxation 
activity of the enzyme. The refolded wild-type enzyme is weak in supercoiling 
with complete loss of relaxation activity. 
The observations discussed above clearly indicate the significance of Ca2+ and the 
Ca2+-binding site. 
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Figure 4.18: Effect of EGTA on the supercoiling and relaxation activity of the 
mutants. (A) Supercoiling activity of GyrA E508A, D509A mutant; (B) relaxation 
activity of GyrA E508A, D509A mutant; (C) supercoiling activity of GyrA D504A, 
E508A, D509A, E514A mutant (D) relaxation activity of GyrA D504A, E508A, 
D509A, E514A. 
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Figure 4.19: Far-UV (180-260 nm) CD spectra of  wild-type GyrA (dialysed in 1 
mM EGTA) and GyrA D504A, E508A, D509A, E514A (dialysed in 1 mM 
EGTA). The spectra were recorded at 20ºC using a J-710 spectropolarimeter (Jasco 
Ltd.). (A) Circular dichroism spectrum for wild-type GyrA (dialysed in EGTA) and 
(B) GyrA D504A, E508A, D509A, E514A (dialysed in EGTA); scaled to adjust for 
concentration effects. 
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4.5 Limited Proteolysis of GyrA  
From the site-directed mutagenesis and refolding experiments it is evident 
that there is an effect of removal of Ca2+ on the activity of GyrA. This effect 
indicates that Ca2+ may have structural and/or functional significance. Limited 
proteolysis experiments with trypsin were performed for GyrA in the presence and 
absence of Ca2+ to investigate protein conformational changes induced by Ca2+, as 
described in the Materials and Methods section.  
As shown in the Figure 4.20, there are differences in the trypsin digestion 
profile of GyrA in the presence and absence of 3 mM Ca2+. One of the characteristic 
differences is the disappearance of a 47-kDa band in the presence of Ca2+ indicated 
by a rectangle in Figure 4.20. The same experiment was repeated with M. 
tuberculosis GyrB in the presence and absence of Ca2+ as a control. As shown in the 
Figure 4.21, little or no difference was observed in the digestion profile of the 
protein due to Ca2+. This indicates that Ca2+ has a structural significance for GyrA 
and the disappearance of the 47-kDa band is a specific effect and is not due to 
changes in the activity of trypsin due to the presence of Ca2+. 
After observing changes in the trypsin digestion profile of GyrA in the 
presence of Ca2+, the next step was to identify the different bands. This information 
will be useful for identifying the 47-kDa band and the protein domain that is affected 
by the presence of Ca2+. 
Edman sequencing was employed to identify the bands obtained by trypsin 
digestion of GyrA. The bands were first electroblotted onto a PVDF membrane as 
described in the Material and Methods section. After electroblotting, the bands 
were cut from the membrane and were sent for sequencing to the Proteomics facility. 
The Edman sequencing work was done under the guidance of Dr. Mike Naldrett 
(John Innes Centre). The bands that were electroblotted and sequenced are shown in 
the Figure 4.22. From the Edman sequencing data, the N-terminal sequences for the 
bands were obtained. 
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Figure 4.20: Tryptic digest of the M. tuberculosis GyrA in the absence of Ca2+ 
(A) and in the presence of Ca2+ (B). M indicates GE low molecular weight marker 
and the rectangle highlights the 47-kDa band.  
  
  
Chapter 4  
 
179 
 
 
   
Figure 4.21: Tryptic digest of the M. tuberculosis GyrB in the absence of Ca2+ 
(A) and in the presence of Ca2+ (B). M indicates GE low molecular weight marker 
and rectangle represents the 47-kDa band.  
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Figure 4.22: Trypsin digestion profile of M. tuberculosis GyrA in the presence 
and absence of Ca2+ at 30 min time point analysed by 10% NuPAGE Novex Bis-
Tris gel (Invitrogen). The bands that were sent for Edman sequencing are indicated 
by numbers. 
  The molecular weight of the bands was estimated by extrapolating the graph 
between the molecular weight of the protein ladder and its mobility as shown in the 
Figure 4.23. Based on the molecular weight and the N-terminal sequence of the 
bands, the sequence coverage of the bands was determined (Table 4.6). 
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Figure 4.23: Molecular weight estimation of the bands. This was done by 
extrapolating the mobility of the band against the graph plotted between the mobility 
of the protein ladder against its molecular weight (kDa). 
  
Table 4.6: Sequence coverage and molecular weights for bands (1- 10). 
 
 
Bands  N-terminal sequence  
( Edman sequencing) 
Molecular weight 
(approx) 
Sequence coverage 
1& 6 R26↓SYID ~ 54-kDa S27- G503 
7 R75↓SVAET ~51-kDa S76 - K542 
2 & 8 R128↓YTEAR ~47-kDa Y129 - K542 
9 R128↓YTEAR ~43-kDa Y129 - G503 
4 & 10 K542↓GVQGA ~ 31-kDa 543G -N839 
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> M. tuberculosis GyrA 
MTDTTLPPDDSLDRIEPVDIEQEMQRSYIDYAMSVIVGRALPEVRDGLKPVHRRVLYAMFDSGFRPDR
SHAKSARSVAETMGNYHPHGDASIYDSLVRMAQPWSLRYPLVDGQGNFGSPGNDPPAAMR↓YTEARLT
PLAMEMLREIDEETVDFIPNYDGRVQEPTVLPSRFPNLLANGSGGIAVGMATNIPPHNLRELADAVFW
ALENHDADEEETLAAVMGRVKGPDFPTAGLIVGSQGTADAYKTGRGSIRMRGVVEVEEDSRGRTSLVI
TELPYQVNHDNFITSIAEQVRDGKLAGISNIEDQSSDRVGLRIVIEIKRDAVAKVVINNLYKHTQLQT
SFGANMLAIVDGVPRTLRLDQLIRYYVDHQLDVIVRRTTYRLRKANERAHILRGLVKALDALDEVIAL
IRASETVDIARAGLIELLDIDEIQAQAILDMQLRRLAALERQRIIDDLAKIEAEIADLEDILAKPERQ
RGIVRDELAEIVDRHGDDRRTRIIAADGDVSDEDLIAREDVVVTITETGYAKRTKTDLYRSQKRGGK↑
GVQGAGLKQDDIVAHFFVCSTHDLILFFTTQGRVYRAKAYDLPEASRTARGQHVANLLAFQPEERIAQ
VIQIRGYTDAPYLVLATRNGLVKKSKLTDFDSNRSGGIVAVNLRDNDELVGAVLCSAGDDLLLVSANG
QSIRFSATDEALRPMGRATSGVQGMRFNIDDRLLSLNVVREGTYLLVATSGGYAKRTAIEEYPVQGRG
GKGVLTVMYDRRRGRLVGALIVDDDSELYAVTSGGGVIRTAARQVRKAGRQTKGVRLMNLGEGDTLLA
IARNAEESGDDNAVDANGADQTGN 
Figure 4.24: The sequence coverage of band  2&8 (~ 47-kDa). Band 2&8 is shown 
by blue bold font and the Ca2+ - binding site is indicated by red  blue bold font. 
↓represent the start and ↑ represent the end of the band 2 &8. 
 
It was possible to obtain sequence information for most of the bands except 
band 5 and 3. Band 5 corresponds to the intact GyrA subunit and may be as a result 
of partial digestion by trypsin. It is clear from the Figure 4.22, that band 5 is absent 
in the presence of Ca2+ which signifies the complete digestion of GyrA subunit by 
trypsin. Band 3 is one of the faintest bands on the gel and this must have affected its 
recovery from the membrane. Band 3 is similar to band 9, which seems to be a 
further degradation product of band 8 and therefore band 3 is probably the result of 
further degradation of band 2.  
The interesting observation from this experiment is that out of all the bands; 
band 7, 2 and 8 includes the putative calcium binding site (504 DVSDEDLIAREDV 
516) as shown in the Figure 4.24. These are bands that exhibit differences in the 
presence and absence of Ca2+. Band 7 disappears in the presence of Ca2+, while band 
8 becomes fainter in the presence of Ca2+ and appears as band 2. This signifies that 
Ca2+ may be inducing structural changes that are exposing the cleavage site and 
making it more susceptible to digestion by trypsin.  Thus the experiment clearly  
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demonstrates that Ca2+ has structural and functional significance for M. tuberculosis 
GyrA. 
4.6 Virtual screening at the Ca2+-binding site 
4.6.1 Introduction 
The identification of a unique Ca2+-binding site in M. tuberculosis GyrA 
encouraged the investigation of this site as a target for discovery of novel inhibitors. 
This is the first preliminary attempt to explore the putative Ca2+- binding site for 
identifying novel inhibitors. Virtual screening was used as a tool to help identify 
inhibitors that can bind to the putative Ca2+- binding site. Ligand and structure-based 
virtual screening has been useful to aid drug discovery in large pharmaceutical 
companies to scan large chemical libraries, saving time and resources. Virtual 
screening can filter out compounds, but it does not necessarily pick out the best 
inhibitor from the library. The method only reduces the number of hits that can be 
tested in the assays. In this case also, virtual screening was used to filter NCI 
diversity set II to identify hits that have the potential to bind to the Ca2+- binding site 
and can inhibit the activity of the enzyme. An alternative approach could have been 
to screen compounds in a high-throughput screening assay and dock those 
compounds into the Ca2+ - binding site that have inhibitory activity. This approach 
would have been resource-intensive. In case of virtual screening, compounds with no 
information about their activity against DNA gyrase were tested for their binding to 
the putative Ca2+ - binding site.  There have been success stories with this approach 
in the past. In a recent publication (Ostrov et al., 2007), novel DNA gyrase inhibitors 
were identified by high-throughput virtual screening. A chemical ligand database 
with approximately 140,000 small molecules (molecular weight less than 500 Da) 
was molecularly docked onto two sites of E. coli DNA gyrase. The target sites were 
(i) a previously unexplored structural pocket formed at the dimer interface of subunit 
A and (ii) a small region of the ATP- binding pocket on subunit B overlapping the 
site targeted by coumarin and cyclothialidine drugs. The approach was successful in 
identifying several small-molecule compounds that inhibited the DNA supercoiling 
activity of purified E. coli DNA gyrase.  
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4.6.2 Docking-based virtual screening 
The virtual screening and docking experiments were done in collaboration 
with Lora Mak (Theoretical Systems Biology, Institute of Food Research Norwich). 
The NCI diversity II dataset (The NCI/DTP Open Chemical Repository: 
http://dtp.cancer.gov) downloaded from the ZINC database (Irwin & Shoichet, 2004) 
was used as the library source for compounds.  The ZINC database was used as it is a 
free database of purchasable molecules available in 3D formats compatible with 
popular docking programs. The NCI diversity II dataset was selected as the 
compounds from this dataset are accessible for research. The NCI diversity II dataset 
is a diversity-derived subset of the NCI/DTP repository of nearly 140000 
compounds. The dataset has a contained 1880 compounds with the molecular mass 
range of 114.1 to 696.12 g/mol. It also includes tautomers and protonation variants 
near physiological pH (5.7-8.2) which increased the number of docking structures to 
2044. 
For the virtual screening experiment, AutoDock Vina v1.0.2 (Goodsell et al., 
1996) was used. The target protein was a homology model of M. tuberculosis GyrA 
(MtGyrA-1BQB) as described in the previous section. This model without the Ca2+ is 
described hereafter as model-1 which was energy minimised using the CHARMm 
(Brooks et al., 1983) force field within the DiscoveryStudio environment (Accelrys) 
to produce another model referred to as model-2. In both the models, the Ca2+ ions 
were removed. The structural quality of model-2 was validated using PROCHECK v 
3.5.4 (Laskowski et al., 1993). The target protein and the ligands were prepared for 
docking using the MGL Tools v 1.5.4 as per the standard procedure 
(http://mgltools.scripps.edu/). Since AutoDock Vina uses the same PDBQT file 
format as AutoDock4, AutoDock tools GUI was used to prepare the protein structure 
for docking. This procedure involved assigning atom type, charge and merging non-
polar hydrogens. To convert ligands to the PDBQT file format, the 
prepare_ligand4.py program of the AutoDock tools was used in the batch mode. 
There were no restrictions to the numbers of bonds selected as rotatable and thus 
accepting the number of active torsions set by the program. The flexible ligands were 
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then docked to both the rigid and flexible model-1 and model-2 using the flexible 
side chains of amino acids having significance in Ca2+-binding.  
 
 
Figure 4.25: Virtual screening of NCI diversity set II. (A) Flowchart depicting the 
applied protocol for virtually screening novel inhibitors for M. tuberculosis DNA 
gyrase and (B) depicting the search area including the N-terminal and C-terminal 
region of GyrA flanking the Ca2+-binding site docked with ZINC1572309. 
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The search box was centered on the putative Ca2+-binding site with the 
coordinates -85, 40, -13 including some of the flanking parts of the C- and the N-
terminal region. The dimensions of the search box in all the three coordinates (x, y, 
and z) were 30, 34, 34 Ǻ as shown in the Figure 4.25. The exhaustiveness of search 
was set to 8 and 16, while all other parameters were at default values. The docking 
was performed on the Norwich Bioscience Institute’s Linux cluster. 
In-silico docking resulted in the selection of a set of 188 and a set of 144 
ligands as potential inhibitors after the rigid and flexible docking to model-1 and 
model-2 respectively.  Three simulations runs per rigid models and four simulations 
per flexible models were carried out. The intersection between these two ligand 
subsets yielded 51 compounds that could favorably bind to GyrA Ca2+-binding site in 
all the simulations after removing the different tautomers of the same compounds. 
The compounds are shown in Figure 4.26. 
 
Figure 4.26: 51 hit compounds from the virtual screening of NCI diversity set II 
centered at the Ca2+-binding site in M. tuberculosis GyrA. 
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 Out of these 51 compounds, 10 compounds (Figure 4.28) were selected for 
assays based on their binding energies. The energy values and pharmacokinetic 
properties of these compounds are listed in Table 4.7. These 10 compounds were 
initially tested for their activity at 100 µM concentration in a supercoiling assay 
followed by assay at the same concentration in the relaxation assay. 100 µM is the 
arbitrary concentration cut off for weak inhibitors. The logic was that any compound 
that inhibits the enzyme activity at 100 µM will be a potential candidate for further 
investigation. Some of the compounds (ZINC13130018, ZINC01690699, 
ZINC01639634, ZINC01736227, and ZINC01572309) showed weak inhibitory 
activity in the supercoiling assay; whereas many of the compounds showed 
inhibitory activity in the relaxation assay, except ZINC00393674. Compounds 
ZINC13130018, ZINC01577889, ZINC05390471 and ZINC01736227 showed more 
or less complete inhibition at 100 µM as shown in Figure 4.27. 
 
Figure 4.27:  Inhibitory activity of the 10 selected compounds (100 µM) against 
the supercoiling (A) and relaxation activity (B) of M. tuberculosis DNA gyrase.  
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Compounds ZINC01572309, ZINC13130018, ZINC01690699, and 
ZINC01639634 showed inhibitory activity against both supercoiling and relaxation 
activity of M. tuberculosis DNA gyrase, but these compounds are more efficient in 
inhibiting relaxation. The H-bonding and hydrophobic interactions for the best 
predicted binding modes of these compounds in the Ca2+-binding site are shown in 
the Figure 4.29 & Figure 4.30. Compounds ZINC01572309, ZINC01690699, 
ZINC1639634, ZINC13130018 and ZINC01736227 were also tested for the in vitro 
activity against M. tuberculosis and compounds ZINC13130018 & ZINC1639634 
showed MIC of ~ 50 µM (Dr. Amanda Brown & Prof. Tanya Parish, Barts and the 
London School of Medicine and Dentistry).  
Thus the above initial results are quite promising as a first attempt to explore 
the predicted Ca2+-binding site in M. tuberculosis GyrA. At this point it is important 
to remember that on EGTA dialysis, the relaxation activity of the dialysed protein is 
affected. Since these molecules have the same effect they can be further explored as 
probes to investigate the significance of the Ca2+-binding site. 
In the absence of a complete crystal structure, a homology model of the GyrA 
Ca2+-binding pocket was used for virtual screening. Homology models have been 
used successfully in drug discovery studies related to receptors of medical 
significance such as dopamine D3, muscarinic M1, and vasopressin V1a (Evers & 
Klebe, 2004a, Neumann et al., 2009, Evers & Klebe, 2004b) for which very few 
crystal structures are available. In this modelling strategy the small molecules were 
docked to two models of GyrA differing with backbone RMSD of 1.50 Ǻ. The 
backbone RMSD between the 12 residues of the Ca2+-binding sites of model-1 and 
model-2 was 1.83 Ǻ (computed using SwissPDBViewer). 
 
 
 
 
 
 
 
  
As with every method
could be resolved in future work. 
1. Conformational changes in the predicted 
considered when
2. Exploring the possibility of ligands to bind sites o
binding site. 
In future these limitations can be resolved along with characterization of the lead 
molecules (IC50 determination; cleavage assay). 
 
Figure 4.28: Chemical structures of 10 selected compounds 
screening that were tested for their inhibitory activity in a standard supercoiling 
and relaxation assay.
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Figure 4.29: Predicted binding modes for ligands ZINC01572309 (A) and 
ZINC01639634 (B). Hydrogen bonds are depicted by dashed lines and 
residues involved in van der Waals interactions are shown with red arcs.  
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Figure 4.30: Predicted binding modes for ligands ZINC01690699 (A) and 
ZINC13130018 (B). Hydrogen bonds are depicted by dashed lines and 
residues involved in van der Waals interactions are shown with red arcs. 
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Compounds Mol.mass FEB 
(kcal/mole) 
#RotBonds XLOGP TPSA 
ZINC01572309 474.56 -11.5 4 5.84 108 
ZINC13130018 310.35 -11.7 1 5.55 49 
ZINC01690699 548.59 -11.0 6 6.89 115 
ZINC01736227 392.45 -10.4 3 6.51 42 
ZINC00393674 314.34 -10.2 2 3.1 66 
ZINC00247785 308.29 -10.0 3 4.41 95 
ZINC05390471 388.42 -9.9 4 5.43 92 
ZINC01639634 488.50 -9.8 6 5.61 139 
ZINC00258800 265.38 -9.6 2 4.15 29 
ZINC01577889 392.45 -9.6 5 5.41 58 
Table 4.7: AutoDock Vina v1.0.2 calculated free energy of binding (FEB), 
number of rotatable bonds (#RotBonds), calculated hydrophobicity distribution 
(XLOGP) and molecular topological polar surface area (TPSA). 
4.7 Conclusion 
Based on the bioinformatics analysis described in Chapter3, a putative Ca2+-
binding site was identified in the M. tuberculosis GyrA. In the absence of a crystal 
structure of the complete subunit, a model was generated to guide biochemical and 
site-directed mutagenesis studies. The model has also been described in detail in 
Chapter 3. 
The inital biochemical studies involved investigation of the effect of Ca2+ on 
the enzyme activity.  In previous studies it has been shown that M. tuberculosis DNA 
gyrase does not show supercoiling and relaxation activity in  the presence of Ca2+ 
alone; unlike E. coli DNA gyrase where Ca2+ can substitute for Mg2+ (Aubry et al., 
2006a). In order to test the hypothesis that the inability of Ca2+ to support 
supercoiling depends on the presence of M. tuberculosis GyrA, individual subunits of 
M. tuberculosis and E. coli DNA gyrase were swapped. Supercoiling activity was 
observed when M. tuberculosis GyrA and E. coli GyrB were assayed in the presence 
of 6 mM Mg2+, but no supercoiling activity was observed when the same assay was 
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repeated in the presence of 6 mM Ca2+ (Table 4.1). This indicates that the ability of 
the Ca2+ to support DNA supercoiling depends on the presence of E. coli GyrA, and 
M. tuberculosis GyrA cannot substitute for it. 
In order to study the effect of removal of Ca2+ bound to GyrA, EGTA dialysis 
and protein refolding experiments were carried out. When GyrA was dialysed in 
EGTA, the dialysis affected the relaxation activity of the enzyme; the EGTA-
dialysed protein was less active in relaxation assays in comparison to the protein 
dialysed in the absence of EGTA. This weaker relaxation activity could be restored 
by adding Ca2+ to the assay. This difference in the relaxation activity of protein 
dialysed in the presence and absence of EGTA was also investigated by a time-
course experiment. Based on the effect of EGTA on the enzyme activity, refolding 
experiments were designed  to investigate the removal Ca2+ tightly bound at the Ca2+- 
binding site. Protein refolding was performed in the presence and absence of EGTA 
assuming that during the refolding process the tightly- bound Ca2+ is released from 
the binding site and is available for chelation by EGTA.  
ICP-AES was used to estimate the concentration of Ca2+ and Mg2+  in the 
samples. The ICP-AES data indicates that EGTA  was effective in reducing the 
concentration of Ca2+   in the sample.  
The effect of dialysis or dialysis and refolding in the presence of EGTA was 
the complete loss of relaxation activity with weak supercoiling activity. On the other 
hand decatenation activity was weak when the protein was dialysed in EGTA, but it 
was completely lost when GyrA was dialysed and refolded in EGTA. This effect was 
specifically due to EGTA treatment and not due to protein misfolding as there was 
little effect on the relaxation, supercoiling and decatenation acitvity of refolded 
enzyme. The CD spectra for the EGTA-dialysed protein also indicated that the 
protein was not misfolded. This indicated that the loss of Ca2+ significantly affects 
the relaxation and decatenation activity with  little effect on DNA supercoiling.  
Based on the homology models MtGyrA-1H71 and MtGyrA-1BQB, mutation 
studies in the Ca2+-binding site were designed to mutate acidic amino acids that have 
significant importance in coordinating Ca2+. For example the quadruple mutant 
(GyrA D504A, E508A, D509A, E514A) involves mutation of two acidic residues 
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D504 and E508 from the model MtGyrA-1H71 and two acidic residues E509, E514A  
from the model MtGyrA-1BQB; E508 is an important acidic residue shown to 
coordinate Ca2+ in both models. The quadruple mutation affected the supercoiling 
activity of the enzyme. A DNA wrapping experiments demonstrated that the weak 
supercoiling activity of the mutant was due to the effect of the mutations on the 
wrapping of DNA around gyrase. But the quadruple mutant did not significantly 
affect the relaxation and decatenation activity of the enzyme. The CD spectra for the 
quadruple mutant (GyrA D504A, E508A, D509A, E514A) shows that the spectra is 
not different from the GyrA wild-type indicating that the mutation has not resulted in 
protein misfolding.  
Limited proteolysis experiments were done with trypsin for GyrA and GyrB 
in the presence and absence of 3 mM Ca2+. As expected, a difference was observed 
in the digestion profile of GyrA but not in case of GyrB. In the case of GyrA, the 
most striking difference was the disappearance of a 47-kDa band in the presence of  
3 mM Ca2+. From Edman sequencing it was shown that the 47-kDa band (band 2 & 
8) included the Ca2+- binding site. This suggests that Ca2+ induces conformational 
changes that involve the Ca2+- binding site. The position of band 2 & 8 is shown in 
the Figure 4.31. 
 A model has been described based on the experimental data in chapter 6. 
According to the model, Ca2+ acts as a regulator that controls the flexibility of the 
arm/linker connecting the GyrA N- and C-terminal domains. Ca2+ may help to 
maintain M. tuberculosis DNA gyrase in a state which would favour all the 
topological reactions. In the absence of topo IV in M. tuberculosis, this may be 
important to keep the enzyme in a state ready for both supercoiling and 
relaxation/decatenation reaction.  
Considering the potential significance of the Ca2+-binding site, virtual 
screening for inhibitors was performed using the NCI diversity set II library from the 
ZINC database. Compounds ZINC01572309, ZINC13130018, ZINC01690699, and 
ZINC1639634 showed inhibitory activity against both supercoiling and relaxation 
activity of M. tuberculosis DNA gyrase. Compounds ZINC13130018 & 
ZINC1639634 have also shown ans MIC of ~50 µM against M. tuberculosis in vitro. 
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Figure 4.31: Representation of the domains affected during the trypsin digestion 
in the presence of 3 mM Ca2+. Structural region (Ca2+- binding site) corresponding 
to band 2 & 8 are coloured while the rest of the structure is in white.  
In this chapter, I have discussed the identification of a Ca2+- binding site in  
M. tuberculosis GyrA. The effect of Ca2+ on the activity of M. tuberculosis DNA 
gyrase indicates that the Ca2+- binding site in M. tuberculosis DNA gyrase belongs to 
the class of Ca2+ sensors. Functionally, EF-hand proteins can be divided into two 
general classes: the Ca2+ sensors and the Ca2+ buffer (Gifford et al., 2007). Ca2+ 
sensors translate the chemical signal of an increased calcium concentration into 
diverse biochemical response. This involves calcium-induced conformation change. 
In case of M. tuberculosis DNA gyrase, Ca2+ is behaving as a signaling switch to 
coordinate its activity as an efficient DNA supercoiling and relaxing enzyme in the 
absence of topo IV. Due to the significance of this site, it was further explored for 
identifying inhibitors for virtual screening. In future, radioactive Ca45 isotope can be 
used to further characterise the putative Ca2+-binding site and its novel inhbitors.
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Chapter 5:  Identification and characterisation 
of novel gyrase inhibitors 
 
Biochemical studies described in Chapter 4 provided the platform for 
identification of novel DNA gyrase inhibitors targeting the M. tuberculosis 
enzyme. In this chapter, three classes of compound: quinolines, aaptamines and 
naphthoquinones were selected for investigation of their potential as inhibitors 
of M. tuberculosis DNA gyrase. Aaptamines and naphthoquinones (Mahapatra 
et al., 2007, Gul et al., 2006) have been shown to have anti-mycobacterial 
activity. Quinolines have been shown to induce cross-resistance to 
fluoroquinolones by generating mutations in DNA gyrase and topo IV 
(Davidson et al., 2008), and also inhibit M. tuberculosis DNA gyrase activity. Out 
of all the three classes of compounds, naphthoquinones were found to be most 
effective and were studied in detail. 
The mechanism behind the inhibitory activity of naphthoquinones was 
studied using gel-based assays, nano-ESI-MS (collaboration with Dr Adam 
McKay; University College London, UK), surface plasmon resonance (guidance 
of Dr. Sandra Grieve; John Innes Centre, Norwich, UK), computational 
modelling (collaboration with Dr Faridoon Yousafzai; John Innes Centre, 
Norwich, UK)  and limited proteolysis experiments.  
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5.1 Introduction 
 Traditional target-based drug screening is performed by high-throughput 
screening of chemical libraries, which may be synthetic/natural products or 
combinations of both (2009, Janda, 1994). I have used a different approach for 
identifying potential new gyrase inhibitors. I decided to investigate selected classes 
of compounds that have published information about their antibacterial activity. 
These compounds also did not have any information about their possible targets. 
There were two advantages of this method.  The first advantage is that since these 
compounds are already been shown to have antibacterial activity, I know that they 
have biological activity and can get into the bacterial cell. The other advantage is that 
if any of these compounds exhibit inhibitory activity against DNA gyrase, then it is 
likely that collaborators would be able to perform synthetic chemistry on the selected 
molecule to design better inhibitors. Although with this method it should be feasible 
to identify novel DNA gyrase inhibitors, like any other screening procedure a 
significant hit will not indicate that DNA gyrase is the only target for that particular 
molecule in-vivo. There may be a possibility of several other targets for the same 
molecule. Three different families of compounds: quinolines, aaptamines and 
naphthoquinones were studied for their activity against M. tuberculosis gyrase. 
Aaptamines and naphthoquinones have been shown to have antibacterial activity 
with no information about their potential targets (Gul et al., 2006), while quinolines 
have been shown to induce cross-resistance to fluoroquinolones (Davidson et al., 
2008). Although representative molecules from each family (chloroquine, 1N, 4N-
didodecyl aaptamine, diospyrin) have been identified as potential inhibitors of DNA 
gyrase, detail studies were done only on naphthoquinones, and specifically on 
diospyrin, due to its comparatively lower IC50 in  in-vitro DNA gyrase assays. 
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5.2 Quinolines 
Quinolines, such as chloroquine, have been used traditionally for the 
treatment of malaria, arthritis, and lupus for many years, but the precise mechanism 
of their action remains unclear (Foley & Tilley, 1998). Members from this family of 
compounds like mefloquine and its analogues also have been reported to have 
antimycobacterial properties (Bermudez et al., 1999). This fact is not surprising as a 
compound isolated from the commercial preparation of chloroquine was modified to 
produce the antibacterial compound, nalidixic acid (Appelbaum & Hunter, 2000). 
Fluorine was subsequently added to produce the fluoroquinolones, resulting in both 
an increase in potency and spectrum (Appelbaum & Hunter, 2000). Due to the 
common origin of fluoroquinolones and chloroquine, their pharmacore is similar 
(Figure 5.1).  
 
Figure 5.1:  Similar pharmacore of the fluoroquinolones and quinolines. 
The antimycobacterial properties of mefloquine and its relatedness to 
fluoroquinolones has led to the development of mefloquine-based ligands as 
potential antituberculosis agents (Jayaprakash et al., 2006). Despite the fact that it 
has not been possible to identify mutants resistant to mefloquine by both in vivo and 
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in vitro selection, microarray studies indicate the role of genes involved in membrane 
transport and cellular replication (Danelishvili et al., 2005). 
In a recent study (Davidson et al., 2008) it was reported that in a remote 
village of South America, 4.8% of the village carried cipro-resistant E. coli with 
QRDR mutations. QRDR mutations are mutations in the gyrase and topo IV 
quinolone-resistance determining regions (Feng-Jui & Hsiu-Jung, 2003 ). The 
ciprofloxacin-resistant E. coli isolates from Guyana had S83L/ D87N mutations in 
gyrA, S80I/ E84G/E84V mutations in parC and S458A, L416F, S458T mutations in 
parE (Davidson et al., 2008). The interesting fact about this observation was that the 
patients had never been exposed to quinolones, but there was an extensive use of 
chloroquine in the population for malaria treatment and prevention. Similarly, 
isolates tested for ciprofloxacin resistance after exposure to chloroquine showed 
D87Y and S801 mutation in gyrA and parC respectively. 
 This observation raises the interesting question as to whether quinolines 
target DNA gyrase in M. tuberculosis. This information could be useful for 
developing the well-known antimalarial quinolines as inhibitors for mycobacterial 
gyrase. Since malaria is prevalent in the parts of tropical countries, where TB is an 
epidemic, treatment for two diseases with a single class of drugs could be beneficial.  
Standard supercoiling and relaxation assay were performed to study the effect 
of choloroquine and mefloquine on the activity of M. tuberculosis DNA gyrase. 
Chloroquine was found to be a more potent inhibitor of DNA gyrase in comparison 
to mefloquine (Table 5.1; Figure 5.2).   
In our lab it has been shown that in the presence of mefloquine, E. coli DNA 
gyrase forms a cleavage complex. Interestingly similar experiments done with  
M. tuberculosis DNA gyrase demonstrate the formation of cleavage complex only in 
the presence of chloroquine as shown in Figure 5.3. 
These experiments demonstrate that quinolines inhibit M. tuberculosis 
DNA gyrase activity and they could be optimised further as potential TB drugs. 
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Quinolines Supercoiling Assays 
IC50 values (approx) 
Relaxation Assay 
IC50 values (approx) 
Chloroquine 80 µM 80 µM 
Mefloquine 300 µM 300 µM 
Table 5.1: IC50 values for Chloroquine and Mefloquine based on supercoiling 
and relaxation assays. 
 
 
 
Figure 5.2: Inhbitory activity of chloroquine and Mefloquine. Supercoiling 
inhibition assay (A) and relaxation inhibition assay (B) of chloroquine against 
M. tuberculosis DNA gyrase. Mefloquine inhibiton of supercoiling (C) and 
relaxation activity (D). NC: nicked Circular DNA, R: relaxed topoisomers, SC: 
supercoiled DNA.  
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Figure 5.3: DNA cleavage assay in the presence of chloroquine (A) and 
mefloquine (B) in the absence of ATP. DNA cleavage is observed in the presence 
of ciprofloxacin and chloroquine, but no linear DNA is observed with mefloquine. 
NC: nicked Circular DNA, L: linear DNA, R: relaxed topoisomers, SC: supercoiled 
DNA. 
5.3 Aaptamines and marine extracts 
 The aaptamine class of compounds is commonly isolated from various 
species of the marine sponge genus Aaptos (Jang et al., 2007). The sponge belongs to 
the order Hadromerida and family Suberitidae. When the marine product was first 
isolated (Nakamura et al., 1982), it was reported to have antineoplastic and α-
adrenoreceptor blocking activity. Isoaaptamine (Nakamura et al., 1987), a closely 
related compound can also be isolated from Aapto aaptos (Figure 5.4). 
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Figure 5.4: Aptos, a marine sponge and a natural source of Aaptamine. 
Since its original discovery a series of research articles have been published 
regarding the total synthetic and semi-synthetic derivatives of aaptamines (Ross 
Kelly & Maguire, 1985, Pelletier & Cava, 1985, Andrew & Raphael, 1987). 
Although the synthetic yield of aaptamine is low from quinoline and isoquinoline 
precursors, still it is likely to be the more cost efficient choice for the production of 
aaptamines (Larghi et al., 2009). Chemically all the aaptamine compounds are 
alkaloids that contain the benzonapthyridine core structure (Figure 5.5). 
Isoquinolones, dopamine and quinolines (anti-malarial) share structural similarity 
with aaptmaine. 
Aaptamine has potent toxicity which can be attributed to its ability to 
intercalate into DNA (Bowling et al., 2008). DNA intercalation is common with 
compounds like aaptamines; they intercalate between adjacent base pairs of intact 
DNA through pi-bond interactions and in some instances several molecules stack 
together in the same area between the base pairs (Bowling et al., 2008).  It has been 
suggested that the inhibition of the S-phase of the cell cycle (Pettit et al., 2004), 
which may lead to cytotoxicity, may be due to interaction with DNA or a 
topoisomerase. Structure-activity relation studies (Shen et al., 1999) have shown that 
the C-9 hydroxyl position is important for the cytotoxic activity and  acylation at this  
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position causes a decrease in activity. The closely related bis (napthalimide) 
derivative DMP 840 (A) has been reported to be a topoisomerase II inhibitor (Nitiss 
et al., 1998) and is currently in phase I clinical trials (Thompson et al., 1999). 
Aaptamines have anti-cancer (Pettit et al., 2004, Shen et al., 1999), antiviral 
(Bowling et al., 2008) and antibacterial (Gul et al., 2006) properties that encourage 
the evaluation of their derivatives for therapeutic potential. Since aaptamines are 
related to quinolines, possess antimycobacterial activity (Pettit et al., 2004) and are 
predicted to  interact with topoisomerases, I decided to assay seven aaptamine 
derivatives and marine extracts: isoaaptamine nonyl dimer, 8- hydroxymanzamine, 
manzamine, aaptamine, isoaaptamine,1N,4N-didodecylaaptamine, kaempferol-3-O-
α-L-(2,3-di-E-Pcomaroyl)-rhamnoside to study their effect on the activity of  M. 
tuberculosis DNA gyrase Figure 5.5. The compounds were kindly donated by Prof. 
Mark T. Hamann (Research Institute of Pharmaceutical Sciences, University of 
Mississippi). The compounds were tested in standard supercoiling assays.  
 
Figure 5.5: Aaptamines and marine extracts. 
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Figure 5.6: Inhibitory activity of aaptamine and kaempferol. Supercoiling 
inhibition assay of aaptamine (A) and kaempferol (B) against M. tuberculosis 
DNA gyrase (0.1 mM). The final concentration of ethanol in the assay is 3% in the 
presence of the aaptamine. Kaempferol is soluble in 100% DMSO and the final 
concentration of DMSO is 5% in the presence of the drug. NC: nicked Circular 
DNA, R: relaxed topoisomers, SC: supercoiled DNA.  
 
 
A. 
B. 
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Out of all the compounds that were tested, 1N, 4N-Didodecyl Aaptamine 
(Figure 5.6) is potentially a good inhibitor of M. tuberculosis DNA gyrase (IC50~10-
20 µM), while Kaempferol-3-O-α-L-(2,3-di-E-P-comaroyl)-rhamnoside (Figure 5.6) 
is a weak inhibitor with an IC50~50- 100 µM. The rest of the compounds did not 
have any effect on the activity of the enzyme. 
5.4 Naphthoquinones  
The use of medicinal plants such as Acacia nilotica, Cassine papillosa, 
Cheopodium ambrosioides, Combretum molle, Euclea natalensis (Figure 5.7) etc. by 
native South Africans to cure TB has been reported (Pujol, 1990.). The indigenous 
people of South Africa extensively use E. natalensis A.DC. for diseases such as chest 
complains, bronchitis, pleurisy, chronic asthma, urinary tract infections, venereal 
diseases and oral health (Van Wyk & Van Wyk, 1997). A significant amount of work 
has been done on the antimycobacterial activity of E. natalensis, which has been 
shown to exhibit activity against drug-sensitive and drug-resistant strains of M. 
tuberculosis (Lall & Meyer, 2001). It is a tree of the Ebenaceae family and is a rich 
source of a class of compounds known as naphthoquinones.  
 
 
Figure 5.7: E. natalensis, a medicinal plant and a natural source of 
naphthoquinones. 
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Naphthoquinones can be represented as derivatives of naphthalene with the 
replacement of two hydrogen atoms by two ketone groups. A well known member of 
naphthoquinone family is 7-methyljuglone (5-hydroxy-7-methyl-1,4-
naphthoquinone). A series of synthetic and plant-derived naphthoquinone derivatives 
of the 7-methyljuglone scaffold such as diospyrin, menadione, shinanolone, 
neodiospyrin, and isodiospyrin are available (Figure 5.8). 
 
Figure 5.8: Naphthoquinones studied for their activity against mycobacterial 
DNA gyrase. 
Naphthoquinones have a broad range of biological activity that can be 
exploited for the design of new antibacterials (Mahapatra et al., 2007), anti-
leshmaniasis (Ray et al., 1998, Yardley et al., 1996) and antitumor compounds 
(Hazra et al., 1984, Ting et al., 2003). 7-methyljuglone and its derivatives (Table 
5.2) have been shown to have antimycobacterial activity (Mahapatra et al., 2007). 7-
methyljuglone is the most potent in-vivo against M. tuberculosis H37Rv. The 
selectivity index is a ratio between IC50 and MIC (IC50/MIC). The bactericidal 
activites were reported by MICs and the compound cytotoxicity for  the Vero cell 
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line was reported by IC50. The selectivity index is a ratio between the IC50 and MIC 
(IC50/MIC). It indicates the target specificity of the compound. A compound with 
higher IC50 and lower MIC will be an effective bactericidal and less toxic. In drug 
development, compounds with a selectivity index of >1,000 are regarded as 
promising candidates for clinical development. 7-methyljuglone has a higher 
selectivity index in comparison to other derivatives. It is suggested that the poor 
selectivity of the derivatives is possibly due their non-specific activity with other 
disulfide reductase (e.g. thioredoxin reductase, lipoamide dehydrogenase) which are 
also found in mammalian cells (Mahapatra et al., 2007). 7-methyljuglone has the 
ability to enhance the activity of the first-line drugs isoniazid and rifampicin against 
both extracellular and intracellular M. tuberculosis (Bapela et al., 2006). The MIC 
values of naphthoquinones indicate that the ketone groups on C1 and C4 or 
aromatictiy between the carbon atoms are important for antimycobacterial activity. 
 
Compound MIC (µg/ml) IC50(µg/ml) Selectivity index 
1. 7-methyljuglone 0.5 15.1 30.22 
2. Diospyrin 8.0 17.8 2.2 
3. Neodiospyrin 10.0 32.0 3.2 
4. Menadione 5.0 6.5 1.30 
5. Shinanalone > 100 - - 
Table 5.2: Antituberculosis activity and cytotoxicity of 7-methyljuglone and its 
derivatives (Mahapatra et al., 2007).  
Besides the antimycobacterial activity of diospyrin, it is also has antitumour 
(Hazra et al., 1984) anti-leshmaniasis and antiprotozoal activities (Hazra et al., 
1995). Diospyrin inhibits the growth of Leshmania donovani promastigotes (Yardley 
et al., 1996), Trypanosoma cruzi, Trypanosoma brucei (Yardley et al., 1996) and 
Plasmodium falciparum (Hazra et al., 1995) in vitro. Further studies performed on 
this compound show that diospyrin interacts specifically with topoisomerase I of 
leishmania but does not inhibit type II topoisomerase of Leshmania donovani and 
requires a much higher concentration to inhibit type I topoisomerase of calf thymus 
  
Chapter 5  
 
208 
 
(Ray et al., 1998). Mechanistically, like camptothecin, diospyrin stabilises the 
topoisomerase I cleavage complex in vitro (Ray et al., 1998).   
A related bisnaphthoquinone, isodiospyrin from the plant Diospyros 
morrisiana also inhibits relaxation and kinase activity of human topoisomerase I. But 
unlike diospyrin it does not stabilise the cleavage complex rather it limits human 
topoisomerase I access to the DNA substrate by direct binding to human 
topoisomerase I (Ting et al., 2003). The exact binding site of isodiospyrin on human 
topoisomerase I is not clear, but it is predicted that cysteine residues in the protein 
could be isodiospyrin’s potential binding site on human topoisomerase I, given that 
naphthoquinones are well known to interact with sulphydryl-containing proteins. 
5.5 Targets for naphthoquinones 
Despite the fact that naphthoquinones exhibit animycobacterial activity, there 
is no defined target for this class of compounds. It is postulated that due to structural 
similarities between 7-methyljuglone and menaquinone it is feasible that 7-
methyljuglone interacts with the enzymes in the mycobacterial electron transport 
chain (Figure 5.9) (Mahapatra et al., 2007). The electron flow might be slowed or 
stopped due to the difference in the redox potential of the incorporated 7-
methyljuglone (van der Kooy et al., 2006). Menaquinone is a natural redox cycler in 
Mycobacterium, which mediates electron transfer between different membrane-
bound enzymes of the respiratory chain (Garbe, 2004). Menaquinone is an attractive 
drug target because M. tuberculosis lacks ubiquinone and makes use of only 
menaquinone in the electron transport chain. There is also the possibility that 7-
methyljuglone binds to the Men enzyme responsible for the formation of 
menaquinone and inhibits the addition of the hydrophobic side-chain, influencing 
ATP production (van der Kooy et al., 2006). 
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Figure 5.9: Structural similarities between 7-methyljuglone and menaquinone.  
Due to their structural similarity it is possible that 7-methyljuglone interacts with the 
enzymes in the mycobacterial electron transport chain (van der Kooy et al., 2006). 
Another predicted target for naphthoquinones is Mycothiol disulfide 
reductase (Mtr) (Mahapatra et al., 2007). Many naphthoqinones are subversive 
substrates for flavoprotein disulfide reductase such as glutathione reductase, 
trypanothione reductase and lipoamide dehydrogenase (Salmon-Chemin et al., 2001, 
Biot et al., 2004).  The functions of these enzymes involve the NAD(P)H-dependent 
reduction of disulfide bonds in proteins or oxidized versions of thiols such as 
glutathione. Glutathione is absent in M. tuberculosis; instead it has millimolar 
concentration of low molecular weight thiol mycothiol (MSH). MSH, analogous to 
glutathione, plays an important role in oxidative stress management and in the 
process is oxidized to disulfide (MSSM). Mtr helps to maintain an intracellular 
reducing environment by reducing MSSM back to MSH, which is essential for the 
growth of M. tuberculosis (Sareen et al., 2003) and MSH-deficient mycobacteria are 
sensitive to oxidative stress (Rawat et al., 2002). According to this hypothesis 
(Mahapatra et al., 2007), naphthoquinones are reduced to semiquinone by Mtr and 
are regenerated by the reduction of oxygen to semiquinone radicals (Figure 5.10).  In 
this way the naphthoquinone substrate is regenerated and the fatal redox cycle 
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continues. The catalytic properties of Mtr were reported using some commercial 
naphthoquinones as substrates (Patel & Blanchard, 1999) and this generates the 
possibility that naphthoquinones could be acting as substrates for disulfide reductase 
found in M. tuberculosis. 
But there is no direct correlation between the substrate efficiency of 
naphthoquinones and their MIC values in whole cell assay (Table 5.3). This 
indicates that the antibacterial activity of naphthoquinones is the consequence of 
their activity against multiple biological targets and Mycothiol disulfide reductase is 
not the target for naphthoquinones. The MIC values obtained from whole cell assays 
were compared with kcat/Km ratio. Km values show the substrate binding affinities and 
the kcat values express the maximum turnover rates. The kcat/Km ratio expresses the 
substrate efficiency of naphthoquinones for M. tuberculosis Mtr. Higher kcat/Km   
values indicate higher substrate efficiency with Mtr. Neodiospyrin has higher kcat/Km 
value in comparison to Diospyrin; however it also has higher MIC which indicates 
no correlation between the antibacterial activity of the compounds and their 
specificity for Mycothiol disulfide reductase. 
 
Figure 5.10: Mycothiol reductase (Mtr) target for naphthoquinones.  
a.) Mycothiol (MSH) and its disulfide reductase: NADPH-dependent Mtr reduction 
of oxidized mycothiol (MSSM) to its reduced form (MSH). b.) Naphthoquinones can 
act as a substrate for Mtr instead of mycothiol (Mahapatra et al., 2007). 
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Compound MIC (µM) kcat/Km (× 105) 
1. 7-methyljuglone 3 931 
2. Diospyrin 21 357 
3. Neodiospyrin 27 488 
4. Menadione 29 152 
Table 5.3: Substrate properties of naphthoquinones with M. tuberculosis Mtr 
(Mahapatra et al., 2007). The kcat/Km expresses the substrate efficiency of 
naphthoquinones for M. tuberculosis Mtr; higher kcat/Km values indicate higher 
substrate efficiency. 
5.6 Naphthoquinones inhibit DNA gyrase 
Naphthoquinones such as diospyrin and isodiospyrin have been reported to be 
inhibitors of Leishmania donovani and human type I topoisomerase (Ting et al., 
2003, Ray et al., 1998). There have been no reports on the activity of this class of 
compounds against type II topoisomerases. Since naphthoquinones have 
antimycobacterial activity, I decided to test them against Mycobacterial DNA gyrase. 
Six different naphthoquinones: 7-methyljuglone, Diospyrin, Neodiospyrin (Figure 
5.11), Menadione, Shinanolone, Iso-diospyrin (Figure 5.12) and crude extracts of 
Euclea natalensis were tested for their activity against M. tuberculosis DNA gyrase.  
Standard supercoiling assays were performed in the presence of different 
concentrations of drugs. Out of all the compounds and extracts that were tested 
7-methyljuglone and diospyrin were found to the most potent inhibitors of  
M. tuberculosis DNA gyrase (Table 5.4). Concentration-dependent inhibition of 
supercoiling activity was observed with these compounds.  
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Figure 5.11: Supercoiling inhibition assay of 7-methyljuglone (A) and diospyrin 
(B) against wild-type M. tuberculosis DNA gyrase. The final concentration of 
DMSO in assay is only 5% in the presence of the drug. NC: nicked Circular DNA, R: 
relaxed topoisomers, SC: supercoiled DNA. 
 
A. 
B. 
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Figure 5.12: Supercoiling inhibition assay of neodiospyin (A), isodiospyrin (B), 
menadione and shinanolone (C) against wild-type M. tuberculosis DNA gyrase. 
NC: nicked Circular DNA, R: relaxed topoisomers, SC: supercoiled DNA. 
A. 
B. 
C. 
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Figure 5.13: Relaxation and decatenation inhibition assays of 7-methyljuglone 
(A) and diospyrin (B) respectively against M. tuberculosis DNA gyrase. NC: 
nicked Circular DNA, R: relaxed topoisomers, SC: supercoiled DNA, kDNA: 
catenated DNA.  
 
 
 
A. 
B. 
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Compound Approx IC50  
1. 7-methyljuglone 10 µM 
2. Diospyrin 10 µM 
3. Neodiospyrin 50 µM 
4. Isodiospyrin 100 µM 
5. Menadione > 200 µM 
6. Shinanalone >200 µM 
7. Methanol plant extract 133.3 ng/ml* 
8. Ethanol plant extract No inhibition 
9. Euclea natalensis crude plant extract 0.25 -2.5 µg/ml* 
10.  Ciprofloxacin 10 µM 
Table 5.4: DNA supercoiling IC50 values for naphthoquinones. 
                *Reported in different concentration units as these are crude extracts. 
7-methyljuglone and diospyrin, the most potent DNA gyrase inhibitors of all 
the tested compounds, have IC50 of ~10 µM, comparable to the IC50 of ciprofloxacin  
(10 µM). Besides inhibiting the DNA gyrase supercoiling activity, these compounds 
also inhibit DNA relaxation and decatenation activity (Figure 5.13, Table 5.5). 
Compound Relaxation assay 
IC50 
Decatenation assay 
IC50 
1. 7-methyljuglone 80-120 µM 10-30 µM 
2.  Diospyrin 40-80 µM 1-10 µM 
Table 5.5: DNA relaxation and decatenation IC 50 values for naphthoquinones. 
7-methylyjuglone and diospyrin also inhibit E. coli DNA gyrase. 7-
methylyjuglone inhibits the supercoiling activity of E. coli DNA gyrase with an IC50 
between 50-100 µM, while diospyrin inhibits the E. coli DNA gyrase supercoiling 
activity with an IC50 between 1-10 µM (Figure 5.14). There is a difference in the 
inhibitory activity of these compounds against E. coli DNA gyrase unlike their 
inhibitory activity against M. tuberculosis DNA gyrase. Diospyrin is 5-10 times more 
effective in inhibiting the supercoiling activity of E. coli DNA gyrase in comparison 
to 7-methyljuglone. 
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Figure 5.14: Inhibition of E. coli DNA gyrase supercoiling activity in the 
presence of 7-methyljuglone and diospyrin. NC: nicked Circular DNA, R: relaxed 
topoisomers, SC: supercoiled DNA.  
As mentioned before, naphthoquinones such as diospyrin have been shown to 
stabilise the topoisomerase I cleavage complex in vitro (Ray et al., 1998). Wild-type 
M. tuberculosis DNA gyrase, like other bacterial gyrases exhibits significant amount 
of cleavage activity in the presence of quinolones such as ciprofloxacin (Kampranis 
& Maxwell, 1998), as in the presence of quinolones the cleavage-religation 
equilibrium is shifted towards the cleaved form (Aubry et al., 2006a). Therefore to 
test whether naphthoquinones inhibit the DNA gyrase activity by stabilizing the 
cleavage complex, DNA cleavage assays were performed in the presence of 7-
methyljuglone and diospyrin. The assay was done in the presence and absence of 
ATP. Unlike the ciprofloxacin control in the assay, no cleaved DNA was formed 
either in the presence or absence of ATP (Figure 5.15, Figure 5.16). This 
observation suggests that naphthoquinones such as 7-methyljuglone and diospyrin do 
not inhibit the DNA gyrase activity by stabilising the cleavage complex. Thus there 
is difference in the mode of inhibition of topoisomerase I and DNA gyrase by 
naphthoquinones. 
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Figure 5.15: DNA cleavage assay in the presence of different concentrations of 
7-methyljuglone (A) and diospyrin (B) and in the presence of 1 mM ATP. 
Ciprofloxacin-induced DNA cleavage is observed in the control; but no linear DNA 
is observed with the DMSO control and drugs. NC: nicked Circular DNA, L: Linear 
DNA, R: relaxed topoisomers, SC: supercoiled DNA. 
A. 
B. 
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Figure 5.16: DNA cleavage assay in the presence of 7-methyljuglone (A) and 
diospyrin (B) in the absence of ATP. Ciprofloxacin-induced DNA cleavage is 
observed in the control; but no linear DNA is observed with the DMSO control and 
drugs. NC: nicked Circular DNA, L: linear DNA, R: relaxed topoisomers, SC: 
supercoiled DNA. 
A. 
B. 
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5.7 E. coli Inhibitory activity  
Naphthoquinones have been shown to have antimycobacterial activity 
(Mahapatra et al., 2007). I wanted to test if these compounds can also inhibit Gran-
negative bacteria such as E. coli. A pilot study done on E. coli NR698 is shown in 
Figure 5.17. E. coli NR698 carries imp4213 allele that increases the outer membrane 
permeability. imp4213 allele is an in-frame deletion allele in the imp gene (increased 
membrane permeability), which encodes a protein essential for outer membrane 
assembly (Ruiz et al., 2005). The inhibitory assay was performed in LB media. OD 
at 600 nm was recorded at different time points for two different concentrations of 
diospyrin (MIC & 10 × MIC). Similarly as a positive control, growth was recorded at 
different concentrations of ciprofloxacin (MIC & 10 × MIC). Appropriate DMSO 
controls were taken to observe the effect of the solvent. There is no apparent effect of 
DMSO in comparison to diospyrin. Inhibitory activity was observed at MIC & 10 × 
MIC for both diospyrin and ciprofloxacin.  
 
Figure 5.17: In-vitro inhibitory activity of diospyrin against E. coli NR698 (Ruiz 
et al., 2005). 0.16% and 1.6% DMSO are equivalent to the concentration of DMSO 
in test samples with 21 µM (MIC) and 213 µM (10 × MIC) diospyrin. Ciprofloxacin 
control showed inhibitory activity at the concentration of 36 nM (MIC) and 362 nM 
(10 × MIC). 
0
0.5
1
1.5
2
2.5
3
1 2 3
Time ( Hour)
O
D 
60
0 
n
m
 0.16%DMSO control
1.6% DMSO control
21µM Diospyrin
213 µM Diospyrin
36 nM Cipro
362 nM Cipro
  
Chapter 5  
 
220 
 
5.8 Diospyrin binding site 
Since functional DNA gyrase exists as an A2B2 complex, it is important to 
identify the DNA gyrase subunit to which naphthoquinones bind or interact. This 
information is necessary to investigate the drug-binding site and to get further insight 
into the mechanism of inhibition. Nanoflow-electrospray ionization mass 
spectrometry (nano-ESI-MS) was employed to identify the DNA gyrase subunit that 
is involved in interacting with diospyrin. These experiments were performed in 
collaboration with Dr Adam Mckay (University College London, UK). All spectra 
were recorded on the high mass modified ESI-ToF mass spectrometer (Waters 
SYNAPT HDMS) with the samples prepared in 250 mM sodium acetate (Materials 
and Methods) except in one instance when Waters LCT Premier XE was used. The 
experiments were performed with diospyrin (MW: 374.35 Da), due to its higher 
molecular weight in comparison to 7-methyljuglone (MW: 188.18 Da). It is easier to 
discriminate the peaks corresponding to the non-covalent binding of higher 
molecular weight ligands to protein on nano- ESI-MS. The diospyrin binding studies 
using nano-ESI-MS were performed on M. tuberculosis GyrA, M. tuberculosis 
GyrB, M. tuberculosis GyrA
 
+ GyrB, E. coli GyrB43 and E. coli GyrB47.  The 
results of the diospyrin binding studies are summarized in Table 5.6. 
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    Table 5.6: Summary results of diospyrin binding studies using nano- ESI-MS. 
 
5.8.1 M. tuberculosis GyrB-diospyrin complex    
M. tuberculosis GyrB was buffer exchanged into 250 mM sodium acetate and 
tested for its stability under the conditions of the mass spectrometry experiment. The 
mass spectrometric profile of GyrB subunit shows two different charge species. 
Analysis of the peaks gives a mass of 79,876 +/- 7 Da corresponding to the M. 
tuberculosis GyrB monomer (theoretically calculated MW: 79262.58 Da) and 76,634 
+/- 26 Da as shown in Figure 5.18. The presence of the low molecular weight 
species could be due to truncation of M. tuberculosis GyrB. Despite the presence of 
lower molecular weight species, the molecular species with mass of 79,876 +/- 7 Da 
is the prominent species. 
   
DNA gyrase subunits         Diospyrin binding 
 
1. M. tuberculosis GyrA 
 
no diospyrin binding observed. 
2.  M. tuberculosis GyrB diospyrin binding observed at 8-fold 
and 16 -fold excess of drug. 
3. M. tuberculosis GyrA + GyrB 
 
 
selective binding to GyrB observed 
with GyrB signals masking the GyrA 
profile. 
4.  E. coli GyrB43 diospyrin binding observed at 16- fold 
excess of drug. 
 
5.  E. coli GyrB47 no diospyrin binding observed. 
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Figure 5.18: Mass spectrometry spectrum of M. tuberculosis GyrB monomer 
(79-kDa). +17 represents the charged state of the peak. 
 
The next step was to determine if diospyrin binds to the M. tuberculosis 
GyrB. Mass spectrometry data was collected for GyrB in the presence of an 8-fold 
excess of diospyrin. Three different charge species are observed with masses 79,960 
+/- 30 Da; 76,646 +/- 7 Da and 80,381 +/- 18 Da as shown in Figure 5.19.  The 
species with a mass of 79,960 +/- 30 Da (theoretically calculated MW: 79,262.58 
Da) corresponded to the monomeric GyrB subunit without diospyrin. The 
experimentally determined molecular weight is more than the theoretically calculated 
molecular weight due to insufficient removal of either solvent and/or buffer ions 
during the electrospray process resulting in an increase in the measured mass as well 
as a broadening of the peaks in the spectrum. This has also been observed previously 
for other non-covalent assemblies (McKay et al., 2006). The species with a 
molecular weight of 76,646 +/- 7 Da is also present, in the all the mass spectrometric 
profile of M. tuberculosis GyrB and is a contamination. Interestingly the third 
molecular species with a mass of 80,381 +/- 18 Da (theoretically calculated MW: 
80,334.35 Da), corresponded to M. tuberculosis GyrB monomer bound with 
M. tuberculosis GyrB 
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diospryin (MW: 374.35). The peaks representing the diospyrin- bound GyrB are 
observed as shoulders adjacent to the peaks representing the GyrB monomer.  
 
Figure 5.19: Mass spectrometry spectrum of M. tuberculosis GyrB in the 
presence of an 8-fold excess of diospyrin. The coloured stars represent the 
shoulder peaks corresponding to the diospyrin-bound species. +15 represents the 
charge state of the peak. 
Similarly, when the same experiment was repeated in the presence of a 16- 
fold excess of diospyrin (Figure 5.20), three different charge species with a mass of 
79,953 +/- 20 Da; 76,606 +/- 9 Da, 80,320 +/- 6 Da are observed as shown in Figure 
5.20. As indicated above, the species with a mass of 79,953 +/- 20 Da (theoretically 
calculated MW: 79262.58 Da) and 80,320 +/- 6 Da (theoretically calculated MW: 
80,327) represented the M. tuberculosis GyrB monomer with and without the bound 
diospyrin. More peaks corresponding to the drug bound protein is observed at 16- 
fold excess of diospyrin due to the resolution being affected by the excess DMSO 
and drug.  
 
 
 
M. tuberculosis GyrB + 8-fold diospyrin 
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Figure 5.20: Mass spectrometry spectrum of M. tuberculosis GyrB in the 
presence of a 16-fold excess of diospyrin. The coloured stars represent the 
shoulder peaks corresponding to the diospyrin-bound molecular species. +15 
represenst the charge state of the peak. 
Similar experiments done with M. tuberculosis GyrA subunit revealed the 
dimeric states of the protein, but no peaks corresponding to the diospyrin-bound  
GyrA are observed. This does not completely eliminate the possibility that diospyrin 
binds GyrA, as it is possible that the peaks due to diospyrin binding could not be 
resolved due to the high molecular weight of M. tuberculosis GyrA (93083.13 Da) in 
comparison to the  extremely low molecular weight of  diospyrin ( 374.35 Da). The 
resolution is further affected by the excess of DMSO and drug. 
When M. tuberculosis GyrA and GyrB were mixed together in equimolar 
concentration in the presence of a 10-fold excess of diospyrin, mass spectrometry 
data revealed peaks of a single species with six different charged states as shown in 
Figure 5.21. Analysis of peaks gives a mass of 80434.18±7.51 corresponding to the 
diospyrin bound M. tuberculosis GyrB. This may be due to the masking of M. 
tuberculosis GyrA signals. The mass spectrometry data in this case was collected on 
Waters LCT Premier XE.  
M. tuberculosis GyrB + 16-fold diospyrin 
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Figure 5.21: Mass spectrometry spectra for protein-diospyrin complexes.  
(A) M. tuberculosis GyrB; (B) GyrB in the presence of a 10-fold excess of diospyrin; 
(C) GyrA and GyrB mixed together in equimolar concentration in the presence of a 
10-fold excess of diospyrin. 
 5.8.2 E. coli GyrB43-diospyrin complex 
Based on the results of mass spectrometry experiments performed with  
M. tuberculosis GyrB, the next step was to identify the domain in GyrB that 
facilitated diospyrin binding. For this experiment the N-terminal domain of E. coli 
GyrB (GyrB43) and the C-terminal domain (GyrB47), were used (Figure 5.22). The 
crystal structure of E. coli GyrB43 with the ATP analogue ADPNP (Brino et al., 
2000, Wigley et al., 1991) is available and has been shown to have the ATP-binding 
site (Ali et al., 1993). GyrB47 interacts with the N-terminal domain of GyrA and 
forms the part of cleavage-religation domain (Brown et al., 1979, Gellert et al., 
1979). 
  
Figure 5
Like M. tuberculosis
conditions of the mass spectrometry experiment. The mass spectrometric profile of 
E. coli GyrB43 subunit shows three different charge species.  Analysis of peaks gives 
masses of 43,279 +/
(theoretically calculated MW:
shown in Figure 5.23
lower molecular weight species with mass of 42,436 +/
be due to the fragmentation of 
 
Figure 5.23: Mass spectrometry
charge state of the peak.
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.22: Representation of GyrB functional domains.
 
 GyrB, E. coli GyrB43 is a monomer under the 
- 2 Da corresponding to the E. coli 
 43023.50 Da); 42,436 +/- 36 Da and 41,025 Da as 
. As observed in case of M. tuberculosis GyrB, the observed 
- 36 Da and 41,025 Da may 
E. coli GyrB43 or contamination. 
 spectrum of E. coli GyrB43. +10 
 
 
 
Chapter 5  
 
 
GyrB43 monomer 
 
represents the 
  
Chapter 5  
 
227 
 
 
 
 
 
Figure 5.24: Mass spectrometry of E. coli GyrB43 in the presence of a 16-fold 
excess of diospyrin. The coloured stars represent the shoulder peaks corresponding 
to the diospyrin-bound species. +11 represents the charge state of the peak. 
  E. coli GyrB43 in the presence of a 16-fold excess of diospyrin, reveals a 
charge species in the spectrum with a mass of 43,723 +/- 7 Da corresponding to 
diospyrin-bound GyrB43 (theoretically calculated MW:  43687.35) in addition to the 
GyrB43 monomer (theoretically calculated MW: 43023.50 Da) with a mass of 
43,313 +/- 10 Da; and lower molecular weight species with a mass of 42,377+/- 40 
Da and 41,025 +/- 8 Da, as shown in Figure 5.24. 
In the case of E. coli GyrB47 in the absence of diospyrin, analysis of the 
peaks gives masses of 49,457 +/- 11 Da; 48,864 +/- 20 Da ; 47,689 +/- 11 Da and 
47,012 +/- 21 Da corresponding to E. coli GyrB47 monomer (theoretically calculated 
MW: 46581.93 Da) as shown in Figure 5.25. 
 
 
 
 
E. coli GyrB43  
+ 16-fold diospyrin 
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Figure 5.25: Mass spectrometry spectrum of E. coli GyrB47. +13 represents the 
charge state of the peak. 
 In the presence of a 16-fold excess of diospyrin, no peaks corresponding to 
the diospyrin-bound E. coli GyrB47 were observed. Analysis of the peaks gives 
masses of 49,516 +/- 26 Da; 48,920 +/- 24 Da; 47,742 +/- 26 Da; 47,077 +/- 18 Da 
corresponding to the GyrB47 monomer (theoretically calculated MW: 46581.93 Da) 
and 46,138 +/- 16 Da (Figure 5.26).  The peaks corresponding to 46,138 +/- 16 Da, 
49,516 +/- 26 Da; 48,920 +/- 24 Da may be due to contamination. This indicates that 
diospyrin does not bind to E. coli GyrB47.  
 
 
 
 
 
 
 
 
E. coli GyrB47 
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Figure 5.26: Mass spectrometry spectrum of E. coli GyrB47 in the presence of a 
16- fold excess of diospyrin. 
5.9 Limited Proteolysis  
Limited proteolysis studies have been performed to study the interaction of 
other DNA gyrase inhibitors such as CcdB (Kampranis et al., 1999c),  novobiocin 
(Kampranis et al., 1999b), quinolones (Kampranis et al., 1999c), and SD8 (Sissi et 
al., 2010) with GyrA,GyrB and A2B2. Results from these studies have shown a 
characteristic proteolysis pattern for E. coli GyrB with the protection of the C-
terminal 47-kDa domain in presence of quinolones, a 13-kDa fragment (derived from 
the digestion of the 43-kDa N-terminal domains) in the presence of novobiocin, and 
delay of a 25-kDa proteolytic fragment in the presence of SD8.  
Since the ESI-MS experiments indicate the N-terminal domain of GyrB as the 
potential target site for diospyrin, limited trypsin proteolysis experiments were done 
with M. tuberculosis GyrB and E. coli GyrB43 with appropriate controls. There is an 
effect of diospryin on the proteolytic profile of M. tuberculosis GyrB and E. coli 
GyrB43. Control experiments with M. tuberculosis GyrA did not show any change in 
the proteolytic profile of this protein. 
In the case of M. tuberculosis GyrB, four distinct bands of ~55- kDa, ~33- 
kDa,~30-kDa and ~25-kDa are observed at 5 and 10 min, with subsequent 
E . coli GyrB47 + 16-fold diospyrin 
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degradation of protein in further time points. The ~33- kDa, ~30- kDa and ~25- kDa 
fragments may be due to further digestion of ~55- kDa fragment (Figure 5.27). 
 
 
 
 
Figure 5.27: Tryptic digest of the M. tuberculosis GyrA (A) and M. tuberculosis 
GyrB (B) in the presence and absence of diospyrin. 4 µM protein was incubated 
with 1 µg/ml trypsin, at 37ºC, in the presence or absence of 100 µM diospyrin. For 
samples without diospyrin, DMSO was added to a final concentration of 2%. 
Samples were taken at various time points and subsequently analysed by SDS-PAGE. 
A. 
B. 
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It has been shown that it is around 20% DMSO that major stimulation in any 
enzyme activity is observed (Rammler, 1967); but the DMSO percentage in all the 
limited proteolysis experiments was not more that 2.5%. Therefore any differences 
observed in the digestion pattern will not be due to the effect of DMSO on the 
enzyme activity of trypsin. In the presence of 100 µM diospyrin, the M. tuberculosis 
GyrB is more labile to digestion by trypsin with the disappearance of ~55-kDa band 
and disappearance of the other three bands. Similar experiments with M. tuberculosis 
GyrA do not show any significant differences in the proteolysis pattern, with bands 
of ~62-kDa, ~45-kDa and ~32- kDa observed in the absence and presence of 
diospyrin, as shown in Figure 5.27. 
Trypsin digestion profiles in the case of E. coli GyrB43 (43- kDa) are 
different in the absence and presence of diospyrin at the 30 min and 60 min time 
points. At the 30 min time point, the ~31- kDa fragment disappears with the 
emergence of a ~17-kDa band, which stays on until 60 min with the complete 
disappearance of the ~31-kDa fragment. This pattern is similar to that observed with 
novobiocin, where a ~13-kDa is protected in the presence of the drug (Kampranis et 
al., 1999b). However like M. tuberculosis GyrA, the E. coli GyrA trypsin digestion 
profile does not change in the presence of diospyrin. Both in the presence of DMSO 
and diospryin, the characteristic bands of ~62-kDa, ~45-kDa are obtained (Figure 
5.28). 
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Figure 5.28: Tryptic digest of E. coli GyrA (A) and E. coli GyrB43 (B) in the 
presence and absence of diospyrin. 4 µM of the GyrA and  
GyrB43 were incubated with 1 µg/ml trypsin and 12 µg/ml trypsin, at 37ºC, in the 
presence or absence of 100 µM diospyrin. For samples without diospyrin, DMSO 
was added to a final concentration of 2%. Samples were taken at various time points 
and subsequently analysed by SDS-PAGE. 
B. 
A. 
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These changes in the trypsin digestion profiles of M. tuberculosis GyrB, and 
E. coli GyrB43, suggest that diospyrin induces conformational changes on binding to 
the GyrB. 
5.10 Surface plasmon resonance 
The nano-ESI-MS and limited proteolysis experiments indicated GyrB as the 
potential binding site for diospyrin. Surface plasmon resonance studies under the 
guidance of Dr. Sandra Grieve (John Innes Centre, Norwich, UK) were performed as 
an alternative sensitive method to study diospyrin binding and to investigate if the 
diospyrin shares partially or completely the novobiocin-binding site. The diospyrin 
binding studies were performed with E. coli GyrB43, M. tuberculosis GyrA and 
GyrB subunits immobilised on to CM5 chips (carboxymethylated dextran covalently 
attached to a gold surface) as described in the Material and Methods section. The 
sensograms were recorded on a BIAcore T100. Initial binding studies were done with 
the well-characterised aminocoumarin novobiocin as a control to verify the binding 
properties of the immobilised protein. SPR studies carried out in the past (Kampranis 
et al., 1999b) with novobiocin  were used as the starting point. 
Novobiocin binding studies, done in triplicate, clearly show drug binding to 
E. coli GyrB43 and M. tuberculosis GyrB with drug concentration between  20 -100 
nM. Although binding was observed at different drug concentrations, regeneration 
with 2 M KCl was not efficient, which in turn affected the quality of the sensograms. 
Although 2 M KCl was reported to be the regenerating agent (Kampranis et al., 
1999b) the sensitivity of  BIAcore T100 could detect inefficient regeneration, which 
may not have been detected in the past by the BIAcore 2000 system. Regeneration 
scouting was done with a range of recommended regeneration agents such as 10 mM 
glycine (pH 2, 2.5, 3), 4 M NaCl, 20 mM NaOH and 40 mM NaOH with different 
percentages of surfactant P20. None of the regenerations were ideal; on the contrary 
some of them were harsh and affected the surface of the chip. Based on the available 
data the apparent estimated Kd for novobiocin for E. coli GyrB43 and M. tuberculosis 
GyrB are in the range of 10-8 M and10-7-10-8 M respectively (Figure 5.29). These Kd 
are consistent
 
with the those reported in the past (Kampranis et al., 1999b). The 
novobiocin control experiment highlighted the problem with regeneration conditions 
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but at the same time verified the binding efficiency of the immobilised proteins on 
the CM5 chip.   
 
 
 
Figure 5.29: Surface plasmon resonance data showing binding of novobiocin to  
E. coli GyrB43 (top panel) and M. tuberculosis GyrB (bottom panel). 
It is important to determine the regeneration conditions to make sure that 
binding sites are available again for ligand binding after repeated cycles of ligand 
injection and regeneration. Precise kinetic data cannot be obtained without efficient 
regeneration. 
 
  
Chapter 5  
 
235 
 
Diospyrin showed binding with E. coli GyrB43 with a response of 50 RU 
units, but like novobiocin there were issues with the regeneration. After trying a 
range of regeneration condition, NaOH in the concentration range of 5.0 – 5.8 mM 
was found to be efficient. Based on the regeneration scouting experiment 5.5 mM 
NaOH was used for regeneration. Sensograms obtained with 5.5 mM NaOH as the 
regeneration conditions were of better quality than previously, but were not ideal for 
kinetic studies (Figure 5.30). Similar studies done with M. tuberculosis GyrB 
showed diospyrin binding. Based on the available data the Kd of diospyrin can be 
estimated to be less than 10-4 M. The higher Kd value is an underestimate due to poor 
regeneration conditions. 
 
Figure 5.30: Surface plasmon resonance data showing binding of diospyrin to  
E. coli GyrB43. 
As seen in Figure 5.30; diospyrin is not reaching equilibrium after a series of 
injections; rather a dissociation slope is seen in the sensogram which is concentration 
dependent. This may be due to several factors, which are as follows:   
1. The complex nature of interaction between the drug and the protein, which may 
involve a combination of specific and non-specific interactions. The competition 
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between the specific and non-specific interactions may be affecting the concentration 
of free drug available for binding over a period of time.  
2. High concentration of drug and DMSO. 
3. Conformational changes in the protein induced by ligand binding (specific and 
non-specific binding). 
With the information available about the diospyrin binding, the next focus 
was to investigate whether diospyrin shares partially or competes for the binding site 
with novobiocin. A single experiment was designed by immobilising M. tuberculosis 
GyrA in one flow cell (FC2) and M. tuberculosis GyrB in another (FC4). The 
immobilised protein quality was determined by recording binding sensograms at 
different concentrations of novobiocin (20 – 100 nM) as shown in Figure 5.31.  
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Figure 5.31: Surface plasmon resonance data shows novobiocin binding to  
M. tuberculosis GyrA (top panel) and GyrB (bottom panel). 
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As expected very little novobiocin binding was observed with M. tuberculosis 
GyrA in relation to GyrB. This was followed by a series of 100 nM novobiocin 
injections (80 injections, 30 µl/min, 50 sec each) until the point of saturation, with no 
regeneration, followed by series of 40 µM diospyrin injections (20 injections, 30 
µl/min, 50 sec each) as shown in the Figure 5.32. The idea behind the experiment 
was that if diospyrin shares the binding site with novobiocin then it should not show 
any binding with the immobilised M. tuberculosis GyrB saturated with novobiocin. 
Diospyrin binding was observed to GyrB after saturating the chip with novobiocin 
(Figure 5.33). A significant difference was also observed in the binding of diospyrin 
to M. tuberculosis GyrA and M. tuberculosis GyrB. Diospyrin binding was specific 
for M. tuberculosis GyrB in relation to M. tuberculosis GyrA as can be seen by the 
difference in the response unit. The weak diospryin binding with M. tuberculosis 
GyrA may be non- specific.  
 
 
Figure 5.32: Experimental design for studying competition between novobiocin 
and diospyrin. 
Thus the surface plasmon resonance experiments confirmed the finding that 
the GyrB N-terminal domain is the potential binding site for diospyrin and that it is 
different from the binding site of novobiocin.  
 
 
  
Chapter 5  
 
238 
 
 
 
Figure 5.33: Raw surface plasmon resonance data showing a series of 100 nM 
novobiocin injections (A) followed by series of diospyrin injections (B).  
M. tuberculosis GyrB (Fc4-3) preferentially binds novobiocin and diospyrin in 
comparison to M. tuberculosis GyrA. 
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The SPR experiments were only able to provide approximate Kd values due 
to the lack of reproducible regeneration conditions. This is a significant problem and 
limitation with SPR when studying small molecules. The process is empirical and it 
varies depending up the sensitivity of the instrument. A range of regeneration 
conditions suggested in the SPR manual were tried. Either the regeneration was not 
efficient or it affected the quality of the protein on the chip.  
5.11 ATP competition assay 
ESI-MS, limited proteolysis and SPR experiments suggest that diospyrin 
binds to the N-terminal domain of GyrB. Diospyrin can bind to M. tuberculosis GyrB 
even after saturating it with novobiocin on the CM5 chip. This also means that 
novobiocin binding to M. tuberculosis GyrB does not affect diospyrin binding to the 
protein.  
Since novobiocin is a competitive inhibitor of ATP, ATP-competition assays 
were performed in the presence of diospyrin to investigate if diospyrin competes 
with ATP for the ATP-binding site of GyrB. Standard supercoiling assays were 
performed at different concentrations of ATP, in the presence of a fixed 
concentration of drug, at approximately the IC50. The principle of the assay is based 
on the fact that if a drug competes with ATP, then the supercoiling activity of the 
enzyme is regained with the increase in concentration of ATP. 
ATP-competition assays were done with M. tuberculosis gyrase, with ATP 
concentrations from 0.02 mM – 2 mM in the presence of  novobiocin (2 µM) as a 
positive control, simocyclinone D8 (10 µM) as a negative control and diospyrin (8 
µM).  
As shown in Figure 5.34, in the absence of any drug, supercoiling activity is 
observed at a range of ATP concentrations. While in case of simocyclinone D8 (10 
µM), which is not a competitive inhibitor of ATP (Flatman et al., 2005), no increase 
in supercoiling activity is observed with the increase in the concentration of ATP. 
Similarly in case of diospyrin, inhibition of the supercoiling activity is observed, 
which does not recover with increased concentrations of ATP. While in case of 
novobiocin, the supercoiling activity is regained with increased concentrations of 
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ATP. This experiment suggests that diospyrin does not inhibit the DNA gyrase 
activity by competing with ATP for the ATP- binding site in GyrB.   
 
Figure 5.34: Effect of ATP concentration on the extent of inhibition. Samples 
containing the estimated IC50s of the drugs were incubated in the presence of a range 
of ATP concentrations. 
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5.12 M. tuberculosis GyrB43- diospyrin complex  
   The results of nano-ESI-MS and surface plasmon resonance indicate that the 
N-terminal domain of GyrB (GyrB43) is the binding site for diospyrin. E. coli 
GyrB43-diospyrin and GyrB43-ADPNP-diospyrin co-crystallisation trials were not 
successful. E. coli GyrB24-novobiocin-diospyrin co-crystallisation (Appendix: 
crystallisation conditions) only showed the presence of novobiocin at the ATP-
binding site. In-silico docking was used as an alternate approach to predict the 
potential binding site of diospyrin. This work was done in collaboration with Dr. 
Faridoon Yousafzai (John Innes Centre). 
Since there is no crystal structure for M. tuberculosis GyrB43, a 3- 
dimensional model of the domain was developed based on E. coli GyrB43. The 
homology model of the N-terminus (Q48 – V466) was built by using the molecular 
modelling package InsightII developed by Accelrys. The amino acid sequence was 
initially sent to the online Fold Prediction Metaserver or GeneSilico Metaserver 
(Kurowski & Bujnicki, 2003) for searching a suitable template. A number of 
potential templates (such as PDB id: 1EI1, 1KIJ and 1S16) were identified but none 
of the template molecules had amino acid residues corresponding to the N-terminal 
residues M1 to A47 and C-terminal residues V419 - A459 of the M. tuberculosis  
GyrB. Hence these residues were excluded from the model-building process by 
deleting them from the amino acid sequence of the M. tuberculosis GyrB. After 
sequence alignment, 1EI1 (E. coli GyrB43) was chosen as a template for the entire 
sequence of the modeled protein, except for two regions. The first region 
corresponds to D263-E274, where the template molecule 1EI1 has a single insertion 
causing structural disturbance in the emerging model. This region was modeled using 
the corresponding portion of 1S16 (E. coli topoisomerase IV subunit B) as a 
template. 1S16 does not have the given insertion. The second region corresponds to a 
34 amino acids insert (V300 – N333) in the M. tuberculosis GyrB sequence, which 
does not have comparable residues in the template molecule 1S16. It was modeled 
using residues E22-P52 of 1AQI as a template. 1AQI was returned as a top hit when 
the insertion sequence of M. tuberculosis GyrB was sent to the PDB to find a suitable 
template. Although, the template region of 1AQI was two residues shorter than the 
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insert itself, it had 41% identity and 65% similarity with the corresponding sequence 
V300 – N333 of the  M. tuberculosis GyrB. Moreover, it had the correct topology i.e. 
α-helices stacked on β-strands observed at the corresponding region of the template 
molecule 1EI1. 
Once template residues were identified for the bulk of the query sequence, a 
crude model was developed by transferring coordinates from the template proteins to 
the target sequence. Those residues of the target sequence that did not receive any 
coordinates, because they had either no template residues or they were intentionally 
excluded for structural reasons, were treated as loops. A complete but unoptimised 
model emerged when loops were built and splices repaired. Finally the structure was 
optimised by removing bumps, correcting chirality and dihedral angles, particularly 
omega values. Bumps were removed by running energy-minimisation protocols that 
used the Steepest Descents and Conjugate Gradients algorithms on a constrained 
structure where the backbone atoms were fixed but the side-chain atoms allowed 
adopting any conformation.  Chirality and omega angles of each residue were 
checked and corrected, if required, either manually or via energy minimization runs.  
 In-silico docking of diospyrin onto the M. tuberculosis GyrB43 model was 
carried out using the Libdock (Diller & . 2001, Rao et al., 2007, Diller & Li, 2003, 
Diller & Merz, 2001) protocol of Discovery Studio 2.5.5, which is a modelling and 
simulation suite developed by Accelrys. Libdock identifies cavities in the 3-
dimensional structure of a protein and treats them as potential binding sites for small 
molecules. Each cavity is defined by a sphere and ranked according to its diameter. 
Both the position and size of the spheres can be adjusted so that they are consistent 
with a known binding site of a protein or requisites for target small molecule. Five 
sites (site: 1, 2, 3, 4, 5) in M. tuberculosis GyrB43 model were identified as the 
potential sites for diospyrin docking. The five binding sites are as shown in Figure 
5.35 and are listed in the Table 5.7. 
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Figure 5.35: Potential diospyrin binding sites in the model structure of M. 
tuberculosis GyrB43. The different sites are indicated by: site-1 (with ADPNP), site-
2 , site-3, site- 4, site- 5 (with diospyrin). 
 Docking at site-3 was unsuccessful while site-4 was too narrow to 
accommodate diospyrin. Site-1 was large enough to accommodate diospyrin and was 
identified as the ATP- binding site.  The second site is close to site-1 and overlapped 
with it to occupy a significant portion of the common space. Initially both the sites 
were treated separately for docking. A total of 49 and 48 docking poses were 
computed at site-1 and site-2 respectively by altering the parameters in Libdock; the 
default parameter gave no results. The two sites (site-1 & site-2) were finally merged 
together because the top hits with the highest Libdock scores for the two sites were 
observed virtually on the edge of site-1. This merged site will be hereafter referred as 
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site-1+2. This was done by moving the sphere of the first site towards the second site 
until the later was fully encompassed. Top 2 scoring poses of the diospyrin at site-
1+2 are shown in the Figure 5.36 referred to as pose-1+2.1 and pose-1+2.2.  
Both the poses are close in terms of their orientation. In Pose-1+2.1, 
diospyrin is making seven hydrogen bonds with Asn44, Gly75 (2 bonds), Gly99 (2 
bonds), Lys100 and Val117, while in Pose-1+2.2, diospyrin is making 2 hydrogen 
bonds with Asn44 and Ser161. Since the  biophysical (SPR, crystallography) and 
biochemical (ATP competitive assay) does not support the hypothesis that diospyrin 
binds to the ATP-binding site and therefore site-1 or site-2 or site-1+2 cannot be the 
potential binding site of diospyrin. However, site-5 appeared interesting as the site 
was originating from a deep broader cleft (Figure 5.37).   
 
Docking sites in M. tuberculosis GyrB43 Position 
Site-1 ADPNP/ATP-binding site 
Site-2 Adjacent to and overlaps with site-1 
Site-3 Below site-5 
Site-4 Below site-3 
Site-5 Predicted diospyrin-binding site 
Table 5.7: Five docking sites in the M.  tuberculosis GyrB43 model. 
Diospyrin docking at this site was successful and the molecule was docked in 
the cleft with 36 poses. Libdock ranked the docking poses on a simple pair-wise 
score, similar to Piecewise Linear Potential (Gehlhaar et al., 1995). Diospyrin does 
not go into the cavity but rather stays in the cleft and forms 3 hydrogen bonds with 
Thr294, Thr302 and His 303 as shown in Figure 5.38.  
A second run of Libdock on the cleft rather than the cavity gave a total of 33 
poses with the top hit scoring 97.9. This was done by making the site sphere 
relatively large and moving it away from the cavity to cover most of the cleft. This 
score is slightly less than the score of 101 recorded for the earlier run on site-5. In 
this pose diospyrin appears to forming five hydrogen bonds with neighboring amino 
acids Glu188, Thr295 (2 bonds) and Asn301 (2 bonds). 
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Figure 5.36: Top 2 scoring poses of the diospyrin at site 1+2 referred to as pose-
1+2.1 (A) and pose- 1+2.2 (B). 
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Figure 5.37: Site-5, potential binding site for diospyrin with a deep cleft like 
binding pocket. 
 
Figure 5.38: Docked diospyrin at site-5 forming 3 hydrogen bonds with Thr294, 
Thr302 and His 303. 
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As the biochemical and biophysical studies do not support diospyrin binding 
at the ATP-binding site, site-5 is preferred over site-1+2 despite the fact that Libdock 
scores 130 and 129 for  pose-1+2.1 and pose-1+2.2, respectively, are significantly 
higher than 101 and 90 for the corresponding poses at site-5. 
 The limitation of in-silico docking as highlighted by the recent study has 
shown that the scoring functions of a number of docking protocols including Libdock 
have failed to identify the pose that is closest to the native-like pose of a binding 
molecule (Wang et al., 2007). Although, the argument applies to different poses at a 
given site, it may be true for different sites as well. 
5.13 Discussion 
Representative members from three class of compounds: quinolines 
(chloroquine), aaptamines (1N, N-Didodecylaaptamine, Kaempferol-3-O-α-L-(2,3-
di-E-Pcomaroyl)-rhamnoside) and naphthoquinones (7-methyljuglone, diospyrin) 
showed inhibitory activity against  M. tuberculosis DNA gyrase. The compounds 
were screened based on standard DNA supercoiling assay. The IC50 values based on 
DNA supercoiling assay are summarised in Table 5.8. 
Since naphthoquinones were found to be the most potent inhibitors, I decided 
to study their mode of inhibition further. Diospyrin (MW: 374.35 Da) was selected 
for study because it has higher molecular weight in comparison to 7-methyljuglone 
(MW: 188.18) which is beneficial for experimental techniques such as nano-ESI-MS 
and SPR experiments. Chemically diospyrin is a dimeric form of 7-methyljuglone. 
These two molecules inhibited all three reactions of M. tuberculosis DNA gyrase: 
supercoiling, relaxation and decatentation, but diospyrin was found to be more 
effective in inhibiting relaxation and decatenation activity in comparison to 7-
methyljuglone. The IC50 values (Table 5.9) are not the same for all the reactions as 
demonstrated for other DNA gyrase inhibitors, such as albicidin which inhibits DNA 
supercoiling and relaxation with different IC50 values (Hashimi et al., 2006).  
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Compound IC50 (approx) 
Quinolines 
Chloroquine 
Mefloquine 
 
80 µM 
300 µM 
Aaptamines: 
1N, 4N-Didodecyl Aaptamine 
Kaempferol-3-O-α-L-(2,3-di-E-Pcomaroyl)-
rhamnoside) 
 
~10 - 20 µM 
200 µM 
Naphthoquinones 
7-methyljuglone 
Diospyrin 
Neodiospyrin 
Isodiospyrin 
Menadione 
Shinanalone 
 
10 µM 
10 µM 
50 µM 
100 µM 
   >200 µM 
>200 µM 
Table 5.8:  DNA supercoiling IC50 values for Quinolines, Aaptamines and   
naphthoquinones. 
 
Compound Supercoiling assay 
IC50 
Relaxation assay 
IC50 
Decatenation assay 
IC50 
1. 7-methyljuglone 10 µM 80 - 120 µM 10 - 30 µM 
2.  Diospyrin 10 µM 40 - 80 µM 1 -10  µM 
Table 5.9: IC50 values of 7-methyljuglone and diospyrin based on supercoiling, 
relaxation and decatenation assay. 
These observations point to the fact that 7-methyljuglone is the active 
chemical scaffold which when duplicated in diospyrin increases its inhibitory 
activity. This hypothesis can be tested in future by designing, synthesising and 
testing compounds which are repetitive units of 7-methyljuglone. This may generate 
a new library of analogues that will be beneficial for naphthoquinone  
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characterisation. The activity of these molecules against E. coli gyrase also 
demonstrates that naphthoquinones can inhibit DNA gyrase from a range of bacterial 
species. 
 Based on nano-ESI-MS and SPR experiments diospyrin was shown to bind to 
the E. coli GyrB N-terminal domain (GyrB43). It does not bind at the ATP-binding 
site (Figure 1.20) as evident from the ATP competition assay and SPR experiments, 
ie. diospyrin is not a competitive inhibitor of ATP. DNA cleavage assays in the 
presence and absence of ATP indicated that it does not inhibit the enzyme activity by 
stabilising the cleavage complex.  
Since co-crystallisation trials with E. coli GyrB43-diospyrin and E. coli 
GyrB43-ADPNP-diospyrin were not successful, in-silico docking of diospyrin was 
performed on the model of M. tuberculosis GyrB43 using Libdock protocol of 
Discovery Studio 2.5.5. Since there is no crystal structure for M. tuberculosis 
GyrB43, InsightII software developed by Accelrys was used to model the structure. 
According to the docking experiments the potential binding site of diospyrin is a cleft 
just below the ATP-binding site described as site-5 where it forms hydrogen bonds 
with neighboring amino acids as shown in Figure 5.39. This cleft below the ATP –
binding site is also present in E. coli GyrB43 as shown in the Figure 5.40. 
At present it is not clear how diospyrin binding at this site affects the enzyme 
activity. The limited proteolysis experiments with trypsin indicate conformational 
changes which may affect the catalytic cycle of the enzyme. There is immense scope 
to investigate this further as it may provide a novel mode of inhibition. One of the 
possibilities that were discussed while studying inhibitory activity of  diospyrin was  
its potential to form S-conjugates (Newton & Fahey, 2002). Table 5.10 shows the 
percentage of cysteine residues present in E. coli and M. tuberculosis DNA gyrase.  
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Figure 5.39: Potential binding site of diospyrin described as site-5 with 
the docked molecule. It is a cleft just below the ATP-binding site. 
 
Figure 5.40: E. coli GyrB43 (red color) superimposed over modeled 
M. tuberculosis GyrB43 (yellow color) with diospyrin docked at site-5. 
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Protein No: of cysteine  residues Cysteine percentage 
1. M. tuberculosis GyrA 2 0.2% 
2. M. tuberculosis GyrB 3 0.41% 
3. E. coli GyrB43 2   0.5% 
4. M. tuberculosis GyrB43 1 0.2% 
Table 5.10: Percentage of cysteine residues present in E. coli and M. tuberculosis 
DNA gyrase.   
According to the docking experiment there is no cysteine in the vicinity of 
 site-5. Thus the three classes of compound were screened to discover novel DNA 
gyrase inhibitors. Naphthoquinones were the most potent inhibitors of DNA gyrase. 
Based on the biochemical data and the computer model we predict a novel binding 
site and speculate a novel mode of inhibition for naphthoquinones that has not been 
observed before for other inhibitors.  
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Chapter 6: General Discussion 
6.1 Introduction 
Most of our understanding of DNA gyrase is based on the enzyme from 
 E. coli, a Gram-negative bacterium, with limited information about the enzyme from 
other Gram-positive bacteria such as M. tuberculosis. The recent initiative of the TB 
Alliance and Bayer to conduct a global clinical development program for 
moxifloxacin has highlighted the significance of M. tuberculosis DNA gyrase as a 
target for the discovery and development of novel antibacterials. Moxifloxacin is a 
fluoroquinolone and an inhibitor of DNA gyrase. Although the GyrA and GyrB 
subunits of the enzyme have been successfully cloned, basic background research for 
this enzyme has not yet been done. Most of the studies have concentrated on 
studying the interaction of the enzyme with known inhibitors such as 
fluoroquinolones. For example, IC50 values have been determined for different 
quinolones such as ciprofloxacin, sparfloxacin, sitafloxacin, clinafloxacin, and 
gatifloxacin (Aubry et al., 2004, Takiff et al., 1994, Onodera et al., 2001). 
The research described in this thesis is an attempt to understand the unique 
features of M. tuberculosis DNA gyrase and to identify potential new classes of 
inhibitors. It has also highlighted a general concern of sequence inconsistency across 
different public databases. In this research project an attempt was made to resolve 
inconsistency in the M. tuberculosis GyrB sequence. 
In the first stage of the project, bioinformatics analyses were performed for  
M. tuberculosis DNA gyrase. Multiple-sequence alignment between the  
M. tuberculosis DNA gyrase with other bacterial gyrases identified the following two 
unique features in each of the DNA gyrase subunits: (a) prediction of the presence of 
40 additional amino acids at the beginning of GyrB and (b) the presence of a 
predicted  putative Ca2+-binding site in GyrA. 
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6.2 M. tuberculosis GyrB promoter analysis 
The presence of 40 additional amino acids at the beginning of the GyrB N-
terminus was not found in all the GyrB sequences retrieved from different databases. 
For example, in the case of NCBI code CAB02426 for M. tuberculosis H37Rv gyrB, 
the 40 additional amino acids are present. But for the same protein cross-referenced 
in UniProtKB/Swiss-Prot as P0C5C5 the 40 additional amino acids are absent. It was 
important to investigate if these 40 additional acids had any effect on the enzyme 
activity, which would also indicate the real starting amino acid for GyrB. The 
investigation was done at the level of promoter, transcript and protein analysis. RT-
PCR (reverse transcriptase-PCR) performed on the RNA prepared from the crude 
extracts of M. tuberculosis cells indicated that there are two species of gyrB 
transcripts.  One of the species exists because of the transcription of the sequence 
that includes the sequence corresponding to the 40 amino acids, while the other 
transcript that is transcribed from the sequence that excludes the sequence 
corresponding to the 40 amino acids. The presence of these species was verified by 
sequencing the PCR products. 
Due to experimental limitations it was not possible to investigate if these 40 
amino acids are present in native protein from M. tuberculosis. Before generating a 
deletion mutant (GyrB N40∆), it was verified by Orbitrap analysis that the 40 
additional amino acids are present in GyrB heterologously expressed in E. coli. The 
enzyme activity of the GyrB N40∆ deletion mutant was compared with the activity 
of GyrB WT. There was no difference in the supercoiling, relaxation and 
decatenation activity of GyrB N40∆ deletion mutant and GyrB WT. This indicated 
that there is no functional role of the additional 40 amino acids at the GyrB N-
terminus.  Based on previous work (Unniraman et al., 2002) there was a possibility 
for the existence of promoter elements in the region that encodes the 40 amino acids 
at the GyrB N-terminus. This was verified by ß-galactosidase-based activity assays 
in M. smegmatis, which confirmed the presence of promoter elements in this region. 
Weak promoter activity was also observed in region upstream of the 40 amino acids. 
Although this data is consistent with the previous publication (Unniraman et al., 
2002)  but the promoter activity was assayed in M. smegmatis.  
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It would be interesting to repeat the same experiment in  
M. tuberculosis because sometimes M. tuberculosis promoters behave differently 
when transformed in M. smegmatis. Thus the data indicate that the real start codon 
for M. tuberculosis GyrB is GTG (Val) and that the additional 40 amino acids 
expressed in GyrB have no structural or functional significance. This information 
will be useful to revise the GyrB sequences available on public database. In future, 
mutations in the promoter elements can be made as a further proof of concept. At 
present, it has not been possible to identify the reason for the existence of two 
transcript species. This also needs further investigation, which raises the possibility 
of post-transcriptional modification, which has not been studied in M. tuberculosis 
with reference to M. tuberculosis GyrB transcripts. Genetic and biochemical studies 
can be performed to understand the physiological significance for the presence of 
two different transcript species. 
6.3 Putative Ca2+-binding site 
Another important observation from the bioinformatics analysis was the 
presence of a putative Ca2+-binding site in GyrA. The Ca2+-binding site ‘504 
DVSDEDLIAREDV 516’ is present at the junction of N- and C-terminal domains of 
GyrA.  Sequences homologues to the Ca2+-binding site are also found in M. bovis, B. 
melitensis and C. diphtheria. Interestingly, C. diphtheria lacks topo IV, which may 
suggest a relation between the presence of the Ca2+- binding site and the absence of 
topo IV. How DNA gyrase manages this dual role in the absence of topo IV has not 
been studied.  
Bioinformatics analysis also demonstrated that the Ca2+-binding sequence 
does not follow the canonical EF-hand helix-loop-helix pattern. There are several 
examples of proteins in prokaryotes that do not follow the canonical definition of EF-
hand Ca2+-binding sites such as the periplasmic galactose-binding protein 
(Salmonella typhimurium; PDB code: 1gcg) (Vyas et al., 1987) and alginate-binding 
protein (Sphingomonas sp.; PDB code: 1kwh) (Mishima et al., 2003) (Figure 3.17). 
However, like most of the EF-hand Ca2+-binding sites it exists in a pair as in the 
GyrA dimer.  
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In the absence of the complete crystal structure, two homology models for  
M. tuberculosis GyrA including the Ca2+-binding site were generated. These models 
(MtGyrA-1H71, MtGyrA-1BQB) were generated based on the sequence similarity of 
the Ca2+-binding site with two other bacterial Ca2+-binding sites (metalloprotease 
from Pseudomonas sp. and S. aureus). According to model MtGyrA-1H71, there is a 
possibility for only one Ca2+ at the binding site, whereas according to the model 
MtGyrA-1BQB there is a possibility for two Ca2+ atoms. In order to investigate these 
models and to study the effect of Ca2+ on the enzyme activity, biochemical and site-
directed mutagenesis experiments were performed. 
The initial biochemical studies involved assaying the supercoiling activity of 
E. coli and M. tuberculosis DNA gyrase in the presence of Mg2+ or Ca2+.  As reported 
in previous studies (Aubry et al., 2006a), unlike E. coli, M. tuberculosis DNA gyrase 
could not supercoil relaxed DNA in the presence of Ca2+. In order to identify the 
subunit that is important for the enzyme activity in the presence of Ca2+, the subunits 
between E. coli and M. tuberculosis DNA gyrase were swapped to generate a hybrid 
enzyme. Supercoiling activity was observed when M. tuberculosis GyrA and E. coli 
GyrB hybrid was assayed in the presence of 6 mM Mg2+, but no supercoiling activity 
was observed when the same assay was repeated in the presence of 6mM Ca2+ (Table 
4.1). This indicates that the ability of the Ca2+ to support DNA supercoiling depends 
on the presence of E. coli GyrA and M. tuberculosis GyrA cannot substitute for it. 
According to the homology models, there is possibility of at least one Ca2+ in 
the Ca2+ -binding site.  Since EGTA is a specific chelator of Ca2+, GyrA was dialysed 
in 1 mM EGTA to remove Ca2+ associated with the native protein. The effect of 
EGTA dialysis was a 2-3 fold loss in relaxation activity without affecting other 
reactions such as supercoiling and decatenation. It was possible to regain the loss in 
relaxation activity by external addition of Ca2+ in the assay. Protein-refolding 
experiments were also done in the presence of EGTA to make sure that any tightly 
bound Ca2+ is removed during protein refolding in the presence of EGTA. ICP-AES 
indicated a decrease in the concentration of Ca2+ in the protein sample refolded in the 
presence of EGTA. The effect of protein refolding in the presence of EGTA was 
drastic which led to the loss of relaxation and decatenation activity with weak 
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supercoiling activity. Interestingly, relaxation and decatenation activities are 
associated with topo IV, which is absent in case of M. tuberculosis. 
 Based on the M. tuberculosis GyrA model described previously, site-directed 
mutagenesis experiments were performed. For the quadruple mutation (D504A, 
E508A, D509A, E514A) in the putative Ca2+-binding site, incomplete supercoiling 
activity was observed. There was no effect of these mutations on the relaxation and 
decatenation activity of the enzyme. By CD experiments, it was verified that this 
effect is not due to protein misfolding. Further investigation into the weak 
supercoiling activity revealed that the mutations have affected DNA wrapping. This 
effect could be due to the loss of Ca2+ at the Ca2+-binding site due to the mutations. 
Thus, there is a functional significance of the Ca2+ and the Ca2+-binding site.  
In order to explain the significance of Ca2+ and the Ca2+-binding site, a model 
is proposed. The proposed model is based on the established model for DNA 
wrapping around the GyrA C-terminal with slight modification due to the presence 
of the Ca2+-binding site in M. tuberculosis GyrA.  
The model is based on the assumption that Ca2+ may act as a pivot or 
regulator that controls the flexibility of the arm / linker connecting the GyrA N- and 
C-terminal domains. It has been suggested in previous studies that the linkage 
between the N- and C-terminal regions may be flexible (Corbett et al., 2004). This 
flexible arm has the Ca2+-binding site as demonstrated by the bioinformatics and 
biochemical studies. The conformation of the GyrA C-terminal domain is important 
for DNA supercoiling (Corbett et al., 2004, Costenaro et al., 2005).  
The DNA wrapping process is a cycle of events in the following sequence 
(Figure 6.1): 
1. Arms-down: In the native state, Ca2+coordinated by the Ca2+-binding site of  
M. tuberculosis GyrA keeps the C-terminal domain down at each side of the 
dimer away from the cleavage active site. In this stage, DNA gyrase is ready 
to catalyse DNA supercoiling or DNA relaxation /decatenation. In a previous 
study (Costenaro et al., 2005) it has been suggested that such a conformation 
would minimise the obstruction of relaxation and decatenation by the C-
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terminal domains and this could be their actual conformation with GyrA 
during these reactions.   
2.  Arms-up: A2B2 tetramerisation followed by DNA wrapping around the C-
terminal moves the arm upwards to make protein-DNA contacts between the 
G-segment and the cleavage active site. Therefore the initiation of 
supercoiling will be the binding of DNA which will move the arms having 
the Ca2+-binding site up towards the cleavage active site in order to facilitate 
the introduction of  the T segment.  It has been previously reported that a 
large conformational change is induced in the enzyme upon DNA binding 
(Costenaro et al., 2005).  
3. Arms-down: Near the end of the catalytic cycle, when the T-segment is 
about to leave the C-gate, the DNA induces conformational changes in the 
arm which again brings it down to its native state, away from the cleavage 
active site. At this stage, the enzyme is again ready for either supercoiling or 
relaxation / decatenation.  
Thus, Ca2+ may help to maintain M. tuberculosis DNA gyrase in a state, 
which would favour all the topological reactions. In the absence of topo IV in M.  
tuberculosis, this may be important to keep the enzyme in a state ready for both 
supercoiling and relaxation/decatenation reactions. In the case of bacterial 
species such as E. coli, lacking the Ca2+-binding site and having a topo IV, the 
relaxation activity and decatenation activity is weaker in comparison to M. 
tuberculosis DNA gyrase. This may be due to the more flexible nature of the 
arms due to the absence of Ca2+, which is stabilised by Ca2+  in case of M. 
tuberculosis DNA gyrase away from the cleavage active site. The flexibility of 
these linkers is evident from the absence of this region in the recent crystal 
structures of GyrA N-terminus (PDB code: 3ILW; 3IFZ). 
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Figure 6.1: Down-UP-Down arm model (DUDAM) proposed for the regulation 
of DNA supercoiling. Black asterix: ATP, yellow stars: Ca2+. 
 
This model can explain the experimental observations. In the biochemical, 
experiments following two observations were made: 
1. Weak supercoiling activity by the quadruple mutation (GyrA D504A, 
E508A, D509A, E514A) without significantly affecting the relaxation 
and decatenation activity.  
The mutations made the arms less flexible in comparison to the native 
protein due to both the loss of Ca2+ and the mutation of acidic amino acids to 
alanine. Because of this, the arms cannot efficiently assist the DNA 
wrapping around the C-terminal domain. I have experimentally demonstrated 
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that the mutations have an effect on DNA wrapping. Since DNA wrapping is 
only important for supercoiling, the mutations have no effect on the 
relaxation and the decatenation activity of the enzyme. I propose that the 
arms are held in a conformation unsuitable for DNA supercoiling, but DNA 
relaxation and decatenation can still occur (Figure 6.2). 
2. EGTA dialysis and refolding lead to loss of the relaxation and 
decatenation activity.  
EGTA is a specific chelator of Ca2+. When GyrA is refolded in the presence 
of EGTA, any Ca2+ tightly bound to the GyrA subunit will be removed by 
EGTA and presumably, the refolded protein will be without any Ca2+. Due to 
the loss of Ca2+ from the Ca2+-binding site, the favoured position for the arms 
is up and close to cleavage active site, which may obstruct 
relaxation/decatenation activity. As a result, the enzyme can catalyse DNA 
supercoiling, but it is weaker than the native protein. This is because there is 
no Ca2+ to provide additional stability or appropriate conformation to the 
arms during the process of DNA supercoiling. Interestingly, weaker 
relaxation activity has also been observed when the protein was dialysed in 
EGTA (no refolding), which can be regained by addition of Ca2+ in the 
assay. This indicates that EGTA dialysis alone is not sufficient to remove all 
the Ca2+. This method is also not reproducible as there are factors associated 
with protein batch and chelation of Ca2+   by EGTA (Figure 6.2).  
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Figure 6.2: Conformational changes in M. tuberculosis GyrA due to quadruple 
mutation (GyrA D504A, E508A, D509A, E514A), Ca2+ and EGTA. Yellow stars: 
Ca2+. 
Limited proteolysis experiments with trypsin also demonstrated that Ca2+ 
induces conformational chances in GyrA and that this effect is specific. One of the 
differences is the disappearance of a 47-kDa band in the presence of Ca2+. Edman 
sequencing confirmed that the 47-kDa band included the Ca2+-binding site. 
Due to the significance of the Ca2+-binding site, virtual screening was done 
with AutoDock Vina v1.0.2 using the NCI diversity II dataset from the ZINC 
database. Compounds ZINC13130018 and ZINC1639634 inhibit the supercoiling 
and relaxing activity of the enzyme and has an in-vitro MIC of ~50 µM against M. 
tuberculosis. 
In future, cross-linking and Fluorescence Resonance Energy Transfer (FRET) 
studies could be done to demonstrate how Ca2+ can control the flexibility of the arm 
connecting N- and C-terminal domain. Cross-linking studies can be performed before 
performing FRET studies. The arms/GyrA C-terminal domain can be cross-linked to 
GyrA N-terminal in arms down conformation as shown in Figure 6.1 A. For cross-
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linking studies, all the cysteines in GyrA will have to be substituted by alanines and 
new cysteine residues will have to be introduced at the site of cross-linking. The 
cross-linking studies will provide information about the significance of the flexible 
arm and its effect on the supercoiling activity of enzyme. FRET studies can be 
performed by labelling the C-terminal domain with a fluorophore and the GyrA N-
terminal domain that makes contact with C-terminal domain with a quencher. Cross-
linked protein can act as a control for the FRET experiment. FRET experiments will 
be helpful to study the flexibility of the arms/ linkers and the effect of DNA and Ca2+ 
on it. 
The significance of the Ca2+-binding site can also be investigated by studying 
the effect of EGTA dialysis on the relaxation activity of the GyrA N-terminal domain 
without the putative Ca2+-binding site. Isothermal titration calorimetry (ITC) can also 
be performed to determine the kinetics of Ca2+-binding at the predicted site in GyrA. 
Further work also needs to be done to determine the IC50S for ZINC13130018 and 
ZINC1639634. Since the quadruple mutant (GyrA D504A, E508A, D509A, E514A) 
has mutations in the Ca2+-binding site, these two compounds can also be assayed 
against it to see if there is any difference in their IC50.    
6.4 Novel
 
DNA gyrase inhibitors 
The main focus of my project was to identify novel inhibitors of M. 
tuberculosis DNA gyrase. I decided to investigate selected classes of compounds that 
have published information about their antibacterial activity. These compounds also 
did not have any information about their possible targets. There were two advantages 
of this method.  The first advantage is that since these compounds have already been 
shown to have antibacterial activity, I know that they have biological activity and can 
enter the bacterial cell. The other advantage is that if any of these compounds exhibit 
inhibitory activity against DNA gyrase, then it is likely that the collaborators would 
be able to perform synthetic chemistry on the selected molecule to design better 
inhibitors. I selected three classes of compound: quinolines, aaptamines and 
naphthoquinones for study. Aaptamines and naphthoquinones (Gul et al., 2006, 
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Mahapatra et al., 2007) were selected because these classes of compound have been 
shown to have anti-mycobacterial activity but no information is available about their 
cellular target. Similarly quinolines, the anti-malarial drugs have been shown to 
induce cross-resistance to fluoroquinolones by generating mutations in DNA gyrase 
and topo IV (Davidson et al., 2008). Out of all the three classes of compounds, 
naphthoquinones were found to be most effective and were studied in detail. 
Initial studies involved IC50 determination for representative compounds. 
Two representative quinolines, chloroquine and mefloquine, were assayed for their 
activity against M. tuberculosis DNA gyrase. Chloroquine inhibited the supercoiling 
and relaxation activity with an IC50 of 80 µM and mefloquine inhibited both the 
reaction with an IC50 of 300 µM. Interestingly, chloroquine exhibited DNA cleavage 
in the absence of ATP. But its DNA cleavage activity was weaker than ciprofloxacin. 
These preliminary results are promising to develop quinolines for 
antimycobacterials. Previous reports on quinoline induced cross-resistance to 
fluoroquinolone also indicate possible interaction between quinolines and DNA 
gyrase (Davidson et al., 2008). In many parts of the world, TB and malaria are 
endemic. Population genetic studies in these areas can be done in future to establish 
correlation between the cases of malaria and TB.  
Aaptamines are related to quinolines, possess antimycobacterial activity 
(Pettit et al., 2004) and are predicted to interact with topoisomerases. Therefore I 
decided to assay seven aaptamine derivatives and marine extracts to study their effect 
on the activity of M. tuberculosis DNA gyrase. Out of all the compounds that were 
tested, 1N,4N-didodecyl aaptamine (Figure 5.6) is a good inhibitor of M. 
tuberculosis DNA gyrase (IC50~10-20 µM). Thus aaptamines can be developed to 
specifically target M. tuberculosis DNA gyrase. 
  The naphthoquinone class have been studied in detail in relation to a  broad 
range of biological activities that can be exploited for the design of new antibacterial 
(Mahapatra et al., 2007), anti-leshmaniasis (Ray et al., 1998, Yardley et al., 1996) 
and antitumor compounds (Ting et al., 2003, Hazra et al., 1984). Although there is 
no established target for naphthoquinones, the predicted targets are the electron 
transport chain and mycothiol disulfide reductase in M. tuberculosis. Nine different 
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compounds and plant extracts were tested against M. tuberculosis DNA gyrase 
supercoiling. 7-methyljuglone and diospyrin were the most potent DNA gyrase 
inhibitors of all the tested compounds. These compounds have an IC50 of ~10 µM, 
comparable to the IC50 of ciprofloxacin (10 µM) in a supercoiling assay. These 
compounds also inhibit DNA relaxation and decatenation activity. 
Besides M. tuberculosis DNA gyrase, 7-methyljuglone and diospyrin also 
inhibited E. coli DNA gyrase supercoiling activity with an IC50 between 50-100 µM 
and 1-10 µM respectively. Diospyrin (MW: 374.35 Da) was selected for further 
study because it has higher molecular weight in comparison to 7-methyljuglone 
(MW: 188.18 Da), which is beneficial for experimental techniques such as nano-ESI-
MS and SPR experiments. DNA cleavage assays in the presence and absence of ATP 
indicated that diospyrin does not inhibit the enzyme activity by stabilising the 
cleavage complex.  
 In order to identify the potential binding site for diospyrin, two different 
biophysical techniques (SPR, nano-ESI-MS) were used. Both of these techniques 
confirmed that the GyrB N-terminus is the potential target site for diospryin. Co-
crystallisation trials with E. coli GyrB43-diospyrin and E. coli GyrB43-ADPNP-
diospyrin were not successful and E. coli GyrB24-novobiocin-diospyrin crystals 
diffraction data did not show bound diospyrin (Appendix). In the absence of a 
crystal structure, in-silico docking for diospyrin was performed on the model of M. 
tuberculosis GyrB43 using Libdock protocol of Discovery Studio 2.5.5.  According 
to the docking experiments, the potential binding site of diospyrin is a cleft just 
below the ATP-binding site. Using an ATP competition assay and SPR experiments I 
have shown that diospyrin does not bind at the ATP-binding site. Although now we 
know the target site for diospyrin, it is not clear how diospyrin binding at this site 
affects the enzyme activity. The limited proteolysis experiments with trypsin indicate 
conformational changes which may affect the catalytic cycle of the enzyme.  
 In future, site-directed mutagenesis experiments can be done to mutate the 
predicted amino acids involved in diospyrin-binding (Glu188, Thr295, Asn301, 
Thr294, Thr302 and His 303) and to study if there is any change in the IC50 for 
diospyrin. GyrB43-diospryin co-crystallistion trials can also be carried out by 
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identifying new crystallization conditions from fresh screens. In order to obtain 
kinetic data for diospyrin-binding, isothermal titration calorimetry (ITC) can also be 
performed. 
M. tuberculosis DNA gyrase is a potential target for discovering novel 
antibacterial. In this project I used different approaches to achieve this goal. One of 
the methods was based on the virtual screening at a unique site (putative Ca2+-
binding site) in the protein and another was investigating the activity of compounds 
against M. tuberculosis DNA gyrase, which have already been reported as 
antimycobacterials with no information about their target. There are different 
approaches for addressing antibacterial drug discovery. The important goal is to find 
new drugs and therapies that can address the problem of epidemics like tuberculosis. 
This can be addressed by exploring sources for new drugs and understanding the 
molecular mechanism behind drug resistance. Drug resistance to several established 
targets is common across different bacterial species. For example DNA gyrase and 
fluoroquinolone resistance and rifampicin resistance and alterations in rpoB cluster I 
in S. pneumoniae, E. coli and M. tuberculosis (Enright et al., 1998). I would like to 
finish with a quote from the TB Alliance 2009 report that highlights the challenge in 
discovering the most convenient, quick and timeless therapy for tuberculosis. 
 
‘‘The precious hopes of new drugs stand in stark contrast to the grim reality of 
the TB epidemic. TB still kills 5,000 people every day... and the problem is 
getting worse. TB anywhere is TB everywhere’’.  
-TB ALLIANCE 2009 Annual Report 
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Crystallisation trials 
Protein Reagent conditions Crystals 
M. tuberculosis GyrA 0.2 M Sodium sulphate, 0.1M Bis Tris 
propane (pH 6.5), 20% w/v PEG 3350 
0.2 M Sodium malonate, 0.1 M Bis Tris 
propane (pH 6.5), 20% w/v PEG 3350 
0.2 M Lithium sulphate, 0.1 M Tris.HCl 
(pH 8.5), 30% (w/v) PEG 4000 
0.2 M tri-Sodium citrate, 20% w/v PEG 
3350 
Needles 
M. tuberculosis GyrB 0.2M Sodium formate, 20% w/v PEG 
3350, 0.1M Bis Tris propane (pH 6.5) 
0.2M Sodium acetate, 20% w/v PEG 
3350, 0.1M Bis Tris propane (pH 6.5) 
Plates 
M. tuberculosis GyrB 
N40∆ 
0.02 M Calcium chloride, 0.1 M Sodium 
acetate (pH 4.6), 30 %(v/v) MPD 
0.2 M Ammonium sulfate. 30 % (w/v) 
PEG 4000 
Needles 
E. coli GyrB43 + 1 mM 
ADPNP  
&  
E. coli GyrB43+ 1 mM 
ADPNP + 1mM 
Diospyrin 
0.1 M HEPES (pH 7.5), 4-9% PEG400, 
0.2 M ammonium sulfate 
Clear drops 
E. coli GyrB24+ 1 mM 
novobiocin 
& 
E. coli GyrB24 + 1 mM 
novobiocin + 1 mM 
diospyrin 
20% - 21% PEG 550 MME, 100 mM 
MES pH 6.5 
Plates/ 
Needles 
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E. coli GyrB24-novobiocin 
                                  (20% PEG 550 MME, 100 mM MES pH 6.5) 
 
 E. coli GyrB24-novobiocin-diospyrin  
                                  (21% PEG 550 MME, 100 mM MES pH 6.5) 
 
E. coli GyrB24-novobiocin-diospyrin 
 (20% PEG 550 MME, 100 mM MES pH 6.5) 
Co-Crystals of E. coli GyrB24-novobiocin-diospyrin and E. coli GyrB24-
novobiocin 
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Diffraction data for E. coli GyrB24-novobiocin-diospyrin co-crystals. (A) The 
crystal diffraction pattern at 2.8 Ǻ (B) Electon density only showing novobiocin 
binding. Diospyrin molecule was not observed. 
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ABBREVIATIONS 
 
 
Ǻ Angstrom (10 -10 m) 
ATP   Adenosine triphosphate 
CD     Circular dichroism 
DMSO    Dimethylsulfoxide 
DNA       Deoxyribonucleic acid 
DTT      Dithiothreitol 
EDTA   Ethylenediaminetetraacetic acid 
EGTA   Ethylene glycol tetraacetic acid 
HEPES  4-(2-Hydroxyethyl)piperazine-1 ethanesulfonic 
acid 
ICP-AES Inductively coupled plasma atomic emission 
spectroscopy 
IPTG   Isopropyl-β -D-thiogalactopyranoside 
kDa Kilo Dalton 
LB Luria Bertani media 
MS Mass spectrometry 
MIC Minimum inhibitory concentration 
MPC Mutant prevention concentration 
MurI  Glutamate racemase 
Nano-ESI Nanoflow electrospray ionisation 
ONP o-nitrophenol 
ONPG o-Nitrophenyl-ß-D-galactopyranoside 
PAGE Polyacrylamide gel electrophoresis 
PCR   Polymerase chain reaction 
PEG    Polyethylene glycol 
PDB Protein data bank 
Rpm   Revolutions per minute 
RT-PCR Reverse transcription-polymerase chain 
reaction 
SAB             Sample application buffer 
SDM     Site-directed mutagenesis 
SPR      Surface plasmon resonance 
TAE     Tris base, acetic acid and EDTA. 
TB Tuberculosis 
Tris Tris (hydroxymethyl)aminomethane 
Tw Twist 
Wr Writhe 
SDS Sodium dodecyl sulfate 
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